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Abstract 
Introduction 
A suitable type of vascular access has to be created to establish a connection between 
the circulation system of the patient and the haemodialysis cycle. The arteriovenous 
fistula (AVF) is considered to provide the best long-term functional vascular access, 
with reduced risk of thrombosis or infection and cost-effective. However, significant 
numbers of AVF, which fail to develop sufficiently for dialysis, are 28-53% of cases. 
This study aimed to explore the potential influence of blood markers and factors on 
the maturation of AVF, in patients who have undergone vascular access surgery and 
to develop and validate a prognostic model to determine the success of AVF 
maturation. 
Methods 
Data from 300 patients was retrieved who had undergone AVF surgery between the 
years 2006 and 2009, from the Royal Infirmary of Edinburgh. A prognostic model 
was developed for the prediction of maturation of AVF using backward stepwise 
logistical regression. This data was analysed using univariable, multivariable logistic 
regression. Model performance was assessed, using the receiver operating 
characteristics (ROC) curve and Hosmer and Lemeshow goodness of fit test. A 
prognostic model was validated with the prospective data of 100 patients who had 
undergone AVF surgery between the years 2009 and 2011, from the Royal Infirmary 
of Edinburgh. 
 
 xvii 
 
Results 
Three variables were identified, which independently influenced fistula maturation. 
Males were twice as likely to undergo fistula maturation, compared to that of females 
(odds ratio (OR) 0.514; 95% confidence interval (CI) 0.308 to 0.857). Patients with 
no evidence of Peripheral Vascular Disease (PVD) were three times more likely to 
mature their fistula (OR 3.140; 95% CI 1.596 to 6.177). A pre-operative vein 
diameter greater than 2.5mm resulted in a fivefold increase in fistula maturation 
compared to a vein size less than 2.5mm (OR 4.532; 95% CI 2.063 to 9.958). The 
model for fistula maturation had good discrimination as indicated by area under the 
ROC curve 0.677 and calibration as indicated by Hosmer and Lemeshow test (p = 
0.79). The model discriminatory power was confirmed in the prospective study 
(validation data set) with area under the receiver operating curve was 0.59 and 
calibration indicated by Hosmer and Lemeshow test (p > 0.05). 
Conclusion 
Successful vascular access provision is the foundation on which successful 
haemodialysis is built. This study has found that female gender, history of PVD and 
vein diameter less than 2.5 mm are the negative significant independent clinical 
predictors of maturation of arteriovenous fistula.  
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1.1 Kidney Failure and Dialysis 
Chronic Kidney Disease (CKD) is a critical condition with considerable public health 
implications. It affects a significant proportion of the general population and when 
progressive, has an increasing influence on morbidity and mortality. An estimated 
10% of adults (more than 20 million people) in the United States have CKD (Centres 
for Disease Control and Prevention 2014). In England in 2008/09 there were 
1,739,443 people aged 18 and over who were registered with stage 3 to 5 CKD (NHS 
Kidney Care 2010). According to the United States Renal Data System (USRDS 
2011), more than 87,000 people die from causes related to kidney failure each year. 
The two most important corollaries of CKD are cardiovascular disease and End 
Stage Renal Disease (ESRD). Once a patient reaches established kidney failure, 
his/her quality of life becomes poor and the life expectancy is considerably 
shortened. Through the provision of Renal Replacement Therapy (RRT) survival and 
quality of life of ESRD patients can be markedly improved. Another important 
determinant of ESRD on a global scale is diabetic nephropathy, which has had a 
growing prevalence since the beginning of the 21st century. The cause of this 
phenomenon is the increasing proportion of individuals who develop type 2 diabetes 
mellitus (USRDS 2011). 
Haemodialysis and peritoneal dialysis are two corresponding treatments in ESRD. 
Despite the right that patients have to choose between these two treatments, often 
this is over ruled by factors, which are more essential, such as access to 
haemodialysis centre, difficulty in the creation or maintenance of vascular access, or 
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the urgent necessity to treat people in a critical condition (uraemic emergencies). In 
order to ensure that the suitable treatment is selected, CKD patients have to be 
referred to a kidney specialist as early as possible. 
1.2 Vascular Access and Arteriovenous Fistula 
The efficiency of haemodialysis treatment relies on a functional status of vascular 
access (VA). According to the National Institute for Health and Clinical Excellence 
Guidelines (NICE) (2008), VA and its related problems represent the main factors 
that determine a rise in the rate of incidence of the disease among haemodialysis 
patients and, consequently, a rise in the healthcare expenses. Vascular access can be 
divided into three categories: arteriovenous fistula (AVF), central venous catheter 
(CVC) and arteriovenous graft (AVG). As highlighted by several researchers 
(Banerjee 2009; Agarwal et al. 2007; Combe et al. 2001; Hoen et al. 1995), CVC has 
a number of disadvantages, including a considerable risk of infection and mortality. 
It also has negative implications for the use of a fistula for dialysis. In contrast, AVF 
is the most beneficial method, as it has a low risk of infection and mortality, and can 
ensure long-term functional access (Iyem 2011; Dixon et al. 2002; Feldman et al. 
1996). Furthermore, there are three configurations of native AVF that can be used for 
haemodialysis providing flexibility of approach depending on risk factors of the 
individual patient. Figure 1 shows the three configurations of native arteriovenous 
fistula used for haemodialysis, that are radiocephalic, brachiocephalic, and 
brachiobasilic fistula (Fitzgerald et al. 2004).  
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Figure 1. Radiocephalic, Brachiocephalic and Brachiobasilic AVF (Adopted 
from Vachharajani 2010) 
 
Radiocephalic AVF 
 
 
Brachiocephalic AVF 
 
 
Brachiobasilic AVF 
The basilic vein is mobilized from 
its usual location and transposed 
superficially through the deep 
fascia in the upper arm to create the 
brachiobasilic AVF. 
The radiocephalic arteriovenous 
fistula at the wrist utilizes the 
forearm segment of the cephalic 
vein and radial artery. 
The brachiocephalic fistula at the 
elbow utilizes the upper arm 
segment of the cephalic 
vein and brachial artery. 
Radial A 
Cephalic V 
Cephalic V 
Brachial A 
Brachial A 
Basilic V 
Cephalic V 
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Both European and North American medical guidelines highly recommend the use of 
AVF (National Kidney Foundation – Kidney Disease Outcome Quality Initiative 
[NKF-KDOQIa] 2006; Tordoir et al. 2007). As explained by Stehman-Breen et al. 
2000), the decision to use AVF is based on a number of patient characteristics, 
including age, sex, education, disability or co-morbidities including obesity, PVD, 
ischaemic heart disease, and diabetes mellitus. The likelihood of European 
population undergoing haemodialysis to have AVF in Dialysis Outcomes and 
Practice Patterns Study one (DOPPS-1) was found to be considerably high (Pisoni et 
al. 2002). 
AVFs are the preferred vascular access type for haemodialysis (National Kidney 
Foundation 2001). However, maintaining an autologous fistula has become more 
important over the last three decades due to diabetes, vascular disease and an ageing 
population (Chiulli et al. 2011). Compared with CVCs or AVGs, AVFs present 
fewer interventions, longer patency rates, low infections and overall lesser mortality 
rates. An autologous fistula is found to have a longer patency rate and, as such, its 
use on dialysis patients has been intensely advocated (Tonnessen and Money 2005). 
The cost of vascular access related care was found to be more than five-fold higher in 
patients with AVG compared to patients with a functioning AVF (Lee et al. 2002). 
The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study examined 
mortality based on access type in 616 haemodialysis patients for up to 3 years of 
follow-up. CVCs and AVGs were associated with approximately 50% and 26% 
increased mortality respectively, compared with AVFs (Astor et al. 2005). 
Furthermore, guidelines have encouraged the use of the patient’s own blood vessels 
for the construction of VA as AVG and CVC are made from prosthetic graft 
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material, which has a low patency rate and a high mortality rate (Pisoni et al. 2009; 
Tordoir et al. 2007). There are two conditions that a fistula must fulfil in order to be 
efficient for dialysis: a sufficiently large diameter for the process of cannulation and 
sufficient blood flow so that the dialysis circuit functions properly. As noted by 
Lomonte et al. (2005), expansion in diameter and increase in blood flow within the 
draining venous vessel happen immediately subsequent to the construction of the 
fistula and is maximal within a few weeks. Traditionally a period of six weeks has 
been allowed for maturation; however, some dialysis units have advocated the use of 
fistula within two weeks (Saran et al. 2004). VA complications represent the main 
factor that determines a rise in the morbidity among haemodialysis patients and, 
consequently, a rise in the healthcare expenses. According to the NICE Guidelines 
(2008), the National Health Service in the United Kingdom consumes 2% of its 
financial resources to renal replacement therapy.  
1.3 Success of Arteriovenous Fistula 
The blood flow rate, which a functional AVF is capable to uphold for the whole 
length of the dialysis treatment, with no recirculation is 350-400 ml/min. The 
complications most often associated with arteriovenous fistula are thrombosis, 
stenosis, aneurysm, ischaemia, and steal syndrome (Allon and Robbin 2002). As 
noted by Beathard et al. (2003), vessel obstruction during the initial three months 
following construction can lead to early fistula failure, which is an important factor 
affecting fistula prevalence. The rate of use of AVF on haemodialysis patients is also 
noted to be affected by the insufficient development of fistulae. As such, it is 
important to identify and intervene early in fistulae which are likely to fail. As noted 
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by Beathard et al. (2003), most fistulae that experience early failure exhibit access 
stenosis. This is a process, which unfolds gradually, ultimately resulting in complete 
occlusion, which causes access thrombosis (Asif et al. 2006).  
The HEMO (Haemodialysis) trial analysed the haemodialysis access types and their 
associated epidemiology; in addition, the project discussed preponderance of grafts, 
as well as the factors that negatively affected the construction of native fistulae for 
haemodialysis. Obesity was indicated as one such factor (Polkinghorne et al. 2003; 
Allon et al. 2000). According to the Dialysis Outcomes and Practice Patterns Study 
(DOPPS), the success rate of AVF construction was higher in younger, male patients 
with a normal BMI, who did not suffer from diabetes or peripheral vascular disease. 
However, Weyde et al. (2008) revealed that there was an 85% success rate in the 
construction of AVFs in obese patients, demonstrating that in the pre-dialysis 
examination the thick adipose tissues offered protection to the vessels in the lower 
arm from iatrogenic damage. The patency rate of AV grafts is approximately 49% at 
one year and 30% at two years (Pisoni et al. 2002) and in the case of dialysis patients 
relying on AV grafts, they have to be subjected to one or more operations annually in 
order to treat thrombosis and ensure proper functioning of the graft (Glanz 1991).  
1.4 Rationale and Aims of the Study 
1.4.1 Rationale of the Study 
Recently, elderly patients and diabetics have been able to undergo dialysis therapy, 
due to the expansion of the selection criteria. Consequently, an increase in co-
morbidity, such as atherosclerotic vascular disease, has been observed in patients 
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undergoing dialysis. A great number of such patients have poor vessels, which 
cannot support the creation of native AVF. What is more, the growing focus on 
patient suitability for dialysis therapy has determined that a higher blood flow rate is 
important as it can enhance the filtering of urea, which means that a larger number of 
patients can undergo dialysis without a considerable increase in the length of the 
treatment.  
To ensure that the dialysis therapy can be efficiently undertaken, all patients need a 
fully developed fistula that is appropriate for the process of cannulation. In order to 
achieve this, several stages have to be covered, namely, pre ESRD treatment by a 
kidney specialist and early referral to vascular surgeons for the construction, 
development, and cannulation of a fistula by dialysis specialists staff. Asif et al. 
(2005) indicated that the percentage of AVFs that fail to develop sufficiently for 
dialysis is 28-53%. The dialysis therapy is often postponed for up to half a year or 
more to allow extra time for the fistula to develop; if this does not happen, the AVF 
is considered a failure. Corpataux et al. (2002) stated that the development process of 
AVF is complicated and it is almost impossible to settle on the precise length of time 
it requires to complete. Research studies conducted on predictive markers of an 
adequate and operative fistula have failed to reach a consensus, due to the fact that 
they have focused on different aspects and have used different definitions of 
maturation, study design, clinical factors and patient sample. Thus, surgeons are 
confronted with the challenge of classifying the different risk factors as well as 
deciding on the parameters to use in order to evaluate the possibility of successful 
fistula development. Multiple studies (Zadeh et al. 2012; Jennings et al. 2011; Kheda 
et al. 2010; Dember et al. 2008; Trimarche et al. 2006; Rooijens et al. 2005; Obialo 
Chapter 1 
9 
 
et al. 2003; Feldman et al. 2003; Mendes et al. 2002; Huber et al. 2002; Robbin et al. 
2002)  have been conducted to determine the factors associated with AVF 
maturation, including patient demographics (age, gender, diabetes, PVD, 
hypertension, smoking, obesity), AVF characteristics (type and side of arm), blood 
markers (lipid profile, coagulation status, uraemic status) and vein diameter. A 
number of studies have observed association of increasing age with early fistula 
failure (Lok et al. 2005; Golledge et al. 1999; Lazarides et al. 1996). Results of 
previous studies have suggested that rate of AVF maturation is higher in male than in 
female gender (Ernandez et al. 2005; Miller et al. 2003) and patients those already 
commenced dialysis before AVF creation (Zeebregts et al. 2002). History of diabetes 
(Zeebregts et al 2005; Ernandez et al. 2005) and PVD (Chan et al. 2008) have found 
to be associated with failure of AVF maturation. Multiple studies had found that 
hypertension (Kaygin et al. 2012; Palmes et al. 2011) and smoking (Ozdemir et al. 
2005; Wetzig et al. 1985) are associated with failure of AVF maturation. Chan et al. 
(2008) observed a relation between insufficient fistula development and a high BMI 
(>30 kg/m2). An observational study carried out in Finland concluded that 
coagulation abnormalities such as short thrombin time and high fibrinogen associated 
with AVF maturation failure (Salmela et al. 2013). Hyperlipidaemia (Gagliardi et al. 
2011) and hyperuricaemia (Bhan et al. 2007) poorly predict AVF maturation. 
Researchers have recommended a number of pre-surgical principles relying on non-
invasive (physical examination includes assessment of the distal arterial pulse and 
course of the superficial upper and forearm veins; duplex ultrasound imaging) and 
invasive (venographic assessment of veins) imaging procedures; however, factors 
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such as cost, time and complexity, hinder the widespread application of these 
principles.  
As noted by Tonnessen and Money (2005), a collaborative medical effort has been 
made to enable more patients to undergo dialysis with a fistula. One of the essential 
factors that determine the success rate of fistula development is the diameter of the 
blood vessels. According to Malovrh (1998), if the pre-surgery vessel diameter was 
smaller than 1.5mm, only a 36% success rate was recorded three months after the 
construction of fistulae for dialysis; this percentage increased to 83% when the vessel 
diameter was greater than 1.5 mm. In addition, the rate of blood flow in the fistula 
was greater in the latter case, in contrast to the former one. Wong et al. (1996) 
corroborated these results, demonstrating that in cases where the diameter of the vein 
or artery was smaller than 1.5 mm, the fistula never reached complete maturation. In 
contrast, it was impossible to predict the success rate of fistula development when 
the diameter of the vessels exceeded 1.5 mm. Allon et al. (2001) revealed that a 
direct association between the vessel diameter and the success rate of fistula 
development could not be established when the diameter requirements for artery and 
vein of 2 mm and 2.5 mm, respectively, were fulfilled. No significant differences 
were observed during the pre-surgical mapping between diabetes and non-diabetics 
with regard to the diameter of the blood vessels. Nonetheless, Sedlacek et al. (2001) 
discovered that diabetics are more prone to developing vascular calcifications (64%) 
than non-diabetics (35%). Both the diameter of blood vessels and the rate of blood 
flow exhibited a rapid increase immediately after fistula creation, reaching a high 
point at six weeks (Lomonte et al. 2005). 
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Vascular surgeons are required to construct mature AVFs to ensure their successful 
maturation and proper functioning to withstand dialysis. AVFs are cheaper, last 
longer, have a lower infection rate, decrease morbidity, and mortality, and reduce the 
chances of repeat intervention (Allon 2007; Polkinghorne et al. 2004). The ultimate 
purpose is to create a functional, long-term access for dialysis, the creation of AVF 
being just a step towards achieving that purpose. The pre surgical assessments of the 
most favourable location for fistula creation as well as patient suitability are highly 
important, but the methods needed to carry out this assessment have not been well 
documented. To enhance the use of fistula it is necessary to have a comprehensive 
and clear understanding of the factors that affect the success rate of the procedure, 
and provide effective solutions. One of the main obstacles is the high incidence of 
early fistula failure caused by early thrombosis or insufficient development and 
maturation, which hinder its use for dialysis. It is noted that when considering the 
maturation of AVF, many areas of controversy and uncertainty persist.  
1.4.2 Research Question 
What are the important blood markers and patient factors that can be helpful in 
determining the success of fistula maturation before surgery? 
1.4.3 Aims of the Study 
The study aims to develop a simple, clinically practical, and user-friendly prognostic 
model to predict which arteriovenous fistula are likely to mature. 
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1.4.4 Primary Objective 
The objective was to retrospectively establish the potential influence of blood 
markers and patients factors (risk factors, kidney function profile, coagulation 
profile, lipid profile, BMI, BP and vein diameter) on the maturation of 
arteriovenous fistula in patients who had previously undergone vascular 
access surgery in the Royal Infirmary of Edinburgh. 
1.4.5 Secondary Objective 
The objective was to prospectively explore the influence of blood markers 
and patient’s factors on the maturation of arteriovenous fistula in patients 
who had recently undergone vascular access surgery in the Royal Infirmary 
of Edinburgh and to validate the prognostic model for the prediction of 
arteriovenous fistula formation. 
1.5 Outline of the Thesis 
1.5.1 Chapter 2 (Literature Review)  
This chapter provides up-to-date evidence on aetiology, predisposing factors, clinical 
features and diagnosis of CKD. In addition, the current management of stage five 
CKD known as ESRD is explained. Furthermore, type of vascular access for 
haemodialysis and different configuration of AVF is provided. Finally, details of 
patients’ factors, blood markers and maturation of AVF is discussed. 
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1.5.2 Chapter 3 (Methods) 
This chapter provides information about the retrospective and prospective part of the 
study. In addition information about the research procedures such as recruitment of 
participants, inclusion and exclusion criteria and details of blood markers are 
provided. Finally, data collection and statistical method adopted is presented. 
1.5.3 Chapter 4 (Results) 
In this chapter, results are presented for both development and validation phases of 
the study. Data analysis on patient’s demographics, univariate and multivariate 
analysis is reported. Statistical analysis to validate the developed model is also 
provided. Finally, external validation of the developed model is presented.  
1.5.4 Chapter 5 (Discussion) 
This chapter discusses the findings related to primary and secondary objectives in 
relation to published work and practice.  
1.5.5 Chapter 6 (Conclusion)  
This last chapter summarises the main findings emerging from this thesis and 
highlights the potential role of the developed model in the prediction of maturation of 
AVF before surgery. Also the strengths, limitations of the study and clinical 
implications is discussed.  
Chapter 2 
14 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
Chapter 2 
15 
 
2. 1 Chronic Kidney Disease 
2.1.1 Introduction 
Kidney disease is an important condition with considerable public health 
implications, which are only multiplied by rising rates of diabetes mellitus, obesity, 
hypertension, and the ageing population (Levey et al. 2007). Chronic renal failure is 
a condition, which develops gradually and has various causes contributing to the 
deterioration of the kidneys, and can progress to ESRD. The definition of chronic 
kidney disease is based on the presence of kidney damage (albuminuria) or decreased 
kidney function (glomerular filtration rate < 60 mL/min per 1·73m²) for 3 months or 
more, irrespective of clinical diagnosis (Stevens and Levey 2009; Vassalotti et al. 
2007; NKF-KDOQIb 2006). Yu (2003) stated that the rate of decline, termed 
progression, is characterised by a great deal of variation. It affects a significant 
proportion of the general population and, when progressive, has an increasing impact 
on morbidity and mortality. In the United Kingdom, renal disease secondary to 
diabetes is the most frequently made primary renal diagnosis (Farrington et al. 2006). 
Studies have shown that diabetes is the main cause for the preponderance of CKD in 
18% to 30% of cases (Dreyer et al. 2009; New et al. 2007; Middleton et al. 2006). In 
addition, CKD is considered an independent risk factor for cardiac disease as well as 
for the evolution of established renal failure. According to Foley et al. (2005), 
atherosclerotic vascular disease increased the likelihood of developing chronic 
kidney disease by 1.5, whereas congestive cardiac failure increased the likelihood of 
developing CKD almost twofold. Once a patient reaches ESRD, his/her quality of 
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life becomes invariably poor and life expectancy considerably shortened (Centres for 
Disease Control and Prevention 2010).  
ESRD is a serious condition affecting a large part of the population and, as such, it 
represents a considerable financial burden for the health sector. Total Medicare 
ESRD expenditures in the USA was 29 billion dollars in 2009 (USRDS 2011). 
Programme budgeting analysis by the department of health estimated in England, the 
total NHS expenditure on kidney care, including CKD, at £1.71 billion in 2009–10 
(Department of Health 2012). The condition is made worse by the fact that a 
proportion of patients (30%) are referred late to the kidney specialist, increasing the 
risk of mortality and morbidity (NICE Guidelines 2008). Worldwide the prevalence 
and incidence of ESRD is growing continuously. CKD places a considerable demand 
on medical resources around the world. Between 2008 and 2009, the number of 
people in England over 18 years of age who were diagnosed with chronic kidney 
disease, stage 3-5, was 1.7 million, which represents 4.1% of the adult population 
(NHS Kidney Care 2010). According to the National Institute of Diabetes, Digestive, 
and Kidney Diseases (2003), diabetic nephropathy represents the major cause for the 
growing preponderance of ESRD. Among the other factors contributing to the 
aggravation of ESRD are hypertension, glomerulonephritis, polycystic kidney 
disease, smoking, and obesity (NHS Kidney Care 2010). 
The principal feature of chronic kidney failure is the persistently abnormal 
glomerular filtration rate, which is associated with a sudden and constant increase in 
the amount of urea and creatinine. This can lead to serious complications, such as 
volume overload, hyperkalaemia, and metabolic acidosis (Scottish Intercollegiate 
Chapter 2 
17 
 
Guidelines Network 2008). Thus, it can be said that chronic kidney failure is a 
gradually developing disease triggered by a number of factors, resulting in varying 
severity of kidney damage. 
Chronic kidney failure features are common to progressive disease and can be 
observed histologically as interstitial fibrosis, glomerulosclerosis, and destruction of 
kidney cells. Three main causes of kidney failure have been identified: a decline in 
renal blood flow, determined in 40-70% of cases by pre-renal factors (Kaufman et al. 
1991; Hou et al. 1983), damage to the parenchymal kidney tissue, brought about in 
10-50% of cases by internal kidney problems, and obstructed urine flow, determined 
in 10% of cases by post-renal factors (Liano and Pascual 1996). 
2.1.2 Aetiology and Pathological Changes 
2.1.2.1 Pre-renal Causes 
Principal pre-renal causes of renal failure are hypovolaemia, renal hypoperfusion, 
hypotension and oedematous state such as cardiac failure (Table 1). The renal blood 
flow and glomerular filtration rate is maintained across different mean arterial 
pressure due to modifications in pre-glomerular and post-glomerular arteriolar 
resistance. If the arterial pressure drops below 70 mmHg, there is a decline in the 
GFR and the renal auto-regulation is affected. As explained by Madala (2007), the 
latter depends on a number of elements, including pre glomerular arteriolar 
vasodilatation, facilitated by nitric oxide and prostaglandins, and post glomerular 
arteriolar vasoconstriction, facilitated by angiotensin II peptide. There are some 
drugs, which can inhibit the mediators, such as selective cyclooxygenase 2 inhibitors 
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or non-steroidal anti-inflammatory drugs, as well as angiotensin converting enzyme 
blockers or angiotensin II receptor inhibitors. In certain cases, such inhibitors can 
determine pre-renal acute renal failure (Wolf and Ritz 2005). The patients that can be 
severely affected by this condition are those with ischaemic heart disease, pre-
existing CKD and renal hypo perfusion, which is brought about by volume depletion, 
low blood pressure, or stenosis of the renal artery (Levey et al. 2003).  
Table 1. Pre-renal Causes of Renal Failure (Waikar et al. 2008; Hilton 2006) 
Hypovolaemia 
• Severe Blood Loss 
• Severe Dehydration (vomiting, diarrhoea, inappropriate diuresis, burns) 
Renal hypo perfusion 
• Non-steroidal anti-inflammatory drugs 
• Angiotensin converting enzyme inhibitors 
• Abdominal aortic aneurysm 
• Renal artery stenosis/occlusion 
• Hepatorenal syndrome 
Hypotension 
• Cardiogenic shock 
• Severe Infection (Sepsis), Anaphylaxis 
Oedematous states 
• Cardiac failure 
• Pancreatitis, Liver cirrhosis 
• Nephrotic syndrome 
Pre-renal kidney failure occurs when a sudden reduction in blood flow to the kidney (renal 
hypoperfusion) causes a loss of kidney function. In pre-renal kidney failure, there are no 
intrinsic abnormalities with the kidney itself.  
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2.1.2.2 Intrinsic Renal Causes 
Diseases, which affect glomeruli, renal tubules, interstitium, or vasculature, can 
trigger intrinsic renal failure (Table 2). Its morphological appearance is characterised 
by fibrosis and destruction of normal renal cells generally as a result of apoptosis and 
invasion of monocytes and/or macrophages, which are the outcome of the interaction 
between vaso-active substances, such as growth factors and cytokines (Singh et al. 
2010). However, the main determinant of intrinsic acute renal failure is acute tubular 
necrosis, generated by the same pathophysiological processes, which cause pre-renal 
hypo perfusion. Among the various factors, which can lead to the development of 
intrinsic acute renal failure, the most frequently encountered is sepsis, which 
develops as a result of hospital acquired infection and can be associated with the 
multiple organ dysfunctions (Mehta et al. 2004). Post-surgery acute tubular necrosis 
is a cause of hospital acquired acute kidney failure, which develops in 25% of cases 
and is generally determined by pre-renal factors (Carmichael and Carmichael 2003). 
Acute radio contrast nephropathy is another condition, which triggers the 
development of hospital acquired acute renal failure (Lameire et al. 2005). 
Clinically, radio contrast-induced nephropathy is defined as a sudden decline in renal 
function after radio contrast administration during image-guided cardiology and 
radiology procedures (Weisbord and Palevsky 2005). Studies showed evidence of 
acute tubular necrosis secondary to radio contrast administration (Detrenis et al. 
2005; Persson et al. 2005). Acute tubular necrosis is caused by renal vasoconstriction 
resulting in medullary hypoxia and due to direct result of the cytotoxic effects of the 
contrast agents (Heyman et al, 2005; Pflueger et al. 2000). 
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Table 2. Causes of Intrinsic Renal Failure (Jha et al. 2013; Hilton 2006) 
Glomerular Disease 
• Inflammatory: post-infectious glomerulonephritis, henoch schonlein purpura, 
systemic lupus erythematosus, glomerulonephritis,  
• Thrombotic: disseminated intravascular coagulopathy, thrombotic microangiopathy 
Interstitial Nephritis 
• Drug induced: non-steroidal anti-inflammatory drugs (NSAID), antibiotics 
• Infiltrative lymphoma 
• Sarcoidosis  
• Tuberculosis 
• HIV associated nephropathy 
• Hepatitis B and C viruses 
• Pyelonephritis 
Vascular 
• Vasculitis 
• Polyarteritis Nodosa 
• Thrombotic Microangiopathy 
• Cholesterol Emboli 
• Renal Artery or Vein thrombosis 
Tubular Injury 
• Prolonged renal hypoperfusion 
• Drugs (such as aminoglycosides), pigments (such as myoglobin), heavy metals 
(such as cisplatinum) 
• Hypercalcaemia 
• Crystals: urate, oxalate 
Intrinsic acute renal failure may be caused by diseases affecting the glomeruli, renal 
tubules, interstitium, or vasculature.   
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2.1.2.3 Post-renal Causes 
Obstructive nephropathy is a rare form of kidney failure but, nonetheless, it needs to 
be identified to ensure an efficient treatment, which can improve kidney function or 
even restore it entirely (Table 3). Patients who are prone to develop this condition are 
men of an advanced age with prostate disease, as well as individuals with abdominal 
malignancy, especially the pelvis (Haynes and Winearls 2010). Vesico ureteric reflex 
accounts for renal failure in young adults. Vesico ureteric junction obstruction is 
more common in males than in females and affects the left ureter more than on the 
right (Lopez-Nova et al. 2010). Upon elimination of the obstruction, patients may 
experience diuresis, and they have to be closely monitored and provided with 
sufficient fluids to prevent volume depletion. 
Table 3. Causes of Post Renal Failure (Lopez-Nova et al. 2010) 
Intrinsic 
• Ureteric (intra-luminal) stone 
• Blood clots in the ureter or urethra 
• Papillary necrosis 
• Intra-mural urethral stricture 
• Bladder tumour 
Extrinsic 
• Pelvic malignancy (such as Prostatic hyperplasia, cervix) 
• Retroperitoneal fibrosis 
Post renal failure is sometimes referred to as obstructive renal failure, since it is often caused 
by something blocking elimination of urine produced by the kidneys.  
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2.1.3 Predisposing Factors 
There are multiple factors that may increase the risk of developing chronic kidney 
disease include 
2.1.3.1 Smoking 
Studies have revealed that smoking is a factor contributing to advancement in 
diabetic nephropathy (Chuahirun and Wesson 2002), primary renal disease (Orth et 
al. 1998), and severe hypertension (Regalado et al. 2000). In addition, it is a risk 
factor for the presence of an excess of serum proteins in the urine, irrespective of the 
existence of diabetes and hypertension, and can contribute to the advancement of the 
disease (Halimi et al. 2000). Orth (2000) also discovered that smokers suffering from 
diabetes, whether or not they are dependent on insulin, are more prone to develop 
kidney disease with an increased rate of development and progression towards end 
stage kidney failure. Smokers that have a high blood pressure can develop 
albuminuria (Horner et al. 1996; Mimran et al. 1994) and may suffer deterioration of 
kidney function (Regalado et al. 2000). Ejerblad et al. (2004) conducted a 
nationwide-population based study in Sweden and discovered that current or former 
smokers are likely to develop chronic kidney failure. Their results contraindicated 
the results of earlier studies (Perry et al. 1995; Nuyts et al. 1995) which did not find 
evidence regarding an association between renal disease and smoking. 
The odds ratio was directly proportional to how often and for how long patients 
smoked. To calculate a ‘pack year’, the number of cigarette packs smoked daily was 
multiplied by the number of years that a person has smoked for. The likelihood of 
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developing chronic kidney disease increased exponentially if a person accumulated 
over 15 pack years (between 16 to 30 pack years equalled 1.32; more than 30 pack 
years equalled 1.52) (Ejerblad et al. 2004). 
2.1.3.2 Asians and African American Descent 
There is a higher prevalence of diabetes mellitus in south Asian populations (Ali et 
al. 2013; Stewart et al. 2006). Li et al. (2004) concluded that the ethnical difference 
in the incidence of CKD might partly be due to a higher prevalence of primary causal 
diseases of CKD such as diabetes. Established renal failure as a complication of 
diabetes is 10 times greater in South Asians than in Caucasians (Jain et al. 2008). A 
recent study involving 1810 patients was conducted in one of the most ethnically 
diverse city (Birmingham) in the UK where the incidence of renal replacement 
therapy for south Asian and Black groups was reported to be, respectively, 1.88 and 
2.16 times greater than for White patients (Lambie et al. 2008).  
A study was carried out by Klag et al. (1997) on a group of men with untreated 
hypertension but without history of diabetes, who had registered in the Multiple Risk 
Factor Intervention Trial (MRFIT). The study results revealed that black individuals 
were more prone to develop end-stage renal disease, without the influence of other 
causes. Another study (Feehally 2005) revealed that African Americans reach end-
stage kidney disease at younger ages than white people (mean age 57 versus 63 years 
respectively). The examination of the basic features of the modification of diet in 
renal disease carried out by Hunsicker et al. (1997) discovered an association 
between black ancestry and a more rapid GFR decrease. This accelerated 
advancement of disease in people of black descent has been attributed to two main 
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factors; the social environment and genetic inheritance. Merkin et al. (2005) 
conducted a study on the connection between these two factors and found that white 
males and black females living in a disadvantaged area or low socioeconomic status 
were more likely to have a rapid progression of chronic kidney disease than if they 
lived in a more affluent area. In contrast, the analysis of white females and black 
males did not reveal any relation between the social environment and predisposition 
towards chronic kidney disease. However, this study had a number of drawbacks, 
since it provided insufficient data on sampling methods and attrition proportion. 
2.1.3.3 Diabetes Mellitus 
According to Bakris (2011) and Van Buren and Toto (2011), the incidence rate of 
diabetic nephropathy has experienced a significant growth in recent years and it is 
currently the main determinant of ESRD on a global scale. In 40% of cases, it also 
has an influence on the development of CKD among adults suffering from type 2 
diabetes. This co-morbidity can lead to disability, causing a strain on the health care 
budget, with annual estimates of $23 billion in the United States (Go et al. 2004). 
The 2009 annual report published by the USRDS indicated the preponderance of 
each stage of CKD associated with type 2 diabetes; stages one to five had the 
following prevalence percentages: 8.9%, 12.8%, 19.4% and 2.7% for the latter two 
combined stage four and five respectively. Individuals suffering from type 1 diabetes 
have a 25% chance of developing chronic kidney disease (Alleyn et al. 2010; Centre 
for Disease Control and Prevention 2007). By analysing a series of factors, such as 
age, family background, earnings, hypertension, serum cholesterol, and ischaemic 
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heart disease, Brancati et al. (1997) observed that men suffering from diabetes have a 
greater predisposition towards ESRD, independent of any diabetic complications. 
The development of diabetic CKD has a number of causes. As explained by Pyram et 
al. (2012), in the early stages of development, adaptive hyper-filtration generates 
longstanding functional deterioration of the nephrons. Type 1 and 2 diabetes 
intervention trials have pointed towards the influence of glycaemia in this process. 
Analyses showed that improved glycaemic levels determined a decrease in the 
advancement rate of albuminuria (UKPDS 1998). 
2.1.3.4 Male Gender 
A number of researchers (Zhang and Rothenbacher 2008; Coggins et al. 1998; 
Jungers et al. 1995; Schieppati et al. 1993; Gabow et al. 1992; Rekola, et al. 1991) 
have argued that kidney diseases, unaccompanied by diabetes, are more likely to 
develop at an accelerated pace in men. Nonetheless, these studies do not follow a 
similar design and methodology. What is more, they have failed to indicate that the 
gender factor is not associated with other factors, such as proteinuria, hypertension, 
and smoking history. Several studies (Seliger et al. 2001; Zduneket al. 2001; Miller 
et al. 1999a) have focused on the different mechanisms involved, as well as the 
increased reaction to angiotensin II in men and the capability of oestradiol to 
overturn transforming growth factor-beta1 (TGF β1) mediated fibrogenesis. 
According to Negulescu et al. (2002), this phenomenon contributes to the positive 
influence of the female gender on the progression of CKD. Hyperuricaemia has also 
been associated with renal dysfunction and CKD. Li et al. (2012) suggested that the 
association of hyperuricaemia with CKD is significantly stronger in males than that 
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in females. A potential explanation for this relationship of hyperuricaemia with the 
prevalence of CKD may lie in the fact that in females oestrogen increases the 
excretion of uric acid in the urine, thus reducing the concentration of uric acid in 
blood plasma (Mok et al. 2012; Johnson and Rideous 2004), and the possible 
mechanism for the gender difference in the hyperuricaemia with the progression of 
CKD. 
2.1.3.5 Hyperlipidaemia 
Among the implications of chronic kidney failure is an increase in the levels of 
triglyceride, oxidized low-density lipoprotein, and depleted Apo lipoprotein. Vaziri 
et al. (2001) highlighted the fact that kidney failure can contribute to the 
development of hyperlipidaemia by decreasing the activity of the enzyme lecithin, 
namely, the cholesterol acyltransferase in the liver and its action in the plasma. 
The experiments conducted by Joles et al. (2000) have revealed that both 
hypercholesterolaemia and hypertriglyceridaemia have the ability to cause 
proteinuria and tubulointerstitial injury; the development rate can be decreased by 
treatments which target the levels of lipids (Oda and Keane 1997). Such conditions 
can cause damage by overproduction of the reactive oxygen species including 
superoxide anion (O-2), hydroxyl radicals (HO-), lipid radicals (oxLDL) peroxynitrite 
(ON-OO-) and nitric oxide (NO-), modulation of mesangial growth and proliferation, 
suppressing the production of nitric oxide, enabling infiltration of monocytes and 
activating growth factor and cytokine release (Park and Oh 2011; Stapleton et al. 
2010; Stevenson et al. 2001). 
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In humans, a raised level of serum lipid is associated with the occurrence of kidney 
insufficiency and advancement of existing kidney disease (Hunsicker et al. 1997). 
Nevertheless, it is still uncertain whether a clear causal relationship exists, 
particularly as the element(s) of the dyslipidaemic milieu that control the 
advancement of the disease are largely unknown (Muntner et al. 2000). A number of 
potential contestants have been proposed, including increase in the levels of 
cholesterol, low and high density lipoprotein, high levels of triglyceride, and Apo 
lipoprotein B consisting of lipoproteins  (Samuelsson et al. 1998). 
2.1.3.6 Recreational Drug Use 
Perneger et al. (2001) and Norris et al. (2001) have indicated that there is an 
association between the use of heroin and other opiates as well as of cocaine, and the 
likelihood of developing ESRD. Cocaine has the potential to aggravate hypertensive 
nephrosclerosis through development of renal ischemia. It has not yet been 
determined if there is a causal connection between heroin and other opiates and the 
predisposition towards the disease or if they are stand-in markers for other factors. 
2.2 Clinical Manifestations 
Chronic kidney disease is usually silent. According to Haynes and Winearls (2010), 
chronic kidney disease only reveals symptoms later on, typically when end stage 
kidney disease is forthcoming. Although every patient may experience these 
symptoms in various ways, the section below covers the most widespread chronic 
renal failure symptoms. 
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• Poor appetite 
• Vomiting 
• Bone pain 
• Headache 
• Insomnia 
• Itching 
• Dry skin 
• Malaise 
• Fatigue with light activity 
• Muscle cramps 
• High urine output or no urine output 
• Recurrent urinary tract infections 
• Urinary incontinence 
• Pale skin 
• Bad breath 
• Hearing deficit 
• Detectable abdominal mass 
• Tissue swelling 
• Irritability 
• Poor muscle tone 
• Change in mental alertness 
• Metallic taste in mouth 
If the kidney function declines to stage 4 or 5 then various other problems may 
develop such as anaemia and an imbalance of calcium, phosphate and other 
chemicals in the bloodstream. These can cause various symptoms, such as tiredness 
due to anaemia, and bone thinning or fractures due to calcium and phosphate 
imbalance. End-stage renal failure (stage 5) is eventually fatal unless treated. 
2.3 Diagnosis of Kidney Failure 
Aetiology and laboratory test results are the conventional foundations for 
determining the presence of CKD. Patient’s history, a physical examination, and 
pathology test results of a particular individual are helpful in providing a differential 
diagnosis of the disease (Table 4). 
Tomson and Bailey (2011) and Haynes and Winearls (2010) provided a list of the 
diagnostics used in identifying renal failure (this is after a physical examination, 
including blood pressure measurement, is completed along with an abdominal 
examination to identify a distended bladder or enlarged kidneys and a full medical 
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history is provided). The diagnostics are: 1) urine analysis which looks for 
proteinuria, albuminuria and haematuria; 2) blood tests to define electrolyte levels, 
kidney function and blood cell counts; 3) a renal ultrasound used to examine the 
kidneys and to identify kidney stones, cysts, masses or other irregularities; 4) a renal 
biopsy which is necessary to identify whether there are any abnormal or cancer cells; 
5) immunological exams which are used to determine whether a patient is suffering 
from vasculitis, myeloma or primary amyloid (these tests are more useful in dealing 
with AKI and rarely find the origins of chronic kidney disease); 6) a CT scan which 
is able to present images of the kidneys. 
Table 4. Diagnosis of Chronic Kidney Disease (K/DOQI. 2002) 
 
Diagnosis 
Review of systems  
Symptoms during 
urination 
Usually suggest disorders of the urinary tract, such as infection, 
obstruction, or stones 
Recent infections May suggest post infectious glomerulonephritis or HIV-
associated nephropathy 
Skin rash or arthritis Suggests autoimmune disease, such as systemic lupus 
erythematosus or cryoglobulinemia. 
Risk factors for parentally 
transmitted disease 
May suggest HIV, hepatitis B, or hepatitis C and associated 
kidney diseases 
Chronic diseases  
Heart failure, cirrhosis, or 
gastrointestinal fluid 
losses 
Usually suggest reduced kidney perfusion (prerenal factors). 
Diabetes† As a cause of chronic kidney disease: Diabetic kidney disease 
usually follows a typical clinical course after onset, first with 
micro albuminuria, followed by clinical proteinuria, 
hypertension, and declining GFR* 
Hypertension† As a cause of CKD: Hypertensive nephrosclerosis is usually 
characterized by severely elevated blood pressure readings over 
a long period, with associated end-organ damage in addition to 
kidney disease. Recent worsening of hypertension, in 
association with findings of diffuse atherosclerosis, suggests 
renal artery disease due to atherosclerosis.  
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 Diagnosis 
Medical history  
Findings from previous 
routine examinations 
May reveal a history of hypertension or proteinuria during 
childhood; during pregnancy; or on examinations for school, 
military service, or insurance 
Previous urologic 
evaluations 
Details may disclose radiologic abnormalities associated with 
kidney disease 
Predominant male 
susceptibility  
Suggests a sex-linked recessive disease, such as the Alport 
syndrome. 
Less frequent than every 
generation  
Suggests an autosomal recessive disease, such as medullary 
cystic kidney disease or autosomal recessive polycystic kidney 
disease 
* GFR glomerular filtration rate, † extremely common in elderly patients and often 
nonspecific. CKD is diagnosed through patient’s medical history, risk factors and clinical 
presentation. Specific diseases are associated with specific risk factors and are manifested by 
specific clinical presentations. 
Chronic kidney disease reveals symptoms only in the late phases; as such, it is 
generally diagnosed by analysing the serum creatinine or testing of protein in the 
urine. A significant proportion of CKD could not be recognized, as serum creatinine 
cannot identify increasing kidney failure in women or old people due to low 
sensitivity (Johnson 2005a; Drey et al. 2003). Guidelines have been introduced in 
clinical practice in Great Britain based on the four elements of the Modification of 
Diet in Renal Disease (MDRD) equation, a simple, rapid, and reliable means of 
assessing kidney function and albumin creatinine ratio (NICE Guideline 2008; 
Johnson 2005b). Furthermore, it is hoped that the use of the estimated Glomerular 
Filtration Rate (eGFR), as well as the preservation of patient’s records with CKD 
stages 3 to 5 (Quality and Outcomes Framework 2003), will lead to a more efficient 
diagnosis of CKD and improvement of treatment methods. The categorization of 
chronic kidney disease employed by the National Service Framework (NSF) is the 
five-stage categorization proposed by NKF-KDOQIb (2006). According to this, the 
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late stages of CKD can be determined by using the eGFR measurements, whilst 
stages 1 and 2 are identified by the constant presence of proteinuria, albuminuria or 
structural abnormalities or haematuria. As shown in Table 5, NICE Guidelines 
(2008) adjusted this categorization by creating two subcategories of stage 3, stage 3a 
and stage 3b. An eGFR level of 60-89 ml/min/1.73m2 which is not associated with 
any of the above mentioned criteria for the different stages of CKD should be taken 
as an indication that the patient does not suffer from CKD. 
Table 5. Stages of Chronic Kidney Disease (NICE Guideline 2008) 
Stage eGFR(ml/min/1.73 m2) Description 
1 ≥ 90 Normal or increased GFR, with other evidence of 
kidney damage 
2 60-89 Slight decrease in GFR, with other evidence of 
kidney damage 
3A 45-59 Moderate decrease in GFR, with or without other 
evidence of kidney damage 3B 30-44 
4 15-29 Severe decrease in GFR, with or without other 
evidence of kidney damage 
5 < 15 Established renal failure 
Glomerular filtration rate (GFR) is the best measure of kidney function. The GFR is the 
number used to classify stage of kidney disease. There are five stages of CKD however 
kidney function is normal in Stage 1, and minimally reduced in Stage 2. 
2.4 Management of Chronic Kidney Disease 
The objective of the treatment of CKD is to take into consideration patient 
requirements and ensure a positive result. There are currently two treatment options 
for individuals who suffer from CKD, medical management or Renal Replacement 
Therapy (RRT) (Figure 2). UK Renal Association guidelines (2011) recommend that 
all patients with stage 5 CKD, who are capable of withstanding such an extensive 
surgical procedure and can adapt to chronic immunosuppression, should have a 
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kidney transplant. Ideally, the kidney should be taken from a living donor, if a 
suitable one exists. However, the waiting lists for living donor transplant are usually 
large, reaching 7,235 in the United Kingdom, a number that increases annually by 
almost 8% (NICE Guideline 2008). The real number of patients requiring a kidney is 
believed to be even higher, but clinicians do not record all of them, as the probability 
of them receiving a kidney is rather low.  
Figure 2. Management of Chronic Kidney Disease 
 
The stepwise management plan of chronic kidney disease. Stage 1-4 CKD can be treated by 
medical management. In stage 5 (End Stage Kidney Disease) RRT is indicated. The decision 
whether to have dialysis or a kidney transplant depends on multiple factors such as 
hemodynamic stability and availability of donors. There are two types of dialysis – 
haemodialysis and peritoneal dialysis. In order to obtain haemodialysis, patients require a 
vascular access. 
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After kidney transplant, haemodialysis and peritoneal dialysis are the best active 
treatment options for people with ESRD (Dhoul et al. 2011). Korevaar et al. (2003) 
conducted a randomised controlled trial examining the differences in treatment 
outcome of haemodialysis and peritoneal dialysis and discovered that there were no 
considerable distinctions, both methods exhibiting a two year quality adjusted life or 
five-year mortality. Peritoneal dialysis is a treatment, which patients can carry out by 
themselves at home. In contrast, haemodialysis treatment generally requires patients 
to go to a medical centre, normally three times a week. Although a small proportion 
of patients undertake home haemodialysis. 
2.4.1 Medical Management  
The goal of treatment for chronic kidney disease is to treat the underlying cause, 
control signs and symptoms, reduce complications, and slow further damage to the 
kidneys (Haynes and Winearls 2010). One of the most important parts of treatment is 
to control the disease that is causing kidney damage such as diabetes or hypertension. 
The main focus of CKD management includes 
 Life style modification 
 Lowering blood pressure 
 Tight glycaemic control 
 Reducing proteinuria 
 Lowering blood cholesterol 
 Management of anaemia 
 Management of mineral and bone disorders 
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2.4.2 Renal Replacement Therapy (RRT) 
2.4.2.1 Introduction 
There are a number of factors, which have to be taken into account when deciding 
the usage of RRT in patients suffering from ESRD, such as evaluation of electrolyte 
and acid-base balance, intravascular volume, uraemia, dietary needs, haemodynamic 
status, urine output, and the development of the disease in each individual case. The 
benefits of RRT have to be compared with the possible hazards of surgical 
intervention, such as bleeding caused by anticoagulants, as well as all types of 
complications that accompany the central venous access. Pannu et al. (2008) have 
argued that, in the case of seriously ill patients, if they have developed metabolic 
acidosis, hypervolemia, and hyperkalaemia, which are unresponsive to any type of 
treatment, RRT is the only viable solution. Despite the fact that, theoretically, there 
are advantages to commencing RRT early on, there is insufficient information about 
when is the right time for patients suffering from acute renal failure to begin dialysis 
(Liu et al. 2006). John et al. (2004) and Drey et al. (2003) have also drawn attention 
to the fact that many types of chronic kidney disease are still unknown, because the 
serum creatinine fails to identify decreasing kidney function, especially in women 
and old individuals. According to the Quality and Outcomes Framework (2003), the 
diagnosis of chronic kidney disease and improvement of treatments will be mediated 
by the introduction of eGFR reporting, as well as by the preservation of patient 
records required of all UK general practitioners. 
As noted by Levin et al. (2008), many patients suffering from chronic kidney disease 
die before they reach ESRD. Nevertheless, the stabilizing prevalence rate of RRT 
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cannot be explained by any prognostic for growing mortality among patients with 
CKD (USRDS 2008). Gallego et al. (2003) proposed that the limited use of RRT as a 
result of patients being referred to kidney specialists late or not at all can be 
considered an additional cause for the stagnation in prevalence. This hypothesis is 
not supported by the statistics, which have revealed that the prevalence rate among 
patients of advanced age, who have an increased likelihood of being affected, has 
exhibited a constant rise. The growing proportion of individuals suffering from 
chronic kidney disease has considerable repercussions for both kidney specialists and 
primary care, from a resource point of view. The existing United Kingdom 
guidelines for CKD in adults suggest that every individual with stage 4 CKD should 
have a discussion with a kidney specialist (Chronic kidney disease in adults: UK 
guidelines 2006). In reality, it may not be possible or even necessary for all patients 
to have these consultations. As a result, the creation of a risk assessment predictive 
model is warranted, in order to enable doctors to decide which cases are most urgent 
and arrange consultations with nephrologists for them. 
2.4.2.2 Function and Types of RRT 
Kidney disease secondary to diabetes is the commonest single cause of ESRD and 
accounts for 24% of incident diagnoses of patients starting RRT in the UK (Byrne et 
al. 2010). Variations in RRT incidence may reflect the quality of chronic disease 
management in diabetes and high blood pressure (Udayaraj et al. 2010; Kramer et al. 
2009). 
The dialysis-based treatment of ESRD patients is aimed towards preserving fluid and 
electrolyte, acid-base and solute homeostasis, safeguarding the kidney from 
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additional damage, stimulating restoration of kidney function and enabling the 
activity of other support measures, such as nutrition. When making a decision related 
to dialysis treatment, it should be taken into account that different methods of 
dialysis have different operative mechanisms through which they provide kidney 
support. One such example is the fact that dialysis is largely viewed as a method to 
remove solute and fluids, as these are the main options utilized for ESRD patients. 
The period 1997-2006 witnessed a substantial increase in the survival rate of patients 
who underwent dialysis or kidney transplant. Kramer et al. (2009) argued that, in 
addition to the technical advancements in renal replacement therapy, the growing 
public awareness of the necessity of identifying and treating chronic kidney disease 
at an early stage meant that patients beginning to receive RRT were in a far better 
physical condition than before, which also contributed to the increase in the survival 
rate (Arora et al. 1999; Eadington 1996; Jungers et al. 1993). Some people are more 
suitable to one type of dialysis than the other as the choice of RRT (kidney 
transplant, haemodialysis and peritoneal dialysis) depends on multiple factors, 
including the primary need underlying indication such as acute or chronic kidney 
failure, hemodynamic stability, other comorbid diseases, availability of local 
expertise, and patient preference and capability for home dialysis. However, not all 
renal units in the UK are able to offer patient choice because in many areas, stretched 
dialysis resources may limit the availability of haemodialysis. Patients receiving 
peritoneal dialysis have a greater chance to develop infections than the general 
population, because of risk factors such as immune deficit and cutaneous access 
point (Mekki et al. 2010). A case control study (Ridao Curty et al. 2014) of 644 
patients was conducted in the RRT outpatient centre for 29-month period. The study 
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results concluded that peritoneal dialysis is the treatment with greater risk of 
infection and mortality, followed by catheter haemodialysis. The lowest risk of 
infection and mortality was observed in the arteriovenous fistula haemodialysis 
group. Most studies suggest that outcomes of patients treated by PD and HD are 
similar (Gokal et al. 1999), and that patients who start with PD first may even have 
better control on kidney function (Heaf et al. 2002). However, other studies 
demonstrated a higher mortality with PD starting from the second year of treatment, 
and suggested possible survival benefits of a timely change over from PD to HD 
(Jaar et al. 2005). The higher PD mortality probably relates to sepsis and peritoneum 
exhaustion (Sinangil et al. 2013; USRDS 2005). Peritoneal exhaustion (peritoneal 
sclerosis) is an extensive thickening of the peritoneal membrane due to fibrous tissue 
and new vessel formation, usually as a result of long-term PD (Nakayama  2005). 
Among the suggested aetiologies are the severe or recurrent peritonitis, bacterial 
endotoxin and inflammatory or foreign body response to the peritoneal catheter 
(Kawanishi and Moriishi 2007; Eltoum et al. 2006).   
Dialysis and transplantation provide alternative ways of taking over the work of 
patients failed kidneys. Transplantation of kidney involves the replacement of an 
abnormal kidney of a recipient with a better functioning kidney of the donor. The 
most efficient form of therapy for ESRD patients is a kidney transplant.  
2.4.3 Kidney Transplantation  
Kidney transplantation is the treatment of choice for selected patients with ESRD 
(Suthanthiran and Strom 1994). However, there is a shortage of donated organs and a 
growing wait-list for transplantation (Whalen et al. 2012; Xue et al. 2001). Many 
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people who are candidates for kidney transplantation are put on a transplant waiting 
list and require dialysis until an organ is available. A successful kidney transplant 
improves the quality of life and reduces the mortality risk for most patients when 
compared with maintenance dialysis (Schnuelle et al. 1998; Portet et al. 1993; Ojo et 
al. 1994).  
Kidney transplant is a much more effective treatment than dialysis for removing the 
symptoms of kidney failure. Among the 46,164 ESRD patients on the kidney 
transplant waiting list in the United States during the period 1991-1997, those who 
received a transplant were 68% less likely to die than those who did not receive a 
transplant, in the subsequent three years (Wolfe et al. 1999). The overall survival rate 
increased by ten years, and in the younger age group this increased to 17 years 
compared to those on a transplant waiting list. The escalation in the survival rate was 
observed equally in males and females, and was particularly high in patients 
suffering from diabetes. A large-scale longitudinal study of survival and mortality 
risk study in 1736 adult patients carried out in Scotland revealed similar results, 
study results concluded that there is a substantial long-term survival advantage for 
transplantation compared with dialysis (Oniscu et al. 2005). 
2.4.4 Peritoneal Dialysis 
2.4.4.1 Introduction 
Peritoneal dialysis represents a method of RRT, which counters the role of HD and 
transplant in the treatment of ESRD. The method helps to eliminate the nitrogenous 
waste products and fluids from the body through a catheter inserted into the 
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peritoneal cavity. As it is a simple and straightforward method, patients can carry it 
out themselves at home after undertaking a short training session. PD does not 
usually necessitate any special equipment, so it can be readily adapted to the 
patient’s lifestyle. In spite of this, it does require a patient to have a lot of storage 
space for the dialysis fluid. 
Peppelenbosch et al. (2008) indicated the benefits of peritoneal dialysis in contrast to 
haemodialysis, such as enhanced quality of life as a result of patient mobility and 
autonomy, ease of use, preservation of residual kidney function, as well as a low 
mortality rate in the years immediately following the start of the treatment. However, 
patients initially improve on PD, and later tend to deteriorate because of volume 
expansion, coinciding with further loss of residual renal function (Ortega and 
Materson 2011). 
2.4.4.2 Complications of Peritoneal Dialysis 
Ortega and Materson (2011) have indicated hypertension to be an important 
consequence of peritoneal dialysis in 29% to 80% of patients, particularly as cardiac 
disease is the most frequent cause of mortality among ESRD population. 
Furthermore, capacity overload also occurs because of the introduction of fluids in 
the body and destruction of residual kidney function. In rare cases, long-term PD can 
lead to the development of massive hydrothorax, which is a severe complication. It 
can develop at any moment during the therapy and can cause severe dyspnoea 
(Nomoto et al. 1989).  
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Despite substantial advances in PD as a renal replacement therapy, PD-related 
infections including peritonitis and exit site infection remains an important 
determinant of disease and death. Peritonitis represents the serious complication of 
PD (Piraino 1998), being not only life threatening, but also the leading risk factor for 
disease in patients undergoing PD and is the major cause of hospitalization, catheter 
loss, and technique failure (Wang et al. 2011; Fried et al. 1996). 
Catheter-related mechanical complications, which include malposition, kinking, and 
entrapment of the catheter, may prevent adequate drainage of the dialysate (Stuart et 
al. 2009). Peritoneal dialysis patients have increased intra peritoneal pressure due to 
the presence of fill volume in the peritoneal cavity, resulted in the risk of abdominal 
wall complications, such as hernias and peritoneal leaks (Peso et al. 2003). After a 
number of years, the peritoneal membrane also becomes less efficient in dialysis due 
to peritoneal sclerosis and fibrosis. Long-term systemic exposure of the peritoneal 
cavity to dialysis solutions results into peritoneal membrane structural and functional 
alterations over time and eventually to technique failure expressed clinically as 
ultrafiltration failure and reduced solute clearance (Fourtounas 2011). 
2.4.5 Haemodialysis 
2.4.5.1 Introduction 
Progressive and permanent renal failure is most frequently treated with 
haemodialysis. Since 2009, the number of patients receiving home HD has increased 
by 23%, from 636 to 780 patients with median age of 66 years (UK renal registry 
report 2011). Haemodialysis has been used to treat renal failure since the 1960s 
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(Grassmann et al. 2006). RRT with haemodialysis does not provide true replacement 
of renal function. However, by removing waste solutes, excess body water and 
restoring biochemical and acid-base balance, haemodialysis has considerably 
improved the morbidity and mortality of ESRD patients. 
The first haemodialysis performed in a human was by Haas in 1924 (Haas 1925; 
Paskalev 2001). Twenty years later Willem Kolff provide a primitive form of 
vascular access, establishing effective anticoagulation and producing reliable 
equipment for widespread use when he created the rotating drum kidney in 1943 
(Kolff and Berk 1944; Konner 2005). 
2.4.5.2 Mechanism of Haemodialysis 
The current haemodialysis machine bears little resemblance to that devised by Kolff 
in 1943 although the design adheres to similar principles (Konner 2005; Kolff and 
Berk 1944). This centres on removing blood from the intravascular compartment, 
passing it through an extracorporeal circuit into a dialyser and removing waste 
solutes and excess water by exposure to conditions that promote diffusion, 
convection, and movement in response to hydrostatic pressure gradients. Dialysed 
blood is then returned to the patient through the venous system. The volume of 
plasma cleared of solute per unit time by dialysis is expressed as the solute clearance. 
Diffusion is the predominant method by which solute clearance from plasma is 
achieved by haemodialysis. The process of diffusion is dependent upon blood from 
the extracorporeal circuit flowing through the dialyser, a collection of microfilament 
fibres bathed in dialysate fluid, which circulates in the opposing direction to blood 
flow (Figure 3). 
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Figure 3. Mechanism of Haemodialysis (Pandya and Farrington 2003) 
 
Blood is withdrawn from the fistula via the needle by a peristaltic pump, circulated through 
the dialyser, and returned to the fistula downstream through the needle. Heparin is infused 
downstream from the blood pump. 
These conditions are favourable to the rapid diffusion of solutes through pores within 
the microfilament fibres, down a concentration gradient from blood to dialysate or 
vice-versa. The rate of diffusion varies with the degree of concentration gradient 
between compartments, the surface area of the microfilament membrane, the number 
and size of pores within the membrane, the molecular size of the solute and the 
relative flow rates of both extracorporeal blood and dialysate (Pandya and Farrington 
2003). 
It can be seen that key determinants in the success of haemodialysis are the 
characteristics of the selectively permeable membranes used to form the 
microfilament tubes within dialyser units. Membranes may now be classified by the 
type of material used in their manufacture (synthetic, cellulose and substituted 
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cellulose), their capacity, surface area, ultrafiltration coefficient, flux and in some 
cases, their ability to be reused (NKF-KDOQIb 2006). 
2.4.5.3 Functional Outcomes of Haemodialysis 
A high level of serum albumin has been considered as a positive measure of survival 
prediction in patients receiving dialysis due to the fact that it is an indicator of 
improved nutrition and reduced inflammatory burden (Avram et al. 1995). Block et 
al. (1998) have demonstrated that a reduced concentration of calcium phosphate is 
also a measure of increased survival rate as it is an indicator of efficient treatment of 
bone disease. Renal anaemia, reflected by low haemoglobin levels (Locatelli et al. 
2004), and low dialysis doses (Held et al. 1996) is associated with unsatisfactory and 
poor outcomes of haemodialysis (Elseviers and van Wadeghem 2003).  
The DOPPS have demonstrated that arteriovenous fistula is exceeding in its benefits 
regarding the provision of vascular access for haemodialysis (Pisoni et al. 2002; 
Young et al. 2002). As such, it is the first option considered for the construction of 
vascular access for dialysis. The construction of the fistula should be undertaken at 
least a month prior to the beginning of the dialysis treatment, as specified in the 
NKF-KDOQIa guidelines (2006). By doing this, a number of potential problems can 
be prevented, including the urgent need for a catheter and its associated 
complications, such as infection, bleeding, thrombosis and vessel damage; 
additionally, the period spent in hospital is reduced. According to Rayner et al. 
(2003), a fistula needs two to six weeks to fully mature. The main objective of health 
care is to create an AVF for the majority of patients prior to formal haemodialysis for 
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the first time. Among the advantages of native AVFs are increased blood flow, 
reduced risk of sepsis, and durability.  
2.4.6 Vascular Access 
2.4.6.1 Introduction 
A suitable type of vascular access has to be created to establish a connection between 
the circulation system of the patient and the haemodialysis cycle, in order to provide 
haemodialysis in ESRD patients. There are generally three types of vascular access 
that can be used for haemodialysis. Of these, the AVF is considered to provide the 
best long-term functional vascular access, with a reduced risk of thrombosis or 
infection and is most cost-effective (Manns et al. 2005). In addition, AVF does not 
necessitate multiple interventions and has a lower mortality and morbidity rate 
among different types of vascular access (Anel et al. 2003). 
Vascular access problems represent the main determinant of morbidity among 
haemodialysis patients and put a considerable degree of financial pressure on the 
healthcare sector (USRDS 2011; UK Renal Registry Report 2011). The three types 
of constructions of AVFs, which are usually employed, are radiocephalic, 
brachiocephalic and brachiobasilic (Figure 1). The pre-surgery non-invasive scan 
imaging help clinicians in the decision making process as to which of these three 
types would be more suitable for the patient. Often, more than one type could be 
suitable and the one that is believed to have a higher success rate is chosen. 
However, when all three options are on the same level, a number of other aspects are 
included in the decision, such as using the non-dominant arm or a more distally 
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placed fistula (radiocephalic) to allow in future an easier formation of proximal 
fistula (brachiocephalic or brachiobasilic) and forming a brachiocephalic fistula over 
a brachiobasilic fistula due to its ease of formation and less surgical stress. 
2.4.6.2 Type of Vascular Access 
Successful haemodialysis depends on the provision of safe, efficient, and durable 
vascular access. Establishing and maintaining effective vascular access is a 
demanding process for both patients and renal services. These demands are set to 
increase in response to an RRT population that is becoming increasingly dependent 
on haemodialysis, whilst also increasing in population size, age, and co-morbidity. 
Initially, vascular access methods relied on repeated peripheral cannulation to deliver 
arterial blood to the dialysis machine and return it to an accompanying vein. In 1949, 
Alwall, made the first attempt to connect an artery and a vein, using glass cannula 
and rubber tubing (Alwall et al. 1949; Konner 2005). This device would allow blood 
to be diverted onto an extracorporeal circuit for dialysis when required. His attempt 
was unsuccessful although it provided the template for the arteriovenous Teflon 
Shunt developed by Quinton et al. (1960). Their device consisted of two Teflon 
cannula inserted into the wrist, one in the branch of the brachial artery in the forearm 
and one in the accompanying antecubital vein. The cannula had its external ends 
connected by flexible tubing from which connection to an extracorporeal circuit 
could be made. This provided nephrologists with the first permanent vascular access 
device and was a decisive breakthrough in the provision of haemodialysis to the ERF 
population. The ‘Scribner’ shunt, as it came to be known, underwent many 
refinements before being ultimately superseded by the successful development of 
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arteriovenous fistulae, arteriovenous grafts, and central venous catheters. 
Nonetheless, the Scribner shunt played a key role in the development of permanent 
vascular access devices. 
The Arteriovenous Fistula 
Cimino and Brescia described a technique where haemodialysis was conducted 
through a simple puncture of the most accessible forearm vein. Patency of the vein 
was assured by the use of an inflatable tourniquet. This allowed needles of varying 
sizes to be used with resultant haemodialysis flows of 150-400 ml/min. Whilst 
successful, this technique was limited by the poor longevity of peripheral veins in 
comparison with that of Scribner’s external arteriovenous shunt. Logical 
development of this technique, however, led to the creation of the first internal 
arteriovenous fistula. The successful use of the new technique was reported in a 
landmark paper (Brescia et al. 1966). The thought process of AVF was based on 
Cimino treating veterans of the Korean war; some of whom had traumatic AVF due 
to gunshot wounds and Cimino noted that venesection in these patients was very 
easy. They reported 12 cases in which successful primary function of an AVF had 
been achieved by creating a side-to-side connection at the wrist between the cephalic 
vein and radial artery. Exposure to high-pressure arterial flow was found to promote 
enlargement and thickening of the venous wall (Figure 4). After approximately six 
weeks maturation, a robust vessel wall had developed that could sustain repeated 
cannulation and allow regular haemodialysis to take place. 
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Figure 4. Arteriovenous Fistula (Permission from Arteriovenous Fistula First) 
Arteriovenous fistula created by connecting an artery directly to a vein, frequently in 
the forearm. This artificial connection allows the vein to become larger and for the 
walls of the vein to thicken, a process termed maturation. 
A year later the technique had been amended to allow the construction of an end-to-
end anastomosis in the lower arm between the cephalic vein and the radial artery 
(Sperling et al. 1967). This technique restricted arterial inflow into the AVF to that 
blood delivered by the feeding radial artery led to a high risk of developing steal 
syndrome (Figure 5).  
This is a clinical condition caused by arterial insufficiency distal to haemodialysis 
AVF due to diversion of blood into AVF. Consequently, the technique latterly 
became regarded as a secondary option available to surgeons when considering 
surgical revision of a failed AVF. The technique was further refined in 1968 by Rohl, 
who devised the radial artery side-to-vein-end anastomosis, with or without the distal 
ligature of the radial artery to the communicating vessels. This allowed a more 
suitable positioning of the AVF with excellent subsequent flows. It is the technique 
that has become the standard AVF creation procedure of choice and has allowed 
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AVF creation surgery to evolve and successfully provide a range of potential sites for 
AVF creation, predominately within the upper limbs (Konner 2005).  
 
Figure 5. Steal Syndrome after AVF Creation (Adapted from Vachharajani 
2010) 
After creation of right sided brachiocephalic fistula, patient complained of pain and 
numbness over right hand. On examination the fingers were blue and cold (A). Panel 
B compares the colour of her hand to a normal pink colour. Upper arm fistulae are 
more likely to cause ischemic symptoms compared to forearm fistulae. The presence 
of poor peripheral vasculature secondary to diabetes, calcification and peripheral 
arterial disease is the primary etiological factor.  
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For practical purposes AVF creation is best conducted on the non-dominant arm with 
use of distal sites where possible; preserving the proximal vascular tree should 
vascular access surgery be required in the future. The longevity, durability, and 
favourable complication rate of the AVF have established it as the leading method of 
establishing permanent haemodialysis vascular access. Around two thirds of 
haemodialysis patients in the UK dialyse using an AVF (Fluck et al. 2007). 
Arteriovenous Grafts 
An alternative to the AVF is the synthetic arteriovenous graft (AVG). This was 
devised following the introduction of the Scribner shunt, which was noted to employ 
a length of flexible tubing to connect the arterial and venous blood flow (Figure 6). 
Thomas (1969) developed this principle by replacing the cannula with Dacron 
patches sutured into the vessel wall and bringing out a loop of connecting silastic 
material to the skin surface. By avoiding the use of intraluminal cannula, this device 
was less prone to thrombosis (Thomas 1969). Meanwhile, the first vein graft had 
been performed using a length of excised saphenous vein, to connect the brachial 
artery to its accompanying vein. By combining each of these three principles direct 
anastomosis of vessels to tubing, looping a section of tubing to connect artery to vein 
and subcutaneous tunnelling of the connecting loop, the modern AVG was created 
(Konner 2005). 
Whilst initially Dacron was the most commonly used graft material, the emergence 
of the synthetic material polytetrafluoroethylene (PTFE) as a pliable, biocompatible 
material that may be repeatedly cannulated yet maintain its structural integrity, led to 
significant improvement in the durability of the AVG.  
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Figure 6. AVG in the forearm (Berardinelli 2006) 
A forearm PTFE loop graft: (A) the arterial anastomosis (a) between a tapered e-PTFE and 
the right brachial artery has been completed. Some oozing of blood through the PTFE can be 
seen. (B) The completed PTFE loop after skin closure showing the graft in a subcutaneous 
tunnel in the forearm, with a distal counter-incision. 
The brachial artery and the basilic vein are usually connected by way of an AVG. 
However, it is also common to connect the radial artery and the basilic vein or the 
brachial artery and the axillary vein with the use of grafts. When vascular access in 
the upper limbs is exhausted, synthetic grafts can be used to establish vascular access 
using the subclavian or axillary vessels, femoral vessels, or may even be 
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anastomosed between the arterial system and the right atrium. Approximately 3% of 
haemodialysis patients in the UK dialyse via an AVG at present (Fluck et al. 2007). 
Central Venous Catheters 
In the early years of haemodialysis, the demand for experienced surgeons to create 
arteriovenous shunts, fistula and grafts outstripped supply. The paucity of vascular 
and transplant surgeons prepared to perform these procedures provoked one UK 
nephrologist, Stanley Shaldon, to develop hand-made cannulae that could undergo 
insertion into the femoral artery and accompanying vein to permit immediate 
haemodialysis access. He made use of the Seldinger insertion technique - a method 
that enables safe catheter placement into the vascular tree introduced by Sven-Ivar 
Seldinger in 1953 (Higgs et al. 2005; Seldinger 1953). 
It was noted that arterial cannulation, in contrast to venous cannulation, is 
accompanied by an abnormally high risk of bleeding and was soon abandoned. 
Gradually different insertion sites were used including the jugular and subclavian 
veins. These had the advantage of allowing central venous pressures to be estimated 
in patients with extracellular fluid depletion (Shaldon 1994), a common occurrence 
in many individuals suffering from acute kidney failure requiring dialysis. The 
insertion of a cannula into the subclavian vein became the favoured approach for 
CVC insertion until the early 1990s when angiographic data demonstrated a 
significantly increased risk of central venous stenosis at the site of cannulation. This 
predisposed patients to a high risk of limb oedema, which could impair the ability to 
create and maintain a functioning AVF (Schillinger et al. 1991). 
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Insertion into the internal jugular veins (Figure 7) is now regarded as standard 
practice although femoral venous cannulation is also performed.  
 
Figure 7. Appropriate tunnel catheter position and anatomy (Banerjee 2009) 
The central venous catheter is a flexible synthetic (man-made) tube that is usually placed in a 
large vein in neck or chest. Dialysis catheters have two lumens attached to two ports (blue 
and red). The red port draws blood from the body and the blue port returns the blood from 
the dialysis machine to the patient. 
CVCs are frequently used temporarily to provide vascular access for haemodialysis 
whilst the patient awaits creation or maturation of an AVF or AVG or because they 
have run out of suitable options for permanent vascular access (Bourquelot 2009). 
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Some CVCs may be tunnelled subcutaneously en-route to entering the vein with a 
securing cuff to stabilise the position of the catheter and reduce potential for 
periluminal infection. Direct transcutaneous cannulation of the vein is often 
performed acutely and tends not to involve subcutaneous tunnelling or use of a 
securing cuff. Polyurethane and silicone are the two materials most commonly used 
in the manufacture of haemodialysis catheters although polymers such as carbothane 
are increasingly common (Banerjee 2009). These materials provide sufficient 
flexibility, durability, and biocompatibility for intravascular use. 
The catheters are the least preferred modality and, in an ideal setting, no patient 
should have a catheter as access. Despite the risks associated with dialysis catheters, 
their use has increased to almost 70% of incident dialysis initiation with catheters 
(Asif 2008). These different methods of obtaining vascular access allow 
haemodialysis to be a viable treatment for most of ESRD patients. The diversity of 
vascular access options available can help nephrologists address a range of clinical 
scenarios more effectively. Late presentation of ESRD is one frequently experienced 
scenario that may have a significant impact on vascular access provision. In this 
setting, the time in which RRT is required to start may arrive before the patient can 
undergo vascular assessment, surgery, and successful maturation of their fistula. This 
phenomenon is often used to explain the relatively high prevalence of ESRD patients 
using CVCs as their first haemodialysis access modality. In the UK renal registry 
vascular access survey of 2006, 66% of patients started haemodialysis on a CVC 
compared with 34% using an arteriovenous fistula or an arteriovenous graft. After 
one year, the percentage of individuals treated with a CVC reached 28% compared 
with 71% using an AVF or AVG (Fluck et al. 2007). UK Renal Association (2011) 
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suggested that 2/3 of all patients requiring dialysis should start with an autologous 
fistula and the remaining 1/3 with CVC as these are described as the “Crash 
Landers”  who have acute or undiagnosed renal failure and do not have time for AVF 
creation and maturation. Similarly, when an AVF or AVG fails, CVCs are a rapid 
means of establishing vascular access and thus play a significant part in providing 
urgent vascular access. Whilst each access type has, its relative attributes, it is vitally 
important to consider the differing degrees of reliability, durability, and 
complications associated with each approach. Whether considering an individual 
patient’s circumstances or planning vascular access provision at a population level, 
understanding the range of complications expressed by each access type and which 
factors predispose to these complications is of fundamental importance in deriving 
maximum benefit with minimal risk. 
2.4.6.3 Functional Outcomes of Vascular Access 
As noted by several researchers (Feldman et al. 1996; Windus 1993), surgical 
interventions of vascular access and their associated problems are important causes 
of morbidity, hospitalisation, and financial pressure. In the US, more than 20% of the 
total number of haemodialysis patients were admitted to hospital as a result of 
vascular access and its complications. The costs generated annually amounts to 
almost $1 billion (Feldman et al. 1996). Studies have shown that dialysis grafts made 
of PTFE are not as long lasting as autologous fistulae (Bender et al. 1994; Coburn 
and Carney 1994); furthermore, they are more likely to develop repeated thrombosis, 
stenosis, and infection (Churchill et al. 1992). The NKF-KDOQIa guidelines (2006) 
recommend the use of AVFs over AVGs due to the advantages of the fistula; the 
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AVGs should only be employed when the creation of natural AVFs is due to the 
exhaustion in the use of the patients veins.  
Clearly, there are logistical hurdles to this late presentation to renal services, fitness 
for surgery, suitable peripheral vascular anatomy, delays due to primary or secondary 
access failure and slow rates of AVF maturation. Consequently, there remain 
situations, especially when starting RRT, where use of an AVG or CVC may be 
required. This is demonstrated by the relative prevalence of CVC use in patients 
starting RRT around the world. Similarly, CVC insertion is the mainstay of vascular 
access provision to the acute renal failure population who require haemodialysis. 
CVCs therefore have an important role in haemodialysis vascular access provision 
but do so at a cost. USRDS data from 2007 suggest that expenditure on catheter 
placement is approximately 2.5 to 2.8 times higher than on AVF and AVG surgery. It 
is suggested that these figures reflect the excess costs the catheter group incur by 
being a predominately in-patient comorbid population compared to the population 
who undergo elective AVF and AVG surgery (USRDS 2008). The association 
between catheter use, comorbidity, and in-patient care is strong. The question of 
whether the adverse features related to catheter use, such as catheter thrombosis and 
bacteraemia, are specifically related to use of a catheter or are simply related to the 
greater level of comorbidity expressed by the population who require catheter 
insertion has been subject to controversy (Parienti et al. 2010).  
CVC insertion for haemodialysis is associated with an increased risk for venous 
thrombosis and subsequent stenosis (Schillinger et al. 1991). When manipulated 
around the obstruction at the innominate vein at the junction of the superior vena 
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cava, the tip of the catheter or its introducer sheath may wear away the endothelium, 
prompting to mural thrombosis (Timsit 2003). Catheters are prone to develop 
infection from 3.8 to5.5 episodes per 1000 days (Hannah et al. 2002). Infection can 
be localized or spread systematically leading to bacteraemia or sepsis (Beathard and 
Urbanes 2008). In AV graft or within its outflow vein where the graft stitched to the 
vein, stenotic lesions are found time and again (Bittl 2010). The underlying 
mechanism is the marked increase in shear stress in the thin-walled outflow vein, 
which activates focal fibromuscular hyperplasia and initiates a fibrotic venous lesion 
to develop (Roy-Chaudhury et al. 2001; Swedberg et al. 1989). 
2.4.7 Arteriovenous Fistula and Success 
2.4.7.1 Introduction 
Vascular access has associated complications that may arise immediately following 
creation or later during regular use. Failure of vascular access is most frequently due 
to thrombosis occurring within or around the AVF, AVG or catheter however other 
significant problems such as infection, aneurysm formation, heart failure, and 
ischaemia distal to the site of access creation may occur. If the fistula reaches full 
development it can provide long-term functional access, has a low rate of thrombosis 
and infection, does not require multiple procedures, and is relatively inexpensive 
(Asif et al. 2006). The prognosis regarding the efficiency of the fistula is made with 
the help of duplex ultrasound (Costanza et al. 2011), which are important 
instruments that enable the evaluation of the success rate of fistula development and 
of whether or not it is capable of providing access for haemodialysis (Manns et al. 
2005; Mendes et al. 2002). It may be possible to enhance the results of vascular 
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access by gaining a more comprehensive picture about the factors involved in the 
efficient development of fistulae. This can generate important data during the pre-
surgery evaluation that surgeons can use to base their decisions on. Thus blood 
markers if available may be beneficial in anticipating the success of fistula 
development without the use of invasive tests and is cost-effective. 
2.4.7.2 Site and Type of AVF Selection 
The growing success rate of treatment of ESRD patients determines durability and 
the potential for the creation of vascular access. These are usually constructed in the 
distal location of the non-dominant arm. Patients who do not have vessels in the 
lower arm adequate for vascular access can have brachiocephalic fistulae. AVF 
created on the basilic vein of the upper arm, which is of sufficient diameter, is 
situated at a considerable depth, and thus cannot be opened up during the process of 
phlebotomy (Allon and Robbin 2002). 
Radiocephalic AVF 
The standard of vascular access positioning is the radiocephalic direct wrist access, 
known as the Brescia-Cimino fistula or the ‘wrist fistula’, was first used in 1966 
(Brescia et al. 1966). As shown in Figure 8, the fistula is constructed by connecting 
the radial artery to the cephalic vein at the wrist. The procedure usually entails one 
incision, which enable the surgeon to ligate any venous tributaries that may intervene 
in the development of the fistula. A number of forms of anastomosis have been used 
with different outcomes with regard to AVF maturation and steal phenomenon 
(Rutherford 2000), the cephalic vein end-to-side form being the most frequently 
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used. It is relatively uncommon to get a steal syndrome with a Cimino fistula 
(<0.5%), more common in the brachiocephalic fistula (5-12%).  
 
Figure 8. Radiocephalic Arteriovenous Fistula (Allon and Robbin 2002) 
Figure shows a radiocephalic fistula which involves end-to-side venoarterial anastomosis of 
the radial artery and cephalic vein at the wrist. After mobilization and division of cephalic 
vein branches, the venous bifurcation was opened to create a broad flare or “branch patch”. 
Finally, brad flare was connected with radial artery. 
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Wong et al. (1996) indicated that early failure of the fistula is likely to occur if the 
diameter of the cephalic vein is below 1.6 mm. The Brescia-Cimino fistula generally 
has had satisfactory results (NKF-KDOQIb 2006). In the case of autologous access, 
if the fistula failure or thrombosis does not happen within a year of the procedure 
then the access rate is bound to be successful. 
Brachiocephalic AVF 
The process of connecting the cephalic vein with the brachial artery usually has a 
positive outcome. The autologous access is known as brachial cephalic direct elbow 
access or brachiocephalic fistula, and is recommended for diabetics as it has a high 
blood flow and maturation rate (Figure 1). However, it may not be possible to use the 
rest of the forearm for the construction of additional accesses. Sparks et al. (1997) 
have published the findings of their ten-year study on 111 cephalic vein autologous 
access. The success rate of brachiocephalic access after 2 years was 66%. Based on 
these results, the brachiocephalic access was determined to be a beneficial option for 
patients of advanced age, women, and patients with a history of diabetes. Revanur et 
al. (2000) obtained a maturation rate of 74% after 12 months monitoring of 137 
surgical interventions. Another study indicated the higher patency and development 
rates of primary brachiobasilic and transposed basic autologous accesses, as opposed 
to brachiocephalic autologous access in 58 diabetics who needed haemodialysis. In 
this study, 70% brachiocephalic AVF did not mature, in contrast to the much lower 
failure rate exhibited by primary brachiobasilic access and transposed brachiobasilic 
fistula, with 27% and 0%, respectively. After a year and a half, brachiocephalic 
AVFs revealed a collective patency of 33%, whereas the brachiobasilic fistula had a 
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collective patency of 78% (Hakaim et al. 1998). A recent retrospective study 
conducted by Ayez et al. (2012),  created 173 autologous upper arm AVFs (87 
Bracheocephalic AVF and 86 Bracheobasilic AVF) to compare the maturation, 
patency, blood flow and complication rates. The study results found no differences 
between the BC and BB AVF except of surgery time and mid upper arm vein 
diameters. However, the main weakness of the study was the non-randomised 
comparison.  
Brachiobasilic AVF 
The brachiobasilic fistula, or basilic transposition, was first created during the 1970s 
by Dagher et al. (1976) and it generally represents the final autologous access option 
for the arm (Figure 1). The surgical intervention consists of mobilization, distal 
sectioning, superficial tunnelling, and the distal end-to-side transfer of the basilic 
vein to connect with the brachial artery. Several researchers (Davis et al. 1986; 
Zielinski et al. 2001) have proposed slightly different interventions, such as lifting 
the basilic vein instead of transferring it or increase the visibility of the basilic vein in 
a staged procedure. Overall, basilic transposition has had positive results, particularly 
in the case of patients who suffer from compromised vasculature distally. 
2.4.7.3 Complications of AVF 
There are a number of problems related to arteriovenous access, including mild 
symptoms to severe complications. Therefore, it is of the utmost importance to 
identify and treat such problems to protect patient health, enhance their quality of 
life, and maintain the AV access in a functional state. 
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Thrombosis 
Thrombosis occurring in AVF is mostly due to intimal hyperplasia secondary to 
needling AV fistula or mobilization of vein for arterial anastomosis in AVF creation 
(Beathard et al. 2003; Falk et al. 2003; Vassalotti 2004). The rate of AVF thrombosis 
is estimated to be 0.2-0.4 incidents per patient per year, in contrast to 0.8-1.2 
incidents per patient per year for AVGs (Woods et al. 1997). 
The main substrate for venous stenosis is endothelial cell injury, most commonly at 
the site of the anastomosis. This results in the up regulation of a pro inflammatory 
cascade, which promotes smooth muscle cell accumulation at the site of injury 
(Stracke et al. 2002). This process may be accelerated in response to shear stress 
arising from turbulent flow (Sterpetti et al. 1992), repeated cannulation and the 
relative difference in vascular elasticity either side of the anastomosis (Hofstra et al. 
1994). Other contributing factors include compression of the fistula or graft between 
dialysis sessions, hypotension, hypovolaemia, and hypercoagulable states (Windus 
1993). 
Primary prevention of AVF stenosis has focussed on selecting an appropriate site for 
vascular access creation, as determined by vascular imaging, and monitoring fistula 
performance. Monitoring relies on assessment of access structure, assessment of 
access blood flow, measurement of delivered dialysis dose and assessment of the 
resistance to blood flow on return to the venous tree. These features may all 
contribute towards determining whether an AVF is at risk of failure. Where 
narrowing of veins more than 50% is discovered, percutaneous angioplasty or 
surgical revision may improve AVF longevity. Intervention on a thrombosed AVF is 
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not likely to lead to restoration of long-term patency, but if an acute, unexpected 
deterioration in AVF performance occurs, then patency should be restored without 
delay. Monitoring of AVF occurs routinely as part of a regulated screening 
programme and undertaken in response to clinical deterioration in a previously 
functioning AVF. Best practice remains uncertain. Despite the fact that many of the 
methods used in detecting venous stenosis and thrombosis are effective, routine 
screening with subsequent intervention has not been proven to reproducibly increase 
the long-term survival of AVFs. Along these lines, prospective monitoring remains 
debatable (Sands 2005).  
Some guideline groups are recommending some form of prospective monitoring for 
all AVFs and AVGs (K/DOQI 2006) whilst others recommend restricting detailed 
AVF and AVG assessment to those with clinical signs of deterioration such as a 
decrease in intra dialytic blood flows (UK Renal Association 2007). 
The issue of antiplatelet agent use in preventing AVF or AVG thrombosis is 
unresolved. Several antiplatelet agents including aspirin, dipyridamole, clopidogrel, 
sulfinpyrazone and ticlopidine have been studied in the past. Many of the studies 
were conducted in the 1970s and 1980s where dialysis populations and treatments 
were very different to those seen today (Antiplatelet Trialists' Collaboration 1994). 
A randomised controlled trial evaluated use of aspirin and clopidogrel although the 
study was stopped early because of a significantly elevated risk of bleeding among 
those receiving antiplatelet therapy (Kaufman et al. 2003). More recently, the effects 
of dipyridamole, 200 mg being administered twice every day, plus aspirin, 25 mg 
administered twice every day, or placebo were evaluated using a randomised 
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controlled trial of 649 patients with a new AVG. The intervention group 
demonstrated greater rates of primary patency with a similar rate of adverse events, 
including bleeding, albeit in a population designed to be of low bleeding risk and 
with relatively short exposure to the antiplatelet on trial (Dixon et al. 2009). Use of 
anticoagulants such as warfarin has not been proven to reduce thrombosis and the 
likelihood of it being accompanied by abnormal bleeding is high (Crowther et al. 
2002). 
Infection 
Infection is a frequent challenge among the haemodialysis population and accounts 
for growing rates of hospitalisation, comorbidity, and mortality. USRDS (2008) 
report demonstrates recent trends in admissions for principle diagnoses of infection 
and bacteraemia/septicaemia in the ESRD population. It has been found that 
approximately 20% of vascular access loss is due to the development of infection. 
Vascular access is the source of the majority of infections within haemodialysis 
units. The predominance of skin commensals as pathogenic organisms in 
bacteraemic patients suggests that inoculation during vascular cannulation is the 
main mechanism by which infection arises (Higgins 1989). Once inoculated, 
synthetic materials such as those used in AVGs have a tendency towards chronic 
infection due to their lack of innate immune defence mechanisms and their 
propensity to develop a bio film compared with autologous AVFs.  
Prevention and treatment of AVF infection is a major element in the safe provision 
of haemodialysis. When considering arteriovenous fistulae and grafts, sterile 
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cannulation is fundamentally important. Poor cannulation technique, often due to 
relative inexperience of the dialysis practitioners, may lead to pseudo aneurysm 
formation or the development of peri fistula haematomas, which is associated with 
subsequent infection, and failure of the fistula (Fan and Schwab 1992). 
Routine antibiotic prophylaxis is controversial. Topical antibiotic use has not been 
found to be effective with benefits in reducing nasal Staphylococcus aureus carriage 
by topical mupirocin treatment being found to be associated with the development of 
resistant pathogens (Laupland and Conly 2003). Consequently most primary 
prevention strategies focus on the ability to ensure aseptic technique when inserting 
or handling vascular access devices. 
Steal Syndrome 
Early thrombosis, infection, and distal ischaemia are the most frequently seen 
problems related to dialysis access surgery. Stolic (2013) notes that diabetics and the 
elderly face a high risk of ischaemia and steal syndrome. Suding and Wilson (2007) 
illustrate the range of ischaemic issues linked to upper extremity dialysis access 
including amputation of hands or fingers due to ulceration, tissue necrosis or distal 
gangrene or nonthreatening complications including discomfort, loss of strength, 
tingling and paleness in fingers which all pass. Schanzer et al. (2006) show that 
blood flow of the hand is not compromised by AVF in the majority of instances 
although Goff et al. (2000) and Leon and Asif (2007) have shown that 1.6 to 8% of 
people do develop unilateral ischaemia in their hand. Overall, ischaemia in the hand 
with a fistula requires particular circumstances, first and foremost low perfusion 
through the arterial system because of arterial occlusive disease proximal or distal 
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from arteriovenous anastomosis. When overly high levels of blood flow occur 
through a widened blood vessel with lowered collateral perfusion and inadequate 
vascular modification, steal syndrome becomes a possibility. Schanzer et al. (2006) 
note that while extreme and prolonged hypoperfusion can result in the death of tissue 
and compelling amputation of the fingers or forearm, this occurs in only 1% of 
patients and ischaemia is usually minor. 
AVF Maturation 
As indicated by Allon and Robbin (2002), the growth of fistula prevalence is 
hampered by early AVF failure caused by thrombosis or lack of development. An 
arteriovenous fistula is considered as “failure to mature” if it does not develop 
sufficiently enough to withstand dialysis or if it blocks during the first three months 
following construction (Beathard et al. 2003). Fistula development depends mainly 
on two factors; appropriate blood flow to maintain the dialysis circuit and adequate 
vessel diameter to enable repeated insertions of cannulae. As such, it is very 
important to intervene accordingly to maintain fistula patency. Most AVFs, which 
fail early on, have exhibited injuries caused by thrombosis or stenosis inside the 
access circuit (Beathard et al. 2003). It has to be kept in mind that stenosis occurs 
gradually which in the end results in total vessel occlusion, thus degenerating into 
access thrombosis (Asif et al. 2006).  
A clinically immature fistula is defined as a fistula having one or more of the 
following characteristics, as determined at physical examination by the dialysis nurse 
or surgeon: (a) appear to be inadequate at inspection (discolouration/swelling), on 
palpation and auscultation (absence of thrill) (b) small-calibre vein at palpation, such 
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that it would be difficult to cannulate the vein with a 17-gauge dialysis needle; (c) 
less than 10 cm of palpable or visible draining vein length to allow cannulation 
(Allon and Robbin 2002; Robbin et al. 2002). 
2.4.8 Prediction of Maturation of AV F 
2.4.8.1 Introduction 
The care of patients suffering from CKD, prior to and during the dialysis treatment, 
is largely inefficient and uncoordinated, which has a negative influence not only on 
patient recovery but also on the healthcare sector (Rastogi et al. 2008). The proper 
functioning of the AVF is vital for the haemodialysis treatment and, as such, it is the 
main concern of kidney specialists and vascular surgeons. In the case of ESRD 
patients, the autologous fistula is the most suitable vascular access option. It has the 
lowest mortality rate in comparison to AVG and CVC, and has the lowest rate of re-
intervention (Konner et al. 2003). Due to these advantages, the NFK-DOQI 
guidelines endorse the use of native AVF, which has been noted to have a 65% 
primary success rate amongst patients about to commence haemodialysis (Brouwer 
et al. 2006). Konner et al. (2003) had also obtained a high success rate (70-90%) of 
native AVF construction in their study on a randomised sample of ESRD patients. 
Despite the fact that it is not without its faults, the arteriovenous fistula offers better 
quality access for dialysis as it has a long-lasting primary patency rate, does not 
necessitate numerous procedures, and has the most reduced rates of morbidity and 
mortality among all types of vascular access (Anel et al. 2003). 
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Being able to generate a prognosis regarding the cases in which the arteriovenous 
fistula is more likely to reach maturity, without additional procedures, would 
contribute to an increase in the prevalence of AVF construction and use. In cases 
where the chances of the fistula maturation are very low, an arteriovenous graft can 
be used. The previous studies on the assessment of predictive markers of fistula 
maturation varied to a great extent with regard to definitions, design, size of the 
study, patient sample and clinical aspects (Wang et al. 2011; Monroy-Cuadros et al. 
2010; Lok et al. 2005; Feldman et al. 2003; Huber et al. 2002; Robbin et al. 2002). 
As a result, surgeons and specialists are faced with the task of deciding which 
possible risk factors are more likely to occur than others, as well as which parameters 
to employ when evaluating the success rate of fistula development in patients 
awaiting the creation of a permanent access. 
The prognosis regarding the efficiency of the fistula is made with the help of duplex 
ultrasound, which are important instruments that enable the evaluation of the success 
rate of fistula development (Manns et al. 2005; Mendes et al. 2002). It may be 
possible to enhance the results of vascular access by gaining a more comprehensive 
picture about the factors involved in the efficient development of fistulae. In 
addition, this can generate important data during the pre-surgery evaluation that 
surgeons can use to base their decisions on. Independent predictive markers may be 
beneficial in anticipating the success rate of fistula development without the use of 
invasive tests and using tests that are cost-effective. The aim of the study is to 
formulate a simple, economical, clinically feasible, and easy to use prognostic model 
to provide an accurate prediction regarding the rate of successful development of 
each AVF. 
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2.4.8.2 Endothelial Function and AVF Maturation 
a) Role of Endothelium 
The endothelium is the largest organ in the body consisting of endothelial cells (ECs) 
lining every blood vessel. Augustin et al. (1994) reported that adults possess enough 
ECs that cover a surface area of approximately 1 to 7 m2, with a total weight of 
around 1kg, and a total quantity of 1,013-6,078 individual cells. In healthy subjects, 
vascular endothelium has many functions: it is able to identify hormonal stimuli 
(vasoactive substances) and mechanical stimuli (pressure and shear stress). ECs are 
able to regulate inflammation, cell proliferation, coagulation, and vascular tone due 
to their output of a number of compounded substances (Kolluru et al. 2012). 
Endothelium produced vasodilatory materials such as C-type natriuretic peptide, 
various endothelium-derived hyperpolarising elements, prostacyclin, and nitric oxide 
(NO), whereas vasoconstrictor materials are reactive oxygen species, thromboxane 
A2, angiotensin II, and endothelin-1 (Schiffrin 2001). In addition, there are a number 
of inflammatory regulators, such as nuclear factor-kB (NF-kB), vascular cell 
adhesion molecule-1, E-selectin, NO, and intercellular adhesion molecule-1. Gresele 
et al. (2010) reported that fibrinogen, prostacyclin, thromboxane A2, plasminogen-
activator inhibitor-1, NO, tissue factor inhibitor, von Willebrand factor, and 
plasminogen activator act as modulators for haemostasis. Permeability, 
inflammation, coagulation, cell adhesiveness, and vascular tone are among the 
variety of local blood vessel operations modulated by endothelium. Antonov et al. 
(1997) stated that in medium to large arteries, healthy ECs contribute to the prevent 
atherosclerosis by inhibiting platelet activation, limiting the entry of cells and lipids 
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into the vessel wall, maintaining a non-proliferative and biochemically inactive 
intima.  
b) Endothelial Dysfunction  
Deanfield et al. (2005) explained that endothelial dysfunction occurs when there is 
an imbalance between the, vasoconstricting and vasodilating materials (produced 
directly or indirectly by the endothelium). Goligorsky (2005) stated that endothelial 
cell dysfunction can be caused by multiple factors such as genetics, advance 
glycation end products, hyperglycaemia, high blood cholesterol, hypertension, 
obesity, diabetes, and smoking. Endothelial dysfunction is associated with higher 
aggregation of platelets, anticoagulant properties, decreased production of NO and 
higher secretion of cytokines, chemokines, or adhesion molecules and increased 
reactive oxygen species production from the endothelium (Al-Isa et al. 2010). 
Furthermore, Dandona et al. (2004) and Yu and Lyons (2005) found that individuals 
suffering from chronic kidney failure exhibit EC dysfunction. There is also a link 
between metabolic changes to nitric oxide synthase (NOS) and chronic kidney 
disease. Kharbanda and Deanfield (2001) explained that NOS is available to ECs in 
two types of isoforms; inducible and constitutive or iNOS and cNOS, respectively. 
Physiological vascular dilation is significantly affected by the constitutive isoform. 
In patients with advanced renal disease, NO production decreased from cNOS has 
been observed as a mechanism leading to impaired endothelium-dependent 
vasodilation in uraemia (Santoro et al. 2010). Furthermore, Passauer et al.'s (2005) 
research found a correlation between reduced NO production and reduced 
endothelium dependent vasodilation in dialysis patients.  
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Endothelial dysfunction has been conclusively shown to b e an early event in the 
progression of atherothrombosis and to have a predictive value for future ischaemic 
cardiovascular events (Deanfield et al. 2007; Verma and Anderson 2002). In the 
context of arterial ischaemic cardiovascular disease, endothelial dysfunction and in 
particular a reduction of the biosynthesis or of the biologic activity of NO, has been 
identified as a fundamental component of the pathophysiology of atherosclerosis and 
shown to be associated with risk factors such as hypercholesterolaemia, 
hyperhomocysteinaemia, diabetes, hypertension and smoking (Deanfield et al. 2007). 
Endothelial dysfunction is coupled with an increased oxidative stress and 
inflammatory changes that play a role in the development and progression of 
atherosclerosis in the early stages, while they increase the vulnerability of fully 
developed plaques facilitating their rupture (Verma and Anderson 2002).  
c) Endothelium and its effect on AVF Maturation 
Early fistula failure is usually due to thrombosis which can be triggered by 
haematoma, low flow rates resulting from low blood pressure, or by a 
hypercoagulable state (Konner 2000). On the other hand, research by De March et al. 
(1996) and Mysliwiec (1997) showed that progressive neointimal hyperplasia in the 
venous outflow system can lead to stenosis, which can cause late thrombosis of 
haemodialysis AVF. Arteriovenous fistula anastomoses need swift proliferation of 
endothelial cells to restore the barrier, permeability, biochemical monitoring roles of 
ECs in managing vascular repair, local thrombosis, neointimal hyperplasia and 
inflammation (Cowan and Langille 1996). Because the migration and proliferation of 
ECs are restricted by uraemia, and because uraemia causes abnormal vascular 
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remodelling, neointimal hyperplasia can sometime be found at the point of 
anastomosis of vascular access. This results in primary access failure and ineffective 
dialysis (Roy-Chaudhury et al. 2006). 
Erdem et al. (1996) discovered that during haemodialysis, turbulent flow, 
intraluminal pressure and regular needle insertion caused endothelial damage, which 
led to haemostatic activation in AVF. Wakefield et al.'s (2008) study indicated that 
thrombus development and blood clotting could be stimulated by higher levels of 
factor V, plasminogen activator inhibitor-1, tissue factor and von Willebrand factor, 
as secreted by a dysfunctional venous endothelium. Furthermore, a dysfunctional 
venous endothelium favours the interactions with circulating tissue factor-bearing 
micro particles, further triggering localised blood clotting activation (Del Conde and 
Lopez 2005). 
According to Rekhter et al. (1993) and Kim et al. (2006), vascular stenosis of 
arteriovenous fistula is primarily the result of neointimal hyperplasia. The 
pathophysiology of neointimal hyperplasia consists of occurrence of extracellular 
matrix deposition, and proliferation, adherence, and migration of vascular smooth 
muscle cell (VSMC), which represents abnormal healing of wounds. Sung et al. 
(2008) found that growth factors and cytokines act as semi-regulators for the changes 
to the VSMC response. Tumor necrosis factor-α (TNF-α) stimulates the synthesis of 
other pro-inflammatory cytokines and adhesion molecules; it has a chemotactic 
activity for monocytes and stimulates migration and proliferation of VSMC. 
Additionally, inflammation is reduced by interleukin-10 due to its ability to hinder 
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cytokines such as TNF-α, which cause inflammation, and it also ceases the activation 
of inflammatory cells (Sung et al. 2008). 
Atherosclerosis and intimal thickening occuring at the bifurcation point of carotid 
artery in the area of low wall shear stress without unidirectional flow and with flow 
separation (Zarins et al. 1983). The association between intimal thickening, low wall 
shear stress, and low blood flow has also been demonstrated by several studies in 
different vascular models (Glagov et al. 1988; Mattsson et al. 1997; Guzman et al. 
1997). Paszkowiak and Dardik (2003) explain that shear stress represents the force of 
blood's friction against the wall of the blood vessel. The researchers have shown that 
an increase in shear stress usually results in endothelial rest and survival. In addition, 
higher levels of shear stress can also lead to the expression of regulators that prevent 
coagulation and inflammation, and can cause the endothelial cells to move along 
with the blood flow (Chiu and Chien 2011). As Guzman et al. (1997) and Keren 
(1997) explained, this generally leads to a lower level of neointimal hyperplasia and 
vessel dilation. 
The shear stress levels revert back to baseline due to these vascular reactions. On the 
other hand, the activation of ECs and proliferation, release of inflammatory and 
procoagulant substances and alterations to cellular shape, are all events that have 
been linked to reduction in shear stress and blood flow. This manifests as raised 
levels of neointimal hyperplasia and vascular constriction (Meyerson et al. 2001; 
Honda et al. 2001). Furthermore, Dardik et al. (2005) has revealed that vascular 
response seems to be significantly influenced by the exact type of shear stress. For 
instance, matrix metalloproteinase up-regulation, higher proliferation of cells, and a 
Chapter 2 
73 
 
pro-inflammatory environment can be caused by oscillatory shear stress (Gambillara 
et al. 2005). On the other hand, normal dilatation and endothelial stability are the 
outcomes of laminar shear stress (Honda et al. 2001).  
Corpataux et al. (2002) discovered that the fistula vein instantly deal with huge 
increase in blood flow following the creation of AVF. Additionally, there is an 
eventual thickening of the fistula vein wall and dilation of the venous lumen. This 
allows the fistula vein to be effectively deliver sufficient blood for haemodialysis and 
can be regularly needled for dialysis circulation. The next most significant 
hemodynamic factor that typically influence on an AV fistula is the circumferential 
or transmural pressure. Transmural pressure is produced inside the blood vessel, 
previous studies (Lehoux et al. 2006; Lehoux et al. 2004; Hayashi et al. 2003) have 
shown that increase in transmural pressure lead to an activation of smooth muscle 
cells, higher levels of extracellular matrix elements, and raised production of 
cytokine. These pathways invariably leads to the thickening of blood vessel wall, 
which resulted in a reduction of transmural pressure revert back to basal level.  
The influence of hemodynamic factors on the remodelling of freshly-generated 
arteriovenous fistula has been investigated by Corpataux et al. (2002), who employed 
Doppler ultrasound methods and echo-tracking to assess blood flow and pressure, 
vessel diameter, and the thickness of cross-sectional walls immediately after patients 
had been operated on. The researchers investigated the same variables at the 1 and 3 
month post-surgery stages. The researchers found that blood flow rose to 539 ml/min 
(range 325-990 ml/min) during the initial post-surgery week. This caused the mean 
shear stress to rise from its standard level of 5-10 dyne/cm2 to 24.5 dyne/cm2. 
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Additionally, the cephalic vein's internal diameter rose from 2,370-4,430 µm at week 
1 (before the operation), to 5,041 µm at the 1 month mark, and to 6,620 µm at the 3 
month mark. This pattern was caused by a reduction in shear stress, which dropped 
to a standard value: 18.1 dyne/cm2 at the 1 month, and 10.4 dyne/cm2 at the 3 month. 
Therefore, a negative correlation was found between vessel diameter and shear 
stress. Additionally, the cephalic vein's cross-sectional wall gradually increased, 
measuring 4.4 mm2 at the 1 week, 5.3 mm2 at 1 month, and 6.9 mm2 at 3 months, 
with a p value of < 0.028. This suggests that the vascular mass had risen. This being 
said, luminal stenosis did not occur due to the rise in the cross-sectional wall area. 
This was due to the rise in the diameter of the cephalic vein. Throughout the study, 
there were no fluctuations in the AV fistulae's blood pressure.  
Vahholder et al. (2001) and Cardinal et al. (2007) indicated that wound healing, 
migration, proliferation, viability, and other fundamental EC biological processes are 
restricted by the uraemic toxins found in the plasma of individuals with ESRD. This 
is particularly true at the site of haemodialysis vascular access. The failure of these 
EC processes has played crucial role in vascular remodelling. According to Chitalia 
et al. (2011), vascular remodelling is negatively impacted by EC dysfunction that is 
caused by uraemia. The result of this is vascular access failure, can be fatal to 
patients with ESRD since it is crucial to achieve vascular access for haemodialysis.  
2.4.8.3 Blood Markers and Factors in the Maturation of AVF 
According to Irish et al. (2009), vessel obstruction or immaturity account for 20-54% 
of cases of primary failure of arteriovenous fistula. The maturity of fistula is believed 
to be reduced by a number of demographic and clinical elements. Pisoni et al. (2002) 
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and Allon et al. (2000) indicated that a high rate of AVF maturation is influenced by 
a lower BMI, young age, male gender, and the absence of PVD and diabetes. 
a) Age as a factor for AVF Maturation 
It is possible that older people are at greater risk of diabetes and peripheral vascular 
disease. A meta-analysis of 13 cohort studies (of which 11 were retrospective) 
provides the best available evidence and finds that elderly individuals with 
radiocephalic AVFs had a higher primary failure rate and decreased patency 
(Lazarides et al. 2007). However, the definitions of “elderly” in the included studies 
ranged from 50 to 70 years, and the review was specific to wrist AVFs. 
Comparative studies on AVF patency in elderly and younger individuals has been 
conducted by Ridao-Cano et al. (2002), Obialo et al. (2003), Lok et al. (2005), Kim 
et al. (2006), Jennings et al. (2009) and Swindlehurst et al. (2011). In particular, the 
effect of the intima-media width of radial arteries on early failure of radiocephalic 
AVF was studied using ninety individuals with ESRD who had undergone vascular 
access surgery (Kim et al. 2006). The surgery removed 10mm long partial arterial 
walls using an elliptical type of microscopic analysis and a link between higher age 
and higher AVF maturation failure and intima-media width was revealed. The result 
of higher intima-media width is the loss of vascular elasticity and the vessel luminal 
narrowing causing a rise in arterial rigidity. Yan et al. (2010) showed that a separate 
risk factor for intima-media width in kidney disease patients is diabetes. 
Other studies, however, did not support worse AV fistula patency rates in patients. 
Lok et al. (2005) conducted a single-centre, retrospective analysis of over 440 AVFs. 
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The study compared the results of AVF in different age groups finding that the 
construction of AVFs should not be affected by age. However, single centre study 
results may limit its external generalizability. Other studies results also showed no 
relationship between primary AVF patency rates and age. Thus, the link between 
degree of AVF success and age is unclear and no definite conclusions can be made 
(Swindlehurst et al. 2011; Weale et al. 2008; Burt et al. 2001; Wolowczyk et al. 
2000). 
b) Gender as a Factor for AVF Maturation 
Research is now questioning the traditional belief that men have larger vessel 
diameters than women. In the Haemodialysis (HEMO) Study, female gender was 
identified as a significant predictor of AVG rather than AVF use (Allon et al. 2000), 
but there is little specific evidence for AVF patency differences between genders. A 
longitudinal study (Astor et al. 2000) examined vascular access complications in a 
large cohort (n = 833) of haemodialysis patients who had a permanent access in use 
one month after starting haemodialysis therapy and compared complications in men 
and women. The study found that female gender was associated to a relative hazard 
of 1.58 (95% CI, 1.05 to 2.35) in AVF patients as compared to male gender. 
However, a retrospective study of over 190 individuals did reveal variations in 
vasculature between men and women. Vessel diameters were calculated at twelve 
arterial sites and seventeen venous sites revealing that no considerable variations 
exist in these diameters between genders. Furthermore, meta-analysis by Rooijens et 
al. (2004) indicated that men and women’s one-year patency levels and maturation 
for radiocephalic AVFs is similar. 
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c) Coagulation Factors (PT, INR) as a marker for AVF Maturation 
Arteriovenous fistula dysfunction remains a major contributor to the morbidity and 
mortality of patients on haemodialysis (Vachharajani 2012). The failure of a newly 
created AVF to mature and development of stenosis in an established AVF are two 
common clinical predicaments. The commonest cause of failure of a mature AVF is 
stenosis of the venous segment, with 20–40% occurring within the first few 
centimetres of vein distal (upstream) to the anastomosis known as the “swing 
segment” (Conte et al. 2009).  
Chang et al. (2005) observed that the infiltration of a great number of macrophages 
and a various number of lymphocytes in the vascular lining of an obstructed AVF 
caused a considerable increase in inflammatory activity. It has long been recognised 
that the endothelium plays a vital role in the prevention of thrombosis, regulation of 
coagulation and lipid transport (Tooke and Lowe 1996). Atherosclerosis can lead to 
disruptions to the vascular endothelium, which enables platelets to accumulate and 
fasten to the endothelium, and initiate the clotting outpouring. This could potentially 
degenerate into obstruction of the vessel (Pearson 1994). When the endothelium 
deteriorates, the endothelial cells produce and release in the plasma a variety of 
substances such as plasminogen-activator inhibitor-1, von Willebrand factor, 
thromboxane A2, fibrinogen, tissue factor, which can be used as indicators of the 
degree of endothelial disruption (Galley and Webster 2004; Verma and Anderson 
2002). 
Warfarin prevents coagulation within the AVF, potentially prolonging the duration of 
patency. A double blind randomised controlled trial (Crowther et al. 2002) was 
Chapter 2 
78 
 
performed to compare the response triggered by administration of low intensity 
warfarin (variation in dosage but intended to maintain an international normalised 
ratio of 1.4 to 1.9) to the response triggered by placebo in maintaining the patency of 
prosthetic AVGs. A random sample consisting of 107 participants, 56 being 
administered warfarin and 51 being administered placebo, was used and monitored 
for two years. The warfarin group revealed an overall graft loss of 73%, whereas the 
placebo group exhibited a 61% loss. Major bleeding was experienced by those 
treated with warfarin (six cases versus zero). The study was stopped prematurely due 
to serious side effects. Therefore, the risk-benefit does not favour anticoagulation 
unless there is another established indication. 
Grontoft et al. (1998) double blind randomised controlled study aimed to verify that 
ticlopidine is both a successful and harmless way of decreasing AVF early failure 
rates. The study consisted of 258 individuals from nine dialysis centres in Linkoping, 
Sweden, who were offered AVF construction for haemodialysis. For a week prior to 
the procedure and for four weeks following it, the medication (either a placebo or 
ticlopidine) was administered to the study participants. The findings revealed that 
19% of the study subjects given the placebo developed thrombosis whereas only 
12% of the study subjects who were given ticlopidine developed thrombosis. In 
regards to preventing thrombosis following AVF procedures, however, the results 
did not reveal that ticlopidine had any noteworthy effect. 
Dember et al. (2008) carried out a randomised, double blind, and placebo-controlled 
trial in numerous centres in United States, which focused on the effects of 
clopidogrel administration to a sample of 877 patients suffering from advanced CKD 
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or ESRD, who had just undergone surgery for fistula construction. However, the 
statistical power of the study to detect the effect of clopidogrel on the outcome was 
limited because the achieved sample size of 877 was 32% smaller than the target 
sample size. The goal of this study was to evaluate the impact of platelet suppression 
on AVF thrombosis and maturity of AVF. Fifty-three patients (12.2%) who had been 
administered clopidogrel developed fistula thrombosis, in contrast to 84 patients 
(19.5%) who had been administered placebo. The study results concluded that 
clopidogrel reduces the incidence of early thrombosis of new arteriovenous fistulas.  
A systematic review was conducted by Osborn et al. (2008) to identify the influence 
of adjuvant drug therapy on fistula and graft patency rates in patients diagnosed with 
ESRD. A total of ten randomised controlled trials using anti-platelet drugs such as 
ticlodipine, aspirin, dipyridimole and clopidogrel or anti-thrombotic drug treatment 
to prevent blockages in the artery and vein access points for dialysis was included. 
Results showed that antiplatelet drugs, including ticlopidine, aspirin, and clopidogrel, 
had a positive influence. As such, it would seem that the administration of 
antiplatelet drugs to patients with AVF is feasible. However, most of the included 
trials had a short follow-up period so that any benefits in the longer term are not 
clear. 
d) Lipid Profile (TC, TG, HDL) as a marker for AVF Maturation 
Thrombosis of AVF is an important cause of morbidity among patients undergoing 
haemodialysis. The part that serum lipid profile plays in this is still largely unknown. 
Kirkpantur et al. (2008) conducted a retrospective three-year study on a group of 99 
patients to analyse the connection between serum lipid profile and fistula thrombosis. 
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The study results showed that the serum levels of cholesterol and the levels of 
triglyceride observed in patients with fistula thrombosis and those with functional 
fistula were similar. Nonetheless, the former exhibited considerably reduced high-
density lipoprotein and albumin, higher low-density lipoprotein and serum C-reactive 
protein levels than the latter. 
The features of classic uraemic dyslipidaemia are high levels of triglyceride, reduced 
high-density lipoprotein, and overall concentration of cholesterol. Advanced kidney 
failure enhances these features, whereas RRT and co-morbidity, such as diabetes 
mellitus, alter the features (Chan et al. 2008). In association with CKD, 
atherosclerosis progresses more rapidly and it manifests as extremely calcified 
plaques which adhere to the subintimal layers of the artery wall. One of the reasons 
for this is that lipids in high concentration interfere with the mediators (angiotensin 
II, endothelin-1, plasminogen activator inhibitor-1, Prostacylin, and Nitric oxide) 
believed to impact on renal function (Heymann et al. 2012). A long-term case-
control study in 60 patients with autologous AVF was carried out to analyse the 
effect of drugs or factors on AVF patency. Mean follow up time was 25 months. 
Study results showed improved fistula patency (71.5 versus 39.1%) at 2 years in 
patients taking folic acid and statin compared to those on no statin therapy (Righetti 
et al. 2009). However, in this small, single centre study, no significant difference was 
noted in HDL, LDL, TG and TC except homocysteine (p<0.01). 
e) Urea, Creatinine and Electrolytes as a marker for AVF Maturation 
The pre-operative treatment of individuals suffering from CKD or dialysis-based 
ESRD is made difficult by the actual renal condition, with the accompanying 
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disruptions of fluid and electrolyte homeostasis and damaged drug filtration system, 
as well as by co-morbidity, such as diabetes mellitus, chronic hypertension, 
cardiovascular and cerebrovascular disease. Several studies (Roy-Chaudhury et al. 
2007; Schwab et al. 1997; Windus 1993; Fan and Schwab 1992) have revealed that, 
in up to 80% of cases, vascular access breakdown is brought about by vascular 
obstruction in conjunction with pre-existing stenosis of the draining vein of the AVF. 
In arteriovenous fistula, thrombosis can also be caused by inflammation. In their 
study, Churchill et al. (1992) found that AVG obstruction was most frequently 
determined by hypoalbuminaemia. Further studies have revealed that 
hypoalbuminaemia, apart from being a sign of dietary deficiency in uraemic patients, 
is also a symptom of inflammation (Kaysen and Don 2003; Kaysen et al. 2000; 
Stenvinkel et al. 1999). From these, an indirect conclusion may be drawn that 
inflammation is involved in AVF thrombosis. 
Endothelial cell dysfunction is often observed in individuals with impaired kidney 
function (Yu and Lyons 2005; Annuk et al. 2001). Plasma from patients with ESRD 
or uraemic toxins, inhibit fundamental endothelial cell biological processes such as 
viability, proliferation, migration and wound healing (Cardinal et al. 2007; 
Vanholder et al. 2001). Abnormalities in these endothelial cell functions play a key 
role in vascular remodelling, especially at the site of dialysis vascular access. 
Arteriovenous fistula require rapid proliferation of endothelial cells to restore the 
barrier, permeability, biochemical regulatory functions of endothelial cells in 
controlling vascular repair, local thrombosis, inflammation and neointimal 
hyperplasia (Cowan and Langille 1996). Since uraemia inhibits endothelial cell 
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proliferation and migration, and eventually results in abnormal vascular remodelling, 
neointimal hyperplasia at the site of anastomosis of vascular access is common. This 
results in primary access failure and ineffective dialysis (Roy-Chaudhury et al. 
2006). 
The association between endothelial function and early stage progressive kidney 
disease has been investigated as a means of uncovering if clinically evident 
atherosclerotic vascular disease in CKD patients is linked to endothelial function 
abnormalities (Thambyrajah et al. 2000). The study consisted of twenty-six healthy 
participants and eighty individuals suffering from chronic renal failure with each 
group similar in regards to gender and age characteristics. Two indices of endothelial 
function were assessed: high resolution ultrasonography to measure flow mediated 
endothelium dependent dilatation of the brachial artery following reactive 
hyperaemia, and plasma concentration of von Willebrand factor. Endothelial 
dysfunction was identified in those with chronic kidney failure including individuals 
with only minor kidney inefficiency. These abnormalities were independent of 
differences in known vascular risk factors and vessel size between the two groups 
and suggest that chronic renal failure may directly induce endothelial dysfunction, 
thereby promoting the development of atherosclerosis.  It is also possible that 
clinically silent atheroma is already present in most patients with renal failure by the 
time of presentation. 
f) Vein Diameter as a marker for AVF Maturation 
Endothelial function is associated with arterial and venous remodelling; this finding 
is associated with basic haemodynamic principles (Owens et al. 2010). As more 
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blood is delivered through the venous outflow limb of the AVF, wall shear stress, 
proportional to the amount of blood flow velocity and lumen diameter, will rise. 
Theoretically, this should lead to venous dilation to normalize the shear stress. There 
is a high degree of correlation between the flow rate through an AVF and the venous 
diameter indicating that flow is a primary determinant of final venous diameter 
(Owens et al. 2010; Wedgwood et al. 1984). It is likely that the magnitude of 
remodelling depends on the hemodynamic stimuli, endothelium-derived mediators, 
and the baseline stiffness of the vessels.  
The inadequate vessels used to construct AVFs have been identified as another cause 
of AVF failure. Allon and Robbin (2002) have proposed the use of pre-surgery 
ultrasound assessment to ensure that the vessels chosen can support the construction 
of AVF. Zadeh et al. (2012) conducted a cross-sectional study using a sample of 96 
haemodialysis patients, all of them with native AVF to determine the relation 
between diameter and maturation of AVF. Study results found an association 
between the vein diameter and the success rate of fistula development; however, a 
similar connection was not observed between the fistula maturation and the artery 
diameter. 
g) Diabetes as a marker for AVF Maturation 
The most preferred type of vascular access used for haemodialysis is AVF (UK 
Renal Registry Report 2011; USRDS 2008). Nevertheless, there has been an increase 
in the rate of AVF failure in the last three decades caused by the growing number of 
elderly CKD patients, who also suffer from diabetes or vascular disease. Diabetes 
has become the major determinant of blindness, kidney failure, and leg amputation in 
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most countries (ADA 1998). In addition, diabetics are more likely to develop 
peripheral vascular disease, particularly if they are also smokers or suffer from 
hypertension and hypercholesterolemia. 
As noted by Aronson et al. (1996), the changes in metabolism that accompany 
diabetes can manifest as pro-thrombotic situation, damage to the endothelium, 
deregulation of growth factors and increase in extracellular matrix deposition. 
Inflammation can participate in the initial development of AVF stenosis and 
thrombosis (Marrone et al. 2007; Chang et al. 2005). 
Endothelial dysfunction has been explained by Deanfield et al. (2005) as a 
disproportion between the amount of vaso-dilatory and vaso-constricting substances 
generated by the endothelium or between the general endothelial activities. 
Endothelial dysfunction can either be a part of the mechanisms of a number of 
diseases, including diabetes mellitus, hypertension, hypercholesterolaemia, or arise 
from these diseases or due to environmental factors, such as exposure to air pollution 
and smoking tobacco products (Cai and Harrison 2000). The deregulation of the 
endothelium manifests as decreased production of nitric oxide, increased platelet 
aggregation, and anticoagulant features (Al-Isa et al. 2010). All these aspects have a 
role in the occurrence of vascular problems in diabetics, such as atherosclerosis.  
A key component of AVF maturation is adequate dilation of the outflow vein. 
Changes in blood flow induce vascular remodelling and the response to flow changes 
is controlled by the endothelium (Dammers et al. 2005; Ene-Iordache et al. 2003). 
Upon damage to the vein during the AVF construction, the endothelium is disturbed, 
succeeding to impair venous remodelling. A retrospective analysis (Conte et al. 
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2011) was performed on the 31 AVF patients to identify factors that may influence 
AVF remodelling. The results indicated that diabetes is a significant, negative 
predictor of venous remodelling. However, the sample size was small and thus the 
significance of the findings may be questionable. 
h) Hypertension as a marker for AVF Maturation 
Risk factors such as cardiovascular disease, hyperlipidaemia, and hypertension 
poorly predict AVF non-maturation, prompting investigations into other risk factors 
such as hemodynamic profile or vessel morphology (Kharboutly et al. 2007). 
Endothelial function is impaired in hypertension (Stefano et al. 2001) which 
decreases vascular relaxation and initiate inflammatory cell infiltration and slight 
inflammation in blood vessels (Satoh 2012). Macrophages and T cells represent the 
basic pathological features of the development of atherosclerosis. From their initial 
location in elastic arteries in spaces that do not come under extreme shear stress, 
these features are propagated to the innermost membrane of the smooth muscle cells 
where they lay down connective tissues and initiate neovascularisation (Griendling 
and Alexander 1994).  
Other studies, however, did not support hypertension as a major risk factor for AVF 
maturation (Kim et al. 2011; Lauvao et al. 2009). A recent study by Kim et al. 
(2011) performed a single centre cohort study (38 men and 12 women) to assess 
patients’ factors, diameter and distensability of the radiocephalic vein at the wrist. 
Study analysis did not find any positive correlation between AVF maturation and 
patients’ factors (that is hypertension, diabetes, and gender). However, the sample 
Chapter 2 
86 
 
size was not large enough to detect the effect between AVF maturation and 
hypertension. 
i) PVD as a marker for AVF Maturation 
The prevalence of PVD in people suffering from diabetes is four times higher than 
those without diabetes (Gregg et al. 2004). PVD has developed gradually as a result 
of systemic atherosclerosis and represents one of the three main symptoms which 
characterise atherothrombosis, together with coronary artery disease and 
cerebrovascular disease (Hiatt et al. 1995). Atherothrombosis manifests as a 
thrombus that develops on top of a ruptured plaque situated at an afflicted part of the 
artery. Atherosclerotic plaques also form at vessel bifurcation point, possibly because 
of damaged protection mechanisms and disruptions in the flow of blood at these sites 
(Warboys et al. 2011).  
In the case of AVF used for haemodialysis access, vessel thrombosis represents the 
major factor, which determines AVF failure. Chang et al. (2005) argued that vascular 
inflammation may participate in this process, as it represents a significant symptom 
of vascular diseases. Ku et al. (2006) recruited 43 pre-dialysis patients awaiting AVF 
creation for the first time to compare the intima media thickness of the vessels 
among uraemic patients, uncomplicated hypertensive patients and healthy subjects 
by using ultrasonographic measurements. Study findings reported that intima media 
thickness measurements during preoperative Doppler ultrasound imaging correlated 
significantly to histologic measures and, more importantly, to AVF thrombosis and 
to inadequacy of an AVF to maintain dialysis at one year. Similarly, a single centre, 
cross sectional study of 225 patients was conducted to evaluate the relationship 
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between ankle-brachial pressure index (ABPI) < 0.9 and vascular access failure. 
Study findings showed that ABPI is a reliable marker for peripheral vascular disease 
and has a significant association with access failure after adjusting for other variables 
(Chen et al. 2009). However, the study subjects were included only in one regional 
hospital and thus the selection of patients was limited and the design of the study is 
observational, therefore it is susceptible to selection bias. 
j) Smoking as a marker for AVF Maturation 
Churchill et al. (1992) and Reilly et al. (1982) have analysed the influence of 
smoking history on vascular access morbidity but did not obtain any conclusive 
results. Wetzig et al. (1985) had earlier shown that smokers undergoing 
haemodialysis exhibited an increased prevalence of early or late AVF failure. The 
discrepancies observed in the results could be attributed to the fact that earlier 
peripheral vascular impairment in former and current smokers can trigger acute AVF 
obstruction. Ozdemir et al. (2005) examined the effects of smoking and blood 
eosinophil count AVF maturation. This cross-sectional study included 141 patients 
with advanced renal failure. AVF thrombosis was detected in 60 patients; in contrast, 
81 patients had no thrombosis. The study findings strongly indicate that smoking in 
conjunction with a high amount of blood eosinophils can play a role in the 
occurrence of AVF failure. One of the limitations of the study was that it was 
retrospective and limited to a single centre. 
In addition, progression of atherosclerosis and ischaemic nephropathy may play a 
part as well (Ritz and Orth 2000). Endothelial dysfunction can be accompanied by 
factors, which increase the likelihood of development of atherosclerosis, including 
Chapter 2 
88 
 
oxidized lipids, diabetes mellitus, and smoking (Brunner et al. 2005; Wilson 2004; 
Hackam and Anand 2003; Madore 2003; Shimokawa 1999). Endothelial dysfunction 
generates a number of biological effect, that aids the advancement of atherosclerosis, 
such as vasoregulation (Landmesser et al. 2004; Widlansky et al. 2003; Keaney 
2000), enhanced blood coagulation (Bombeli et al. 1997), facilitating the penetration 
of inflammatory cells and lipids into the innermost wall layer (Schwartz et al. 1999), 
and enhancing the movement and multiplication of vascular smooth muscle cells 
(Raymond et al. 2004). 
k) Obesity as a marker for AVF Maturation 
The number of obese ESRD patients, who also are diagnosed with type 2 diabetes, is 
experiencing a constant growth (Postorino et al. 2009). This group of patients are 
associated with a higher rate of AVF failure as they are predisposed to 
arteriosclerosis and the vessels in the forearm are more difficult to reach due to thick 
fat tissue (Kats et al. 2007). This also increases the difficulty of performing 
phlebotomy on the fistula situated at a considerable depth. Chan et al. (2008) carried 
out a retrospective cohort study on a group of 1486 patients to analyse the connection 
between obesity and vascular access complications, using BMI of less than 30 kg/m2 
as reference for obesity. The study results found that there was no connection 
between obesity and a higher rate of fistula failure; however, a relation between 
insufficient fistula development and a high BMI was observed (Odd Ratio 3.66, 95% 
CI-1.27–10.55, p = 0.017). Because this study represents the fistula outcomes from a 
single dialysis centre, the findings may not generalize to all dialysis centres. For 
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example, in centres not using routine preoperative vascular mapping, the frequency 
of fistula placement may be lower in obese, as compared to non-obese patients.  
Generally, in the case of patients who are obese, diabetics, of female sex, older than 
65 years, or patients who suffer from vascular diseases, native AVF is constructed to 
provide access for haemodialysis (Weyde et al. 2008; Allon et al. 2000). In obese 
patients, low rates of long-term AVF preservation are usually caused by early vessel 
thrombosis, which is considered to degenerate from advanced myointimal 
hyperplasia, determining an earlier occurrence of vessel stenosis. The theory is 
corroborated by the fact that a connection has been found between hyper 
insulinaemia and high levels of serum interleukin 6, and advanced myointimal 
hyperplasia, as well as an increased incidence of vessel thrombosis in patients 
undergoing haemodialysis (De Marchi et al. 1996). Interleukin 6 stimulates the 
production of C-reactive protein, high levels of which have been recorded in obese 
patients (Ramkumar et al. 2004). In addition, Kuji et al. (2005) revealed that C-
reactive protein contributes to the advancement of myointimal hyperplasia, which 
provides further evidence in the high rate of AVF failure in obese patients. 
l) Dialysis as a marker for AVF Maturation 
Late referral of patients initiating dialysis therapy with a temporary CVC can impair 
the patency rate and fistula maturation. If the fistula is constructed after the patient 
has begun the dialysis therapy it could lead to the extension of the haemodialysis 
treatment with the temporary CVC, which could determine the development of a 
number of complications, such as insufficient blood flow, haematoma formation, 
recurrent thrombosis or failure, fibrosis and vessel wall damage and bacteraemia 
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(Ravani et al. 2004; Avorn et al. 2002; Roubicek et al. 2000; Schwab and Beathard 
1999).  
Previous studies examined the complications related to central venous catheter use 
before AVF construction and have reported venous thrombosis rates as high as 58%, 
with a susceptibility for thrombosis in the cephalic and basilic vein (Abdullah et al. 
2005; Allen et al. 2000). Through a prospective observational study results have 
shown that a temporary catheter used at the initiation of dialysis is linked to a higher 
risk of vascular access failure (Rayner et al. 2003). The authors hypothesized that 
AVF patency rates and maturation could be influenced by catheter utilisation and 
related problems. This research used a substantial study sample of dialysis patients 
(n=3674) and involved an epidemiological study that took place in over 300 
institutions across Europe, in America and in Japan. However, as pointed out by the 
authors themselves, because of an observational study, it is not possible to make a 
causal link between cannulation and catheter utilization and subsequent fistula 
failure. 
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3.1 Research Design 
This is a single centre exploratory study, to evaluate the effect of blood markers and 
risk factors in the prediction of maturation of AVF. This study has been divided into 
two parts. In the first part a regression model was developed on retrospective data of 
300 patients, who had undergone vascular access surgery (AV Fistula) between 2006 
and 2009 in Royal Infirmary of Edinburgh. In the second part (prospective) data of 
100 newly recruited participants, who had undergone the surgical procedure (AVF 
creation), was used to validate the model developed from retrospective data. This 
method of development and validation of prediction model was adopted to estimate 
the probability of developing a particular outcome in the future (prognosis) as in our 
study, maturation or non-maturation of AVF (Collins et al. 2011; Mallett et al. 
2010). The purpose of developing a model was not intended to replace clinical 
judgment, prediction models have a clear role in strengthening clinical judgment. 
Studies have shown prediction models provide more accurate and less variable 
estimates of risk compared to more subjectively made predictions (Kattan et al. 
2013; Ross et al. 2002).  
Before considering whether to use a clinical prediction model, it is essential that its 
predictive performance be empirically evaluated in datasets that were not used to 
develop the model (Steyerberg et al. 2013; Altman et al. 2009). This is referred as 
external validation (Steyerberg et al. 2009). Performance is typically characterised 
by evaluating a model’s calibration and discrimination (Kuehn 2013). Reasons for 
assessing performance in other datasets include quantifying optimism from model 
over fitting or deficiencies in the statistical modelling during model development and 
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evaluating the transportability of the model in different locations consisting of 
plausibly similar individuals (different case-mix). External validation is exploring 
genuine differences in characteristics of the cohorts (between the development and 
validation cohorts) and examining how well the model performs. 
3.2 Sample Size 
The goal was to explore associations between maturation of arteriovenous fistula 
(dependent variable) and biomedical variables (independent variables) in predicting 
fistula maturation. Maturation of fistula can be determined by predictive logistical 
regression models that may become imperative tools to estimate patient outcome 
probabilities (mature/immature AVF). Sample size analysis is a key component in 
designing a statistical study. It investigates the optimal allocation of study resources 
to increase the likelihood of the successful achievement of a study objective. For 
binary logistical regression, effective sample size can be estimated by the number of 
events or non-events (van Houwelingen and le Cessie 1990). 
The proportion of events (failure of the fistula to mature adequately to support 
dialysis therapy) is approximately 50% (Mendes et al. 2002) with 100 sample data 
that may mean that this would provide only 50 events. It is thought that, a minimum 
of 100 events and 100 non-events are suggested to obtain adequate power in the 
development of model. The power of a statistical test is the probability of rejecting 
the null hypothesis in favour of an alternative hypothesis when the alternative 
hypothesis is true (Maxwell et al. 2008). Samples with around 100 events had 
approximately 80% power to identify significant variations in model performance 
(Vergouwe et al. 2005). Prognostic models do not always work well in practice, as 
Chapter 3 
94 
 
often they are too optimistic, so it is extensively suggested that they need to be 
validated in patients other than those from whose model was developed (Altman and 
Royston 2000).  
The external validity of a model does not only depend on the development process of 
the model, but also on the new patients for whom the model is applied. A total of 400 
participants were recruited, with two thirds (300, retrospective) for model 
development and one third (100, prospective) for the model validation (Stone 1974). 
3.3 Ethical Approval 
This study was reviewed and given favourable ethical opinion by the South East 
Scotland NHS Research Ethics Committee, NHS Research and Development and the 
Queen Margaret University ethics committee (Appendix I). 
3.4 Informed Consent 
Patient’s participation in this research was entirely voluntary. Written informed 
consent was obtained from all study participants and those not capable to provide an 
informed consent have been excluded (Appendix II). All ethical guidelines were met 
to ensure the safety and well-being of the participants and the researcher. A detailed 
information sheet was prepared to provide the patients all the information required in 
order to make an informed decision regarding participation in the project (Appendix 
III). Participants were aware that they can withdraw from the study at any point, 
without giving a reason and the withdrawal did not affect their treatment in any way. 
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3.5 Retrospective Study (Development of Prognostic Model) 
Retrospective study was performed systematically in different steps from 
identification, screening, recruitment, data collection of potential participants and 
finally data analysis by using appropriate statistical test (Figure 9)  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 9. Flow Diagram Showing Steps of Retrospective Study 
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3.5.1 Recruitment of Participants 
The vascular access nurse specialists provided significant help in identifying the 
potential candidates to the research project. The potential participants were carefully 
chosen by the researcher on the basis of inclusion and exclusion criteria from those 
who underwent vascular access surgery at the Royal Infirmary of Edinburgh. 
Initially, a list detailing patients who had undergone vascular access surgery was 
obtained from vascular access nurse specialists. Purposive sampling technique was 
used for patient’s recruitment. A retrospective case note review was performed on all 
patients identified from the hospital vascular access database as having undergone 
construction of AVF. The medical case files of the patients who had undergone 
fistula surgery between 2006 and 2009 were retrieved from the medical records 
(Proton® software, and Apex® software) at the Royal Infirmary Edinburgh. At the 
beginning all potential participants’ records were screened comprehensively. From 
the data, reports of patients were developed from the pre-operative assessment papers 
and the clinical results of their operation obtained from the clinical records and 
follow up case notes. 
A total of 1008 fistula were constructed during the period. From these 300 cases 
having first time AVF creation and 708 patients were excluded due to incomplete 
information in relation to the fistula outcomes or those already undergone prior AVF 
creation. 
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3.5.2 Inclusion Criteria  
• Aged 18 years and older.  
• Both genders (Male/Female) were eligible for the study. 
• Patients diagnosed with end stage renal disease. 
• Patients underwent AV fistula creation at the Royal Infirmary of Edinburgh. 
3.5.3 Exclusion Criteria 
 Patients who had undergone a repeat AVF creation (2nd and further fistula 
creations) 
3.5.4 Outcome Measures 
The portfolios of the measures to be used were: 
3.5.4.1 Demographics 
In this study patient age, gender, surgeon, type of fistulae, dialysis therapy before 
AVF creation has been included in the analysis as previous research found their 
association with   the maturation of AVF.  A number of studies supported worse AV 
fistula patency rates in elderly versus non-elderly patients (Obialo et al. 2003; Ridao-
Cano et al. 2001; Burt et al. 2001). Increased age has been associated with increased 
intima-media thickness associated with AV fistula failure (Kim et al. 2006).  
In the HEMO Study, female sex was identified as a significant predictor of graft 
rather than AVF use (Allon et al. 2000). Results of a retrospective study reveals that 
female gender is one of the risk factor for fistula maturation failure (Rodriguez et al. 
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2000). However, a meta-analysis of eight prospective and 30 retrospective studies 
did not reveal statistically significant differences in gender and age (Rooijens et al. 
2004). 
In a systematic review of 34 studies, primary patency rates of upper arm fistulae 
were approximately 81% compared with 71% in forearm fistulae (Huber et al. 2003). 
Although AVF failure rates have varied slightly from study to study and across 
patient populations, forearm fistulae in particular are well documented as failing to 
mature at rates greater than that of upper arm fistulae (Huber et al. 2003; Miller et al. 
2003). In spite of this, forearm fistulae remain the primary vascular access of choice 
due to relative ease of creation and preservation of proximal vasculature for future 
access attempts. 
Moreover late nephrology care is associated with frequent use of short-term central 
venous catheters, whose complications may increase the risk of arteriovenous fistula 
failure, especially due to central venous stenosis and early cannulation of the native 
vascular access (Ravani et al. 2005). A case-control study was conducted to assess 
the association between past peripherally inserted central catheters and lack of 
functioning AVFs in 282 (El Ters et al. 2012). Study results found a strong and 
independent association between peripherally inserted central catheters use and lack 
of a functioning AVF (OR, 3.2; 95% CI, 1.9 – 5.5; p < 0.001). 
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3.5.4.2 Risk Factors (DM, HTN, PVD and Smoking) 
Diabetes is a well-known risk factor for vascular disease and arteriosclerosis. 
Leapman et al. (1996) concluded that patients with diabetes are at risk of poor 
outcomes with the arteriovenous fistula. Konner et al. (2002) found AVF survival 
similar to that of nondiabetic patients. However, steal syndrome was more common 
in the diabetic group. Maturation of AVFs was found to be worse with hypertension 
patients in recently published studies (Kaygin et al. 2012; Palmes et al. 2011). After 
the fistula creation, vessel calcifications were detected in diabetics and hypertensive 
patients, leading to arteriosclerosis and thickening of the arterial wall (Erkut et al. 
2006; Chin et al. 2004). 
The presence of peripheral vascular disease has been associated with an increased 
risk of AVF failure. Ku et al. (2006) reported that intima media thickness 
measurements during preoperative Duplex ultrasound imaging correlated 
significantly to histologic measures and, more importantly, to AVF thrombosis and 
to inadequacy of an AVF to maintain dialysis at 1 year. Similarly, ankle-brachial 
pressure index, a reliable marker for peripheral vascular disease, had a significant 
association with access failure after adjusting for other variables (Chen et al. 2009). 
Multiple studies have suggested that smoking has the negative effect on the AVF 
maturation (Monroy-Cuadros et al. 2010; Gheith and Kamal 2008; Wetzig et al. 
1985). A cross-sectional study included 141 patients to determine the effects of 
smoking and blood eosinophil count on the development of AVF thrombosis. Study 
indicated that smoking and high blood eosinophil count contribute to the 
development of AVF thrombosis (Ozdemir et al. 2005). 
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3.5.4.3 Kidney Function Tests (Na, K, Ca, HCO3, Urea, Creatinine, eGFR) 
The kidney function test which examines that the kidneys are working correctly, 
measures the level of uraemic toxins in the blood such as urea, creatinine, eGFR and 
electrolytes (Na+, K+, Ca++ and HCO3). High levels of uraemic toxins may reduce 
endothelial and cardiac function worsening blood flow to the vascular access (Ravani 
et al. 2004). A recent retrospective cohort study, to test uraemia as a predictor of 
AVF maturation in 16 patients with advance kidney disease concluded that uraemia 
is not a predictor of time-to-AVF maturation or primary patency failure (Pannu and 
Misra 2012). However, the number of subjects was minimal and research utilising a 
bigger study group is required. 
3.5.4.4 Coagulation Profile (PT and INR) 
Early failure of fistulas due to thrombosis or inadequate maturation is a barrier to 
increasing the prevalence of fistulas among patients with end stage renal disease. The 
time required for coagulation to take place is known as prothrombin time. The 
shortness of time is determined mainly by prothrombin concentration. The 
International Normalised Ratio (INR) is a ratio of the persons PT to a normal control 
sample raised to the power of international sensitivity index (International 
Committee for Standardisation in Haematology 1985).  
Recent retrospective analysis of results of AVF created for haemodialysis in CRF 
patients suggested that judicious use of antiplatelet/anticoagulant agents in cases of 
AVF for haemodialysis access can be beneficial in preventing the chances of 
occlusion of AVF and thus helps in its long term patency (Yogi et al. 2012). A 
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randomized, double-blind, placebo controlled trial was conducted at nine US centres 
composed of academic and community nephrology practices in 2003-2007 (Dember 
et al. 2008). Eight hundred seventy-seven participants with end stage renal disease or 
advanced chronic kidney disease were followed up until 150 to 180 days after fistula 
creation. Study results showed that Fistula thrombosis occurred in 53 (12.2%) 
participants assigned to clopidogrel compared with 84 (19.5%) participants assigned 
to placebo (relative risk, 0.63; 95% confidence interval, 0.46-0.97; p = 0.018). 
3.5.4.5 Lipid Profile (TC, HDL and TG) 
Findings of previous studies revealed a close relationship between vascular access 
thrombosis and hyperlipidaemia as indicated by higher values of cholesterol, 
triglycerides, low-density lipoprotein cholesterol and lower values of high-density 
lipoprotein cholesterol (Serati et al. 2007; De Marchi et al. 1996). Moreover, results 
of a retrospective study suggested that not total cholesterol, but lipid subfractions 
(LDL and HDL) were associated with AVF thrombosis (Kirkpantur et al. 2008). 
3.5.4.6 Vein Diameter 
Multiple studies were published that report good or improved AVF outcomes 
achieved with the use of pre-operative ultrasound. Almost all report a higher rate of 
AVF in preference to arteriovenous grafts (AVG) and better primary patency AVF 
(McGill et al. 2005; Nguyen et al. 2003; Ascher et al. 2000). A Meta-analysis of 
preoperative Duplex ultrasound vessel diameters for successful AVF placement 
revealed that the use of Duplex ultrasound is important in determining preoperative 
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vessel diameter size, and subsequent functional success rate of fistula placement 
(Glass et al. 2009). 
3.5.4.7 Body Mass Index 
In prospective study including patients receiving a first fistula or graft during a 2-
year period the access outcomes were compared between obese (BMI ≥ 30 kg/m2) 
and non-obese (BMI < 30 kg/m2) patients (Kats et al. 2007). Study results showed 
obesity was the only significant factor predicting secondary fistula failure (hazards 
ratio 2.93; 95% CI, 1.44–5.93; p = 0.004). However, Chan et al. (2008) examined 
AVF outcomes for 1486 haemodialysis patients and compared those with a BMI < 30 
versus > 30 kg/m2 but were unable to confirm BMI as a factor in predicting AVF 
revision or failure. However, an increased risk of failure to mature was identified for 
those patients with BMI > 35 kg/m2. 
3.5.5 Data Collection 
The details of patient’s factor and blood markers were explored by complete review 
of the patient’s inpatient and outpatient medical record (containing all information 
pertaining to medical and surgical consultations and all previous hospital admissions 
and management) via an electronic database. All the data was entered into an Excel 
spreadsheet (Microsoft, USA). The following variables were collected: 
 Demographic including age, gender and risk factors; peripheral vascular 
disease; diabetes mellitus; hypertension; smoking (ever versus never) and 
dialysis (ever versus never) were collected. Fistulae characteristics that were 
ascertained include fistulae type and side of the arm. 
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 Measurement of brachial artery blood pressure and the participant weight and 
height was retrieved. Patients were defined as obese when their body mass 
index was greater than 30 Kg/m2, consistent with the World Health 
Organization classification (2014). 
 Clinically important biomedical markers, estimated glomerular filtration rate; 
Serum Urea; Creatinine; Potassium; Sodium; Calcium; Bicarbonate; 
Prothrombin Time; International Normalization Ratio; High Density 
Lipoprotein; Triglyceride; Total Cholesterol and Vein diameter were obtained 
 Results of Duplex investigation of the veins (measure the diameter of arm 
veins) was also recorded. 
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3.6 Prospective Study (Validation of Prognostic Model) 
The prospective study was performed systematically in different steps from 
identification, screening, recruitment, data collection of potential participants and 
finally data analysis by using appropriate statistical test (Figure 10). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 10. Flow diagram showing steps of prospective study 
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3.6.1 Recruitment of Participants 
The recruitment process occurred at the vascular department in the Royal Infirmary 
of Edinburgh. The vascular consultants and vascular access nurse specialists 
provided significant help in identifying the potential candidates to the research 
project. The potential participants were chosen by the consultant vascular surgeon 
and the vascular access nurse specialists on the basis of inclusion and exclusion 
criteria as the patients came into the hospital for vascular access surgery. 
The initial approach to the patient and their parent/carer occurred during the routine 
appointment in the vascular department. The patients were introduced to the 
researcher by the vascular consultants. The recruitment process for this study began 
by providing verbal information about the study. If the patient appeared to be 
interested, then an information pack containing a comprehensive information sheet 
and a consent form was provided to the patients. After one week, the researcher 
contacted the patients, to answer any further enquiries and to take back the 
completed consent form if they agreed to participate in the study. The participant 
information leaflet contained the contact information of the investigator and 
independent advisor, if the patients wished to discuss the study further (Appendix 1). 
A total of 168 patients were contacted for prospective clinical research who had 
undergone surgery for AVF at the Royal Infirmary of Edinburgh between the years 
2009 and 2011. Out of the 168 patients contacted for this trial, 23 were unwilling to 
participate in this trial, 10 drop out at follow-up and 35 were excluded from the study 
because they did not meet the inclusion and exclusion criteria. The most often cited 
reason for a patient not being willing to participate was personal commitments. 
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Moreover, excluded patients includes non-native English speakers (unable to give 
informed consent) and second attempt of AVF creation. Thus, a total of 100 patients 
were recruited into the prospective study. 
3.6.2 Inclusion Criteria 
• Aged 18 years and older.  
• Both genders (Male/Female) were eligible for the study. 
• A projected life expectancy of > 6 months. 
• A projected/ diagnosed ESRD with expected initiation of haemodialysis within six 
months of enrolment, or current dialysis dependence. 
• A planned procedure for first time arteriovenous fistula creation. 
• The patient was supposed to receive dialysis at the Royal Infirmary of Edinburgh 
facility for at least three months. 
• Ability to give informed consent. 
3.6.3 Exclusion Criteria 
• Pregnancy or breastfeeding. 
• Bleeding diathesis. 
• Illness/ Inability to give informed consent. 
• Involvement in another medical trial. 
• Expected on-compliance with medical care. 
• Current unstable angina or uncontrolled diabetes  
• Participant’s refusal. 
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3.6.4 Data Collection 
After taking informed consent, patient assessments were conducted on the day of 
their Duplex investigation. All procedures were carried out by the regular NHS staff. 
However, in order to make sure the patients data was collected according to standard 
NHS operating procedures, the researcher was present at all times. The assessment 
process was conducted as follows: 
 The participant had the chance to ask questions and raise any issues before, 
during, and after each assessment. 
 Baseline demographic information was collected including age, gender, previous 
history of dialysis and risk factors such as diabetes, hypertension, peripheral 
vascular disease and smoking. 
 A general physical examination consisted of inspection and palpation of the 
vessels of the upper arm and forearm and measurement of brachial artery blood 
pressure. Subsequently, height and weight details were recorded in order to 
calculate the BMI values by a nurse. For the assessment, participants were 
required to remove their outer clothing so the weight and height were accurately 
recorded. 
 Participants’ blood samples were obtained. For the participants blood analysis 
approximately 10 ml of blood was obtained by inserting a needle into a vein in the 
arm. Blood samples were obtained by NHS staff, as a regular procedure for pre-
operative tests. From the blood analysis, kidney function status, coagulation 
profile, and lipid profile were calculated. The blue bottle is used for haematology 
tests involving the clotting system, which require inactivated whole blood for 
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analysis (Figure 11). Bottle contains buffered sodium citrate, which acts as a 
reversible anticoagulant by binding to calcium ions in the blood and subsequently 
disrupting the clotting cascade. Sodium citrate is also added to blood products for 
transfusion, and acts as a preservative by stopping them from clotting in the bag. 
 
Figure 11. Blue bottle used for haematological tests 
 Figure 12 shows yellow bottle that was used for test requiring separated serum for 
analysis, including urea, creatinine and electrolytes (Na, K, Ca) and lipid profile 
(TC, HDL, TG). This bottle is known in the lab as the serum separating tube. It 
contains two agents; silica particles and a serum separating gel. The silica 
particles work to to allow the blood to clot fully. The serum separator consists of 
an inert polymer gel which floats as a layer between the blood cells and plasma to 
form a physical barrier between them. This means that the sample can be 
centrifuged (spun) in the laboratory and the separated serum easily removed. 
 
Figure 12. Yellow bottle use for kidney function test and lipid profile 
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 Duplex investigation of the veins was performed to measure the diameter of arm 
veins according to a standard protocol by vascular access nurse specialists.   
3.7 Statistical Analysis 
In the retrospective study a total of 300 participants were recruited for the prognostic 
model development. Descriptive statistics were produced giving mean and standard 
deviation for demographic data. The association between dependent variables and 
independent variable were assessed utilising univariate logistical regression. An 
important note to consider is that the pre-selection of predictors based on univariate 
statistical significance is arbitrary. It is a better choice to make use of previous 
research and expert opinion for the first selection of predictors without relying too 
much on statistical pre-selection alone. From a set of 300 patient’s data, the 
following set of clinically important predictors of mature fistulae were identified:  
Kidney Function Test 
 estimated Glomerular Filtration Rate (eGFR)  
 Blood Urea  
 Creatinine  
 Serum potassium (K+) 
 Sodium (Na+)  
 Calcium (Ca++) 
 Bicarbonate (HCO3) 
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Coagulation Test 
 Prothrombin Time (PT)  
 International Normalization Ratio (INR)  
Lipid Profile 
 Total Cholesterol (TC)   
 Triglyceride (TG)  
 Low Density Lipoprotein (LDL)  
 High Density Lipoprotein (HDL)  
In addition to these biomedical markers demographic data were analysed.  
 Age 
 Body Mass Index (BMI) 
 Vein Diameter  
 Diabetic status 
 Hypertension (HTN) 
 Peripheral Vascular Disease (PVD) 
 Dialysis (ever versus never) 
 Smoking status (ever versus never)  
Statistical analysis was performed using SPSS (IBM SPSS Statistics 20.0). Data are 
expressed as mean and 95% confidence interval (CI) or as proportions. Initially, the 
relationship between each individual predictor was investigated with the outcome 
measure in a model that only includes the predictor and outcome measure. Univariate 
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analysis of categorical variables by Chi square test was performed. This was to 
establish which of the risk factors differed significantly between fistulae of mature to 
needle and those that failed to mature (inadequate for dialysis). The association 
between independent variables and dependent variable, mature fistula, was assessed 
utilising univariable logistic regression. The criteria for a variable to enter the model 
was p < 0.25.  
Regression model was used for the prediction of AVF outcome. There are different 
types of regression modelling.  
 Linear Regression (if outcome variable is continuous) 
 Multinomial Logistic Regression (if outcome variable is more than two) 
 Logistic Regression (if outcome variable is binary or dichotomous) 
 Cox regression model (can be used for a “time to event” model) 
Logistic regression is used to analyse relationships between a dichotomous 
dependent variable and metric or dichotomous independent variables. Logistic 
regression does not make any assumptions of normality, linearity, and homogeneity 
of variance for the independent variables. Because it does not impose these 
requirements, it is preferred to discriminant analysis when the data does not satisfy 
these assumptions 
The equation for simple linear regression is: 
𝑌 = 𝑎 + 𝑏𝑥 + 𝑒𝑖 
Where y-outcome, a- intercept, b- slope related to x (explanatory variable), e- error 
term or random noise. 
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𝑌 = 𝑙𝑜𝑔𝑖𝑡 (𝑝) = 𝑎 + 𝑏𝑥 + 𝑒𝑖 
log (
𝑝
1 − 𝑝
) = 𝑎 + 𝑏𝑥 + 𝑒𝑖 
The regression equation estimated by logistic regression is given by: 
log (
𝑝
1 − 𝑝
) =  𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2+. . . . . . +𝛽𝑛𝑋𝑛 
Where p is the probability of event and effect of independent variable (x) increase or 
decrease risk of this event. β0 is the intercept and β1 till βn are the regression 
coefficients. 
 
A model was developed utilising multivariable stepwise logistic regression with the 
variables found to be significant from the univariable regressions. In backward 
selection all the selected variables were initially entered at the same time into a 
model. Subsequently the variables with the highest p-values were manually removed 
(i.e. those variables contributing the least). Then the model was re-run. This step was 
repeated until all the variables left had a p-value smaller than 0.05. The odds ratios 
and associated 95 per cent confidence intervals for variables in the final predictive 
model were obtained. We considered a p value less than 0.05 to be statistically 
significant.  
Logistical regression models often experience serious multi collinearity problems 
resulting from strong correlations between independent variables. Correlations 
among the independent variables included, were investigated to avoid multi 
colinearity. The criterion for removal for variable exhibiting multicolinearity was 
correlation coefficient > 0.7. Once a final model was derived, model performance 
was assessed by both calibration and discrimination. 
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Performance of Prognostic Model 
Once a prognostic model has been developed, there is a need for it to be investigated 
to find out how well the model works; in other words how well does the model 
predict outcomes (mature or immature AVF)? The Hosmer-Lemeshow test was used 
to investigate how well the predicted probabilities agree with the observed 
probabilities. This test should not be statistically significant, p value greater than 0.05 
showing that the model fits the data. A better way of assessing the fit of a logistic 
regression model is to compare the expected and observed numbers of positives for 
different subgroups of the data. If the observed and expected numbers are sufficiently 
close, then we can assume that we have an adequate model. 
ROC curve was generated to determine the discriminatory power of the model to 
differentiate between mature and immature AVF, which range from 0 to 1. A value 
of 0.5 means that the model is useless for discrimination (equivalent to tossing a 
coin) and values near 1 means that higher probabilities will be assigned to cases with 
the outcome of interest compared to cases without the outcome. To generate the 
ROC, we have to save the predicted probabilities from the model. The larger the 
AUC, the better the diagnostic test. If the area is 1.0, the test is “ideal” because it 
achieves 100% sensitivity and 100% specificity. If the AUC is 0.5, then you have a 
test that has effectively a 50% sensitivity and a 50% specificity, which is no better 
than flipping a coin (Brubaker 2008). The area under the ROC curve for a prognostic 
model is typically between 0.6 and 0.85 (Royston et al. 2009). Sensitivity and 
specificity analysis were reported. Sensitivity is the proportion of the true positive 
outcomes (e.g., truly diseased subjects) that are predicted to be positive. Specificity 
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is the proportion of the true negative outcomes (e.g., truly disease-free subjects) that 
are predicted to be negative. 
Validation of Developed Model 
The validation of model is the most important part of developing a prediction rule. In 
other words, validating the model explores how well predictions generated by the 
prognostic model agree with predictions for future patients or comparable patients 
not part of the study population. Predictive logistic regression models are important 
tools to provide estimates of patient outcome probabilities (Vergouwe et al. 2005).  
In general, there are two forms of validation. The first, internal validation, is 
performed in the context of an individual study, for example by splitting the study 
data set into one data set to build the model (development set) and one data set to test 
performance (test set, also called the validation set). The appealing feature of internal 
validation is its convenience, as it does not require collection of data beyond the 
original study. The second, external validation on a different data set provided by a 
different study circumvents these issues. Validation on heterogeneous external data 
sets allows for evaluation of the generalizability of the risk prediction tool to wider 
populations than originally reported. 
A total of 100 participants were recruited for the model validation phase. A model 
precisely predicting probabilities for patients in the retrospective data would not 
guarantee accurate predictions for new patients from related populations, e.g. patients 
treated not long ago or patients from a different centre, therefore, the performance of 
prognostic models needed to be verified in the newly treated patient group (external 
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validation) (Harrell et al. 1996). External validation was performed on those data 
obtained from an independent set of consecutive patients who had undergone 
vascular access surgery using the final development model. Predicted probabilities 
for individual patients in the validation set were calculated. Model discrimination 
was assessed by ROC curve analysis. Evaluation of calibration is important if model 
predictions are used for making clinical decisions. A calibration plot formed by the 
Hosmer-Lemeshow test, which illustrates how the observed and expected 
proportions compare, assessed the calibration of the final model for the maturation of 
the fistula.  
3.8 Data Protection 
All information about participants collected during the study was secure and was 
accessible only to the research team members. A 'master copy' of individual 
identification numbers unique to each participant was stored in a safe place in the 
vascular department at the Royal Infirmary of Edinburgh and was accessible only to 
the named key investigators/collaborators. This identification number corresponded 
with the participant’s personal details and any participant information material and 
consent forms. This number was used throughout the research of the study to 
correspond with any scientific data collected, no personal and identifying 
information were used. All data was collected by the chief investigator throughout 
the study, access to data was only to the key investigators and associated 
collaborators. 
Data was collated and stored electronically on the designated research laptop hard 
drive and back-up discs. The laptop and back-up discs were password protected, 
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including the master copy of participants identification numbers (stored in a separate 
secure location within the vascular lab at Royal Infirmary of Edinburgh). Patients’ 
confidentiality was paramount during the dissemination of findings and submission 
of manuscripts for publication. The published literature did not include any names 
other than basic demographic data such as subject number, age, sex, height etc.  
Written documentation and data were also stored in a paper format in the 
participant’s medical notes as per normal clinical practice. 
The storage and subsequent destruction of data are compliant with the Data 
Protection Act 1998. Written documentation and data have been stored in a paper 
format in the participants’ medical notes as per normal clinical practice. These will 
be destroyed after 5 years following discharge as per the health care records policy. 
All forms of data were securely kept in locked cabinets within locked rooms. Only 
the principal investigators and associated members had permission to use and access. 
All information that was collected during the course of the research were kept strictly 
confidential. All data was anonymised as much as possible, and the participant would 
not be identifiable from any of the data collected. Participant’s names were 
exchanged with a number and it would not be possible to be identified individually. 
3.9 Indemnity 
If participants had any reservations about any aspect of this study, they could seek 
help from the investigator. Alternatively, they could also contact the independent 
advisor (contact details given), who knows about the project but is not directly 
involved in this research.  
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Royal and Sun Alliance insurance provides indemnity for QMU sponsored or co-
sponsored clinical study (Appendix IV). This is a no-fault compensation policy and 
covers any person taking part in a clinical trial including their dependants, executors, 
heirs, administrators and legal representatives. Cover applies automatically to clinical 
trials and general clinical research within wide parameters without the need for 
referral although there are exclusions. In this study no complaints were received. 
3.10 Validity and Reliability 
3.10.1 Measurement of Body Mass Index 
The Body Mass Index (BMI) represents the standard method used by both the World 
Health Organisation (WHO) and the governmental health sectors of the majority of 
nations to determine whether a person is obese or overweight. The BMI is 
determined by dividing the weight of an individual by his/her height measured in 
metres and quared. If the BMI is below 30 kg/m2, the individual is not obese; if the 
BMI exceeds 30 kg/m2, then the individual is considered to be obese. The height of 
the participants was determined with the use of a portable instrument composed of a 
vertical measuring board and a horizontal headboard, known as a stadiometer. This 
entailed the participants having to take their shoes off and stand against the vertical 
board with the knees straight and the heels touching each other. Additionally, the 
head had to be in the anatomical position, known as the Frankfurt Plane, meaning 
that the head has to be positioned in such a way that an imaginary line going through 
the upper border of the ear canal and the lower margin of the orbit would run parallel 
to the ground, as shown in Figure 13. The stature of the participant was measured in 
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metres with a metre/height scale with the participant in standing position without 
their shoes and socks. 
 
Figure 13. Positioning of participant when measuring height. (NHANES 2007) 
The weight of the participant was measured on a weighing scale of range suitable to 
the participant’s size. It was ensured that the scales were at zero. Accuracy of the 
scale was checked using standard weights. The participant’s shoes and outer clothing 
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was removed prior to weighing and participants were weighed in minimum clothing 
where possible. Weight reading was recorded in kilograms with the participant 
standing still. 
3.10.2 Measurement of Blood Pressure 
Prior to the measurement of the blood pressure, each participant was allowed to rest 
in an average room temperature (20-25 0C) for ten minutes, the inflatable cuff of the 
sphygmomanometer, which was adjusted to fit each participant, being positioned on 
the left upper arm in such a way as to be 2 to 3 cm above the ante-cubital vein. 
Furthermore, the arm was laid on a flat surface to ensure that the cuff was aligned 
with the heart. 
 Small Cuff (16-23cm) 
 Medium Cuff (24 - 36cm) 
 Large Cuff (37 - 45cm) 
 Extra Large Cuff (45 - 60cm) 
In accordance with Beevers et al. (2001) and Perloff et al. (1993), the procedure was 
explained to the participants in order to provide reassurance in the event that their 
blood pressure was initially high. 
Sphygmomanometer 
There are three types of sphygmomanometer – light, dial and mercury-based. Before 
each procedure, it must be verified that the sphygmomanometer is on zero and that 
the monitor readings are clear.  A number of studies (Markandu et al. 2000; Nolan 
and Nolan 1993; Petrie et al. 1986) have indicated that almost half of the existing 
sphygmomanometers are not precise, thus there is a high possibility that their 
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readings are incorrect. In order to verify the accuracy of the instruments, whether or 
not they fulfil the required standards, maintenance or recalibration tests have to be 
carried out every year by biomedical technicians. Petrie et al. (1986) also specified 
that the date of the most recent calibration has to be recorded. 
The component parts of the inflatable cuff – bladder, tubes, inflation bulb, and valves 
– have to be checked to ensure that they function properly. Cuffs made of nylon have 
to be disinfected after every use. Cuffs made of fabric have to be washed on a regular 
basis. 
The bladder has to be long enough to envelop the arm of an individual and has to be 
positioned in such a way so that its central part lies above the brachial artery. This 
prevents ‘cuff hypertension’, which could cause incorrect blood pressure readings 
(Beevers et al. 2001). 
With regards to breadth, the cuff bladder is normally two-thirds of the total length of 
the upper arm of an adult, from the proximal end of the ulna, the olecranon process, 
to the acromion process of the shoulder blade, the scapula. As emphasised by de 
Swiet et al. (1989), the dimensions and placement of the cuff are highly important 
elements that contribute to the precision of the blood pressure readings. 
3.10.3 Biochemistry Tests 
Assessment of the lipid profile, and kidney function test was undertaken at the 
Clinical Biochemistry Laboratory, Royal Infirmary of Edinburgh, Scotland, UK, 
using an Olympus AU2700 automated analyser. (Note Olympus® has been 
subsequently taken over by Beckman®). 
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Serum Urea  
Kinetic UV test was used to calculate the serum urea. Through hydrolysis, urea is 
decomposed into ammonia and carbon dioxide. In the presence of glutamate 
dehydrogenase, the ammonia reacts with α-oxoglutarate and NADH, producing 
glutamate and NAD. The change in absorbance of the solution (caused by the 
oxidation of NADH) is measured photometrically at 340nm. 
Kinetic UV, Cat No OSR6534 
Calibrator Olympus system Calibrator 66300 
Reference Range 2.5-6.6mmol/L 
Serum Sodium (Na+) and Potassium (K+) 
Analysis of electrolytes in whole blood was performed using potentiometric ion 
selective electrode (ISE) of Beckman Coulter AU analyser at the Royal Infirmary of 
Edinburgh. All electrolytes are measured simultaneously within a single chip. 
Calibration 66320 ISE buffer 
66317 ISE Low serum Std 
66316 ISE High serum Std 
66313 ISE Na+ / K+ Selectivity check 
Na+- Reference range 135-145 mmol/L 
K+- Reference range 3.6-5.0 mmol/L 
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Bicarbonate (HCO3) 
Latex immunoassay whereby agglutination of antigen-antibody complexes causes a 
change in absorbance at 572 nm.  
Olympus System CRP Latex reagent 
Calibrator (Normal set: ODC 00026, highly sensitive set: ODC 00027) 
Cat No OSR6199 
Ref Range 17-23 mmol/L 
Serum Creatinine 
To make sure that the non-haemolysed serum samples used have attained stability (to 
allow the blood to clot fully), they are kept for two or more days at a room 
temperature of between 18 to 25°C or for seven days at a temperature of between 2 
to 8°C. Standard kinetic Jaffe method was used to calculate the serum creatinine rate 
of absorbance change measured photometrically at 500nm. The Olympus System 
calibrator, connected to the National Institute of Standards and Technology Standard 
Reference Material, was employed to measure the reaction. 
Kinetic Jaffe, Cat No OSR6178 
Calibrator 66300 
Reference range 60-120 umol/L 
Calibration frequency is more difficult. The electrolytes are calibrated daily or as 
required and most other tests probably monthly. Creatinine is weekly and HbA1c 
only with column changes or if required by troubleshooting. 
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Total Cholesterol (TC) 
Enzymatic reaction involving cholesterol esterase. Formation of a coloured dye is 
measured photometrically at 500nm. 
Enzymatic colour test, Cat No OSR6116 
Calibrator - Olympus System Cal 66300 
Reference Range - 5.0 mmol/L or less  
HDL Cholesterol 
Uses a detergent to solubilise HDL, which then reacts with other compounds to form 
a coloured dye, measured photometrically at 604 nm.  
Enzymatic colour test: Cat No OSR6187 
Calibrator HDL cholesterol calibrator ODC0011 
Reference Range 1.1-1.7 mmol/L 
Triglyceride 
Enzymatic reaction involving glycerol phosphate oxidase. Formation of a red dye is 
measured photometrically at 500 nm.  
Enzymatic colour test: Cat No OSR6118 
Calibrator: 66300 
Reference Range 0.8-2.1mmol/L  
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3.10.4 Measurement of eGFR 
An effective way of assessing how well the kidneys are functioning is to calculate 
the glomerular filtration rate (GFR). The GFR is a calculation of the amount of waste 
fluids in millilitres filtered by the kidneys in one minute. Thus, the GFR indicates the 
functioning state of the kidneys. It has been estimated that kidneys, which function 
properly, can filtrate over 90 ml/min/1.73 m2 of blood per minute. 
Only a formula-based estimation of the GFR can be obtained. Due to the fact that a 
precise direct measurement of the eGFR is not possible, only a formula-based 
estimation of the GFR can be obtained, which is known as eGFR. Generating this 
estimation entails the determination of the amount of waste product termed creatinine 
present in a sample of blood; demographic factors, such as age, gender, and ethnicity, 
have to be born in mind when conducting this test. The outcome is equated with the 
functioning percentage of healthy kidneys, so that if, for instance, the eGFR is 50 
ml/min/1.73 m2 it means that the functioning capacity of the kidneys is 50% (Harris 
and Stribling 2007). 
In order to estimate the GFR, the equation of isotope dilution mass spectrometry 
(IDMS) with modification of diet in renal disease (MDRD) was used, based on 
creatinine assays compared against standard accredited material.  
Calculation of GFR uses MDRD (Modification of Diet in Renal Disease Study 
Group) equation (Traynor et al. 2006).  
𝑬𝒔𝒕𝒊𝒎𝒂𝒕𝒆𝒅 𝑮𝑭𝑹 (𝒎𝒍/𝒎𝒊𝒏/𝟏. 𝟕𝟑𝒎𝟐)  = 𝟏. 𝟖𝟔. 𝟑 × (𝑪𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆/𝟖𝟖. 𝟒)-1.154 
× (Age) – 0.203 × (0.742 if female) × (1.210 if black)  
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The creatinine assays should be definite and unbiased when contrasted to IDMS. If 
non-specific assays are used, such as the Jaffe assessments, are employed and certain 
adjustment elements have to be applied to reduce the variation in the results obtained 
by different laboratories. The laboratory processing of the blood samples was carried 
out within 12 hours after they were collected.  
3.10.5 Coagulation Screen 
Prothrombin time and INR was measured at the Clinical Laboratory, Royal Infirmary 
of Edinburgh, using ACL TOP 700 coagulation analyzer, Instrumentation Laboratory 
(IL), UK (Reagent: HemosIL Recomboplastin 2G  IL UK).  
The normal range of prothrombin time calculated was 10.5 - 13.5 seconds. The 
analysers themselves were validated prior to installation. Each analyser is validated 
for PTs/ INRs when a new lot of thromboplastin reagent is introduced, prior to the 
current batch running out. The laboratory at the Royal Infirmary of Edinburgh 
established the mean normal PT using healthy volunteers and then go on to 
determine the international sensitivity index (ISI) of the reagent using WHO 
calibrant. This is further validated by running Internal Quality Control (IQC) and 
External Quality Control (EQC). 
Routine operation of the analysers involves IQC being performed post daily 
maintenance procedure and every 6 hours after this or when a vial of thromboplastin 
is changed. Tests cannot be performed if the IQC fails. IQC was performed using a 
normal and abnormal sample control, to ensure that a method is under control at 
different levels of an analyte, since relatively minor changes in an analytical process 
may be more apparent when testing an abnormal control. This means that within 
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limit QC results can confirm that the method is under control for both normal and 
abnormal sample analysis. QC sample tests was performed with normal levels and 
one further level where the result is outside the reference range. 
EQC involves registration with United Kingdom National External Quality 
Assessment Service (UK NEQAS). UK NEQAS facilitates optimal patient care by 
providing a comprehensive external quality assessment service in laboratory 
medicine which sends out several surveys at regular intervals throughout the year.  
3.10.6 Measurement of Vein Diameter 
All participants underwent routine preoperative vascular mapping. The Duplex scan 
was a non-invasive method of obtaining pictures of the veins of the arm. The 
technique used sound waves to construct a scan. Ultrasound scan was performed by 
vascular access nurse specialists at the Royal Infirmary of Edinburgh in the presence 
of the researcher. Vascular access nurse specialists looked specifically at the 
patient’s upper limb. The test required patients to be lying down and involved the 
placement of a small device on the skin of the arm. Ultrasound gel was used to 
improve the quality of the scan. The gel acts as both a lubricant and an energy 
conductor. The purpose of the gel is to convey the acoustic energy (sound waves) 
from the ultrasound head (transducer) to the tissue without crossing through the air at 
any point. A transducer is a handheld pointer that looks very much like a small 
microphone. When the transducer is rubbed along the skin, a picture of the inside of 
the body begins to emerge on the ultrasound monitor. Whilst the patient was lying 
down, each limb was examined. It was not necessary to use a tourniquet to make the 
veins more visible, as this was achieved with an ultrasound scan device (Siemens 
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with 5-MHz, 7-MHz, or 10-MHz scanning probes). The axillary and subclavian 
veins were examined to rule out outflow obstruction. The non-dominant arm is 
always selected first as if any complication occur post-surgery, the dominant arm is 
preserved. The ultrasound scan imagining device enabled the calculation of the vein 
diameter at eight important locations (wrist, distal, mid and proximal forearm, and 
anterior area of the elbow, distal, mid and proximal arm) as indicated in Figure 14. 
With regards to quality standards, the Medical Physics Department at the Royal 
Infirmary of Edinburgh conducted a yearly examination of the ultrasound scan 
device with the use of an ultrasound phantom to make sure of correct calibration. 
 
Figure 14. Upper extremity vein mapping (Adapted from Mendes et al. 2002) 
Cephalic v. of forearm 
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3.11 Maturation of Fistula 
Maturation refers to the possibility of ensuring continuous operative haemodialysis at 
six weeks after the creation of a fistula (Patel et al. 2003). The decision as to when 
the fistula was ready to undergo the process of cannulation, as well as the actual 
process, were made by dialysis specialist nurse with substantial practical experience. 
If the process failed, the vascular surgeon at the Royal Infirmary of Edinburgh 
carried out a reassessment of the fistula. 
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4.1 Descriptive Statistics 
A search of the renal unit electronic patient record (Proton® and Apex® software) at 
the Royal Infirmary of Edinburgh was conducted to identify all patients who had 
vascular access operations between the years 2005 and 2009. A total of three 
hundred patients were identified of whom 200 (66.7%) were male and 100 (33.3%) 
were female.  
In this study population, age ranged from 19 to 87 years, with a mean age of 60.45 ± 
15.9 years. Of the 300 AVF procedures performed, 73.7% (n = 221) were created in 
the left arm and 26.3% (n = 79) were created in the right arm. Percentage of patients 
found to have diabetes was 38% (n = 114) and smokers were 13.7% (n = 41). There 
were 78% (n = 234) of patients had history of hypertension and 16% (n = 48) of the 
participants were known case of peripheral vascular disease. Prior to AVF creation 
37.3% (n = 112) of study participants had haemodialysis through temporary venous 
catheter or arteriovenous graft. Nearly one third (n = 80) of study participants had 
BMI greater than 30. More than a half (62.7%) participants had received 
brachiocephalic AVF, 27% (n = 81) had received radiocephalic AVF and in 10.3% (n 
= 31) of the participants brachiobasilic AVF was created. General distribution of 
independent predictive variable for maturation of AVF are shown in Table 6.  
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Table 6. Distribution of Independent Predictive Variable for Maturation of 
AVF 
Clinical 
characteristics 
n (300) % Total Clinical 
characteristics 
n (300) % Total 
Arm   Creatinine (µmol/L)   
Left 221 73.7 ≤ 120 3 1 
Right 79 26.3 >120 to ≤400 163 54.3 
Fistula   >400 134 44.7 
B/C 188 62.7 Urea (mmol/L)   
R/C 81 27 ≤ 6.6 47 15.7 
B/B 31 10.3 >6.6 to  ≤15 56 18.6 
Surgeon   >15 197 65.7 
Surgeon A 204 68.0 eGFR    
Surgeon B 75 25.0 (mm/min/1.73m2)   
Surgeon C 7 2.3 ≤15 190 64.6 
Surgeon D 5 1.7 >15 109 35.4 
Surgeon E 9 3.0 SBP (mm Hg)   
PVD   ≤130 159 53 
No 252 84 >130 141 47 
Yes 48 16 DBP (mm Hg)   
DM   ≤85 272 90.7 
No 186 62 >85 28 9.3 
Yes 114 38 BMI (Kg/m2)   
Smoker   ≤30 220 73.3 
No 259 86.3 >30 80 26.7 
Yes 41 13.7 PT (seconds)   
HTN   ≤13.5 260 86.7 
No 66 22 >13.5 40 13.3 
Yes 234 78 INR   
Dialysis   ≤1.2 264 88 
No 188 62.7 >1.2 36 12 
Yes 112 37.3 TC (mmol/L)   
K+ (mmol/L)   ≤ 5 228 76 
> 5 137 45.7 >5 72 24 
≤ 5 163 54.3 TG (mmol/L)   
Na+ (mmol/L)   ≤ 2.1 190 63.3 
< 135 44 14.7 >2.1 110 36.7 
≥ 135 256 85.3 HDL (mmol/L)   
Ca++ (mmol/L)   ≤ 1.1 153 51 
≤ 2.5 261 87.0 >1.1 147 49 
> 2.5 39 13.0 Vein Size (mm)   
HCO3(mmol/L)   ≤2.5 38 12.7 
≤ 23 135 45 >2.5 262 87.3 
>23 165 55    
Independent patient factors and blood markers distribution in the subgroups. Data values are 
expressed as number and percentage (%). n- number of participant, B/C-Brachiocephalic, 
R/C- Radiocephalic, B/B- Brachiocephalic, PVD-Peripheral Vascular Disease, DM-Diabetes 
Mellitus, HTN-Hypertension, K-Potassium, Na-Sodium, Ca-Calcium, HCO3-Bicarbonate, e-
GFR- Estimated Glomerular Filtration Rate, SBP- Systolic Blood Pressure, DBP- Diastolic 
Blood Pressure, BMI- Body Mass Index, PT-Prothrombin time, INR- International 
normalized ratio, TC- Total Cholesterol, TG- Triglyceride, HDL- High density lipoprotein. 
Chapter 4 
132 
 
 
4.1.1 Gender and AVF Maturation 
Out of 200 male participants, 120 (60%) developed mature fistula and in 80 (40%) 
participant’s fistula failed to mature (Table 7, Figure 15). Significant difference (p = 
0.005) was observed between mature and immature AVF among male gender. On the 
other hand, 48 (48%) of fistulas had matured in 100 female participants. No 
significant (p = 0.68) difference was observed between mature and immature AVF 
among female gender. Success of AVF maturation was found to be associated (p = 
0.048) with male and female gender (Table 7). 
 
Table 7. Gender and Maturation Rate of Fistula 
 Mature Immature Total Chi-Square P value 
Female 48 52 100   
Male 120 80 200 3.896 0.048 
Total 168  132 300   
 
Table 7 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and Gender. The p value = 0.048 indicating that AVF surgery outcomes was 
dependent of the patients gender.  
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Figure 15. Gender and AVF Maturation 
 
Figure 15 showing relationship between success and failure of AVF maturation among male 
and female gender who had undergone AVF surgery. Numbers written within the bar 
indicated the percentage and black line over the bars indicates level of statistical significance 
(Chi square) between mature and immature AVF among male and female gender. 
 
 
 
 
60.00%
48.00%
40.00%
52.00%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Male Female
%
 O
F
 M
A
T
U
R
A
T
IO
N
GENDER
Mature
Immature
p = 0.005
p = 0.68
Chapter 4 
134 
 
 
4.1.2 Right or Left handed AVF and Maturation 
Out of 300 patients, 221 (73.7%) had left sided and 79 (26.3%) received right sided 
fistulae (Table 8). Maturation of the AVF was successfully attained in 50 (63.3%) 
procedures and 29 (36.7%) fistulae failed to mature in the right sided AVF. 
Significant difference (p = 0.02) was observed between mature and immature AVF 
among right sided AVF. In contrast 118 (53.3%) fistula successfully matured and 
103 (46.6%) failed to mature in the left arm (Figure 16). No significant difference (p 
= 0.313) was observed between mature and immature AVF among left sided AVF. 
Success of AVF maturation was found to be independent (p = 0. 128) of arm selected 
for procedure (Table 8). 
 
Table 8. Maturation in Left or Right Sided AVF  
 Mature Immature Total Chi-Square P value 
Right 50 29 79   
Left 118 103 221 2.314 0.128 
Total 168  132  300   
 
Table 8 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and side of arm (right or left). The p value = 0.128 indicating that AVF surgery 
outcomes was independent of the arm selected. 
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Figure 16. Maturation of Left /Right Sided AV Fistula 
 
 
 
Figure 16 showing relationship between success and failure of AVF maturation in right sided 
and left sided vascular access. Numbers written within the bar indicated the percentage and 
black line over the bars indicates level of statistical significance (Chi square) between mature 
and immature AVF created in right or left side of patients arm. 
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4.1.3 Type of Fistula and Maturation 
Of 300 participants included in the study, 188 (62.7%) received a brachiocephalic 
AVF, 81 (27%) received a radiocephalic AVF, and 31 (10.3%) received a 
brachiobasilic AVF (Table 9). Maturation of the AVF was successfully accomplished 
in 113 of the BC AVF (60.1%), 42 of the RC AVF (51.9%) and 13 of the BB AVF 
(41.9%). Failure rate of the fistulae was 39.9% (n = 75), 48.1% (n = 39) and 58.1% 
(n = 18) in BC, RC and BB AVF respectively (Figure 17). Significant difference (p = 
0.006) was observed between mature and immature AVF among BC AVF. However, 
no statistical difference was found between mature and immature AVF for RC (p = 
0.74) and BB (p = 0.37) AVF. Success of fistula maturation between different sites 
of AVF (BC, RC and BB) was compared with no statistical difference (p = 0.114) 
found (Table 9). 
Table 9.  Type of Fistula and Maturation of AVF 
 Mature Immature Total Chi-Square P value 
BC 113 75 188   
RC 42 39 81 4.341 0.114 
BB 13 18 31   
Total 168  132  300   
 
Table 9 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and type of AVF. The p value = 0.114 indicating that AVF surgery outcomes 
was independent of the type of AVF.  
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Figure 17.Type and Maturation of AV Fistula 
 
 
 
Figure 17 showing relationship between success and failure of AVF maturation in three 
different types of AVF. Numbers written within the bar indicated the percentage and black 
line over the bars indicates level of statistical significance between mature and immature 
AVF among three different AVF (B/C-Brachiocephalic, R/C-Radiocephalic, B/B–
Brachiobasilic). 
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4.1.4 Surgeons and AVF Maturation 
Of three hundred participants included in the study, 204 (68%) participants AVF was 
created under the care of surgeon A, 75 (25%) treated by surgeon B, 07 (2.3%) 
treated by surgeon C, 5 (1.7%) treated by surgeon D and 9 (3%) treated by surgeon E 
(Table 10). Out of 204 AVF, created under the care of surgeon A, 115 (56.4%) 
matured and 89 (43.6%) did not mature. Likewise AVF created by surgeon B, 42 
(56%) matured and 33 (44%) did not mature, AVF created by surgeon C, 5 (71.4%) 
matured and 2 (28.6%) did not mature, AVF created by surgeon D, 2 (40%) matured 
and 3 (60%) did not mature and fistula created by Surgeon E, 4 (44.4%) matured and 
5 (55.6%) did not mature (Figure 18). Significant difference was observed between 
mature and immature AVF among AVF created by surgeon A (p = 0.07) and B (p = 
0.03). However, no statistical difference was found between mature and immature 
AVF constructed by surgeon C (p = 0.26), D (p = 0.65) and E (p = 0.74). 
Nevertheless, due to the small number of procedures performed by Surgeons C, D 
and E, these results should be interpreted with caution. No significant association (p 
= 0.792) was found between AVF created by different surgeons and successful 
fistula maturation found (Table 10). 
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Table 10. Surgeons and Maturation of AVF 
 Mature Immature Total Chi-Square P value 
Surgeon A 115 89 204   
Surgeon B 42 33 75   
Surgeon C 5 2 7 1.695  0.792 
Surgeon D 2 3 5   
Surgeon E 4 5 9   
Total 168  132  300   
Table 10 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and surgeons performed surgery. The p value is 0.792 indicating that outcomes 
of AVF surgery was independent of the surgeons.  
Figure 18. Surgeons and AVF Maturation 
 
Figure 18 showing relationship between success and failure of AVF maturation created by 
different surgeons at RIE. Numbers written within the bar indicated the percentage and black 
line over the bars indicates level of significance (Chi square) between mature and immature 
AVF created by surgeons in the department of vascular surgery. 
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4.1.5 Diabetes and AVF Maturation 
Out of 300 included participants, there were 114 diabetic patients and 186 non-
diabetic patients (Table 11). The researcher did not find any significant differences 
between outcome measures that are mature and non-maturation of fistulae in diabetic 
patients. The success rate of fistula in the DM participants was 57 (50%) that of 
equal with failure rate 57 (50%). In the non-diabetic group 111 (59.7%) achieved 
mature fistulae and 75 (40.3%) failed to mature. Significant difference (p = 0.008) 
was observed between mature and immature AVF among non-diabetic population. 
However, no statistical difference was found between mature and immature AVF in 
diabetic patients (Figure 19). Success of AVF maturation was not found to be 
associated (p = 0.128) with diabetic and non-diabetic patients (Table 11). 
 
Table 11. Diabetes and Maturation of Fistula 
 Mature Immature Total Chi-Square P value 
Diabetics 57 57 114   
Non Diabetics 111 75 186 2.314 0.128 
Total 168  132  300   
 
Table 11 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and diabetes. p = 0.128 indicating that AVF surgery outcomes was independent 
of the presence and absence of diabetes.  
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Figure 19. Diabetes and Maturation of AV Fiatula 
 
Figure 19 showing relationship between success and failure of AVF maturation in diabetic 
and non-diabetic participants who had undergone AVF surgery. Numbers written within the 
bar indicated the percentage and black line over the bars indicates level of significance (Chi 
square) between mature and immature AVF in patients with diabetes and without. 
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4.1.6 Hypertension and AVF Maturation 
A total of 234 (78%) participants were hypertensive and 66 (22%) were non 
hypertensive (Table 12). In the hypertensive participants, success of AVF maturation 
was 57.3% (134) while failure rate was 42.7% (100). On the other hand, 51.5 % (34) 
AVF matured in non-hypertensive participants and 48.5% (32) failed to mature 
(Figure 21). Significant difference (p = 0.026) was observed between mature and 
immature AVF among hypertensive patients. However no significant association (p 
= 0.8) was found between mature and immature AVF among non-hypertensive 
patients (Figure 20). Success of AVF maturation was not found to be associated (p = 
0.406) with hypertensive and non-hypertensive patients (Table 12). 
 
Table 12. Hypertension and Maturation of Fistula 
 Mature Immature Total Chi-Square P value 
Hypertensive 134 100 234   
Non Hypertensive 34 32 66 0.691 0.406 
Total 168  132  300   
 
Table 12 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and high blood pressure. p = 0.406 indicating that outcomes of AVF surgery 
was independent of the presence and absence of hypertension. 
 
 
 
 
 
Chapter 4 
143 
 
 
 
Figure 20. Hypertension and Maturation of AV Fistula 
 
 
Figure 20 showing relationship between success and failure of AVF maturation in 
hypertensive and non-hypertensive participants who had undergone AVF surgery. Numbers 
written within the bar indicated the percentage and black line over the bars indicates level of 
significance (Chi square) between mature and immature AVF within group of patients with 
and without hypertension. 
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4.1.7 PVD and AVF Maturation 
Of 300 participants included in the study, 48 (16%) were diagnosed with PVD and 
252 (84%) did not have the history of PVD (Table 13). Approximately 33.3% (16) of 
the study participants with peripheral vascular disease successfully achieved mature 
fistula and 66.7% (32) failed to mature. Significant difference (p = 0.021) was 
observed between mature and immature AVF among patients with PVD. In contrast, 
maturation of AVF among participants with no history of PVD was 60.3% (152) and 
the failure rate was 39.7% (100) summarized in Figure 21. Significant difference (p = 
0.001) was found between mature and immature AVF in patients without history of 
PVD. Success of AVF maturation was found to be associated (p = 0.001) with the 
patients with and without a history of PVD (Table 13). 
 
Table 13. Peripheral Vascular Diseases and Maturation of Fistula 
 Mature Immature Total Chi-Square P value 
PVD (Yes) 16 32 48   
PVD (No) 152 100 252 11.915 0.001 
Total 168  132  300   
 
Table 13 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and PVD (Peripheral Vascular Disease). p = 0.001 indicating that AVF 
surgery outcomes was dependent to the presence and absence of PVD. 
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Figure 21. PVD and Maturation of AV Fistula 
 
 
Figure 21 showing relationship between success and failure of AVF maturation in patients 
with presence of PVD and no history of PVD who had undergone AVF surgery. Numbers 
written within the bar indicated the percentage and black line over the bars indicates level of 
significance (Chi square) between mature and immature AVF within cohort of PVD and no 
history of PVD. 
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4.1.8 Smoking and AVF Maturation 
The impact of the smoking was analysed for all participants (300) enrolled in the 
study. Forty one were smokers and 259 were non-smokers. Sixty one per cent (25) 
achieved maturation and thirty nine per cent (16) failed to mature in smokers (Table 
14, Figure 23). No significant difference (p = 0.33) was found between mature and 
immature AVF among patients with history of smoking.  The success rate of AVF 
was 55.2% (143) and 44.8% (116) failed to mature for haemodialysis among non-
smokers (Figure 22). No significant difference (p = 0.09) was observed between 
mature and immature AVF among patients without history of smoking. Success of 
AVF maturation was not found to be associated (p = 0.49) with smoking (Table 14). 
 
Table 14. Smoking and Maturation of Fistula 
 Mature Immature Total Chi-Square P value 
Smokers 25 16 41   
Non Smokers 143 116 259 0.477 0.49 
Total 168  132  300   
 
Table 14 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and smoking. p = 0.490 indicating that AVF surgery outcomes was 
independent of the presence or absence of smoking history. 
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Figure 22. Smoking and Maturation of AV Fistula 
 
 
  
Figure 22 showing relationship between success and failure of AVF maturation among 
smokers and non-smokers participants who had undergone AVF surgery. Numbers written 
within the bar indicated the percentage and black line over the bars indicates level of 
significance (Chi square) between mature and immature AVF within cohort of smokers and 
non-smokers.  
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4.1.9 Dialysis and AVF Maturation 
Of the 300 adults who underwent AVF formation, 112 (37.3%) went on to receive 
dialysis and 187 (62.7%) did not receive dialysis therapy. In the dialysis population, 
60 (53.6%) AVF were successfully mature and 52 (46.4%) failed to mature (Table 
15, Figure 24). Patients who had not been on dialysis before the vascular access 
surgery had a success rate of 57.2% (107) and failure rate of 42.8% (80) summarize 
in Figure 23. Significant difference (p = 0.04) was observed between mature and 
immature AVF among patients with no history of dialysis therapy. However, no 
significant difference (p = 0.45) was found between mature and immature AVF 
among patients receiving dialysis therapy prior to AVF creation. Success of AVF 
maturation was not found to be associated (p = 0.539) with dialysis therapy (Table 
15). 
 
Table 15. Dialysis and Maturation of AV Fistulae 
 Mature Immature Total Chi-Square P value 
Dialysis (Yes) 60 52 112   
Dialysis (No) 107 80 187 0.378 0.539 
Total 168  132  300   
 
Table 15 shows the distribution and relationship between outcomes of AVF surgery (mature 
or immature) and history haemodialysis therapy prior to AVF creation. p = 0.539 indicating 
that AVF surgery outcomes was independent of the presence or absence of haemodialysis 
therapy before AVF creation. 
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Figure 23. Dialysis and Maturation of Fistula 
 
 
 
Figure 23 showing relationship between success and failure of AVF maturation in patients 
received dialysis therapy before AVF creation and those never have been on dialysis 
machine. Numbers written within the bar indicated the percentage and black line over the 
bars indicates level of significance (Chi square) between mature and immature AVF within 
cohort of patients received or not haemodialysis before creation of AVF.  
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4.2 Univariable Analysis of Independent Variables 
A logistic regression model neither assumes linearity in the relationship between the 
risk factors and the response variable, nor does it require normally distributed 
variables (Hussain 2008). Firstly, the relationship between each individual predictor 
was investigated with the outcome measure (mature or immature) in a model that 
only included the predictor and outcome measure (univariate). The relationship 
between the predictor and outcome were evaluated against p-value of 0.25. If the 
predictor had a lower p-value, then this was considered as relevant and included in 
the next step. The selection strategy in this study consisted of a univariable screening 
step followed by stepwise multivariable selection among the univariably significant 
predictors. Retrospective assessment of the beginning set of 300 AVF that were 
constructed between 2005 and 2009 discovered a failure to mature rate of 44% (n = 
132). AVF characteristic and univariable examination of clinical variables for 
prediction of maturation of fistula is shown in Table 16. The relationship between 
each individual predictor is investigated with the outcome measure. Univariable 
exploration discovered the nine variables to be involved with the maturation of AVF. 
Gender (p=0.049; OR 0.615; 95% CI 0.379, 0.998), side of arm (p=0.129; OR 1.505; 
95% CI: 0.877-2.553), type of fistulae (p=0.115; OR 0.21; 95% CI: 0.423-1.208),  
PVD (p=0.001; OR 3.04; 95% CI: 1.585-5.829), Diabetes (p=0.102; OR 1.48; 95% 
CI: 0.925-2.367), SBP (p=0.101; OR 1.468; 95% CI: 0.927-2.325), INR (p=0.140; 
OR 0.589; 95% CI: 0.292-1.189), TG (p=0.24; OR 1.294; 95% CI: 0.804-2.084) and 
vein size (p<0.0001; OR 4.254; 95% CI 1.983, 9.126). A further 2 variables, Pre 
surgical haemodialysis (p=0.513; OR 1.17; 95% CI: 0.731-1.873) and eGFR 
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(p=0.459; OR 0.834; 95% CI: 0.516-1.349) were added to the model secondary to 
their strong clinical association with the maturation of AVF. 
Table 16. Univariate Analysis of Independent Variables to Maturation of AVF 
Clinical 
Characteristics 
Mature AVF 
% 
Total 
% 
Crude OR (95% CI) P Value 
Age    0.45 
> 50 yrs. 57.2 76.3   
≤ 50 yrs.  52.1 23.7 0.814(0.477-1.389)  
Gender    0.049* 
Male 60 66.7   
Female 48 33.3 0.615 (0.379-0.998)  
Arm    0.129* 
Left 53.4 73.7   
Right 63.3 26.3 1.505(0.887-2.553)  
Fistula    0.115* 
BC 60.1 62.7   
RC 51.9 27 0.715 (0.423-1.208)  
BB 41.9 10.3 0.479 (0.222-1.036)  
Surgeons    0.788 
Surgeon A 56.4 68.0   
Surgeon B 56 25.0 0.985 (0.578-1.679)  
Surgeon C 71.4 2.3 1.935 (0.367-10.206)  
Surgeon D 40 1.7 0.516(0.084-3.154)  
Surgeon E 44.4 3 0.619 (0.162-2.373)  
PVD    0.001* 
Yes 33.3 16   
No 60.3 84 3.04 (1.585-5.829)  
DM    0.102* 
Yes 50 38   
No 59.7 62 1.48 (0.925-2.367)  
Smoker    0.49 
Yes 61 13.7   
No 55.2 86.3 0.789 (0.402-1.547)  
HTN    0.406 
Yes 57.3 78   
No 51.5 22 0.793 (0.458-1.371)  
Dialysis    0.513 
Yes 53.6 37.3   
No 57.4 62.7 1.17 (0.731-1.873)  
K+    0.948 
≤ 5 56.2 54.3   
> 5 55.8 45.7 1.015 (0.642-1.605)  
Na+    0.439 
≥ 135 55.1 85.3   
< 135 61.4 14.7 1.295 (0.673-2.494)  
Ca++    0.525 
≤ 2.5 56.7 87   
> 2.5 51.3 13 0.804(0.41-1.577)  
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Table 16 continued 
Clinical 
Characteristics 
Mature AVF 
% 
Total 
% 
Crude OR (95% CI) P Value 
HCO3    0.743 
≤ 23 57 45   
>23 55.2 55 0.926 (0.586-1.465)  
Creatinine    0.676 
>400 57.5 44.7   
>120 ≤400 55.2 54.3 0.913(0.576-1.447)  
≤ 120 33.3 1 0.37 (0.033-4.182)  
Urea    0.949 
>15 55.3 65.7   
>6.6-≤15 57.1 18.7 1.076 (0.591-1.960)  
≤ 6.6 57.4 15.7 1.09 (0.73-2.073)  
eGFR    0.459 
≤15 57.4 64.6   
>15 52.9 35.4 0.834 (0.516-1.349)  
SBP    0.101* 
≤130 51.6 53   
>130 48.4 47 1.468 (0.927-2.325)  
DBP    0.786 
≤85 56.3 90.7   
>85 53.6 9.3 0.897 (0.411-1.958)  
BMI    0.563 
≤30 55 73.3   
>30 58.8 26.7 1.165 (0.694-1.957)  
PT    0.413 
≤ 13.4 56.9 86.6   
> 13.5 50 13.4 0.757 (0.389-1.474)  
INR    0.140* 
≤ 1.2 57.6 88   
> 1.2 44.4 12 0.589 (0.292-1.189)  
TC    0.24* 
≤ 5 57.9 76   
>5 50 24 1.294 (0.804-2.084)  
TG    0.289 
≤ 2.1 53.7 63.3   
> 2.1 60 36.7 0.773 (0.48-1.244)  
HDL    0.874 
≤ 1.1 55.6 51   
> 1.1 56.5 49 1.037 (0.658-1.637)  
Vein Size    <0.001* 
≤2.5 26.3 12.6   
>2.5 60.3 87.4 4.254 (1.983-9.126)  
Independent patient factors and blood markers that underwent in univariate analysis and their 
association with the maturation of AVF. Data values are expressed as value (%), Odds Ratio (OR), 
Confidence interval (CI) and level of significance (p). *Is used for significant variables having p value 
<0.25, B/C-Brachiocephalic, R/C- Radiocephalic, B/B- Brachiocephalic, PVD-Peripheral Vascular 
Disease, DM-Diabetes Mellitus, HTN-Hypertension, K-Potassium, Na-Sodium, Ca-Calcium, HCO3-
Bicarbonate, e-GFR- Estimated Glomerular Filtration Rate, SBP- Systolic Blood Pressure, DBP- 
Diastolic Blood Pressure, BMI- Body Mass Index, PT-Prothrombin Time, INR- International 
Normalization Ratio, TC- Total Cholesterol, TG- Triglyceride, HDL- High Density Lipoprotein. 
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4.3 Correlation 
Logistic regression models often experience serious multicolinearity problems, 
resulting from strong correlations between independent variables. A significant 
correlation between variables affect the selection of predictors. It is therefore 
judicious to generate a correlation table, including all potential predictors. When 
variables are strongly correlated (correlation coefficient > 0.70), it is rational to 
choose which variables are going to use in building the model. However, there is no 
problem with variables strongly correlating with each other, i.e. the correlation 
between the dependent and the independent variable. A correlation coefficient was 
computed to assess the association among the independent variables. Overall, there 
was no substantial association found between independent variables summarized in 
Table 17.  
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Table 17. A Table to Show Correlation Matrix between Independent Variables 
 
 
 
 
 
 
 
 
 
 
 
Arm-Side of arm for AVF, R/C Radiocephalic, B/B- Brachiocephalic, PVD-Peripheral Vascular Disease, Pre HD-Haemodialysis before surgery, DM-
Diabetes Mellitus, e-GFR- Estimated Glomerular Filtration Rate, SBP- Systolic Blood Pressure, INR- International normalization ratio, TC- Total 
Cholesterol, V Size-Vein size. 
 
 Constant Gender Arm R/C B/B DM PVD Pre HD eGFR SBP INR TC V Size 
Constant 1.0 -.072 -.173 -.272 -.099 -.276 -.423 -.385 -.177 -.246 -.008 -.105 -.666 
Gender -.072 1.0 -.046 .086 .018 .044 -.098 .070 .038 -.006 .075 -.159 -.100 
Arm -.173 -.046 1.0 -.012 .036 -.009 .004 .073 .073 .045 -.027 -.004 .047 
R/C -.272 .086 -.012 1.0 .170 -.138 -.038 -.046 -.075 .045 -.141 .033 .312 
B/C -.099 .018 .036 .170 1.0 -.039 .000 .130 -.084 .126 .062 -.069 -.057 
DM -.276 .044 -.009 -.138 -.039 1.0 -.140 .257 .070 -.012 .088 -.062 .022 
PVD -.423 -.098 .004 -.038 .000 -.140 1.0 -.006 .024 -.008 .019 .003 -.009 
Pre HD -.385 .070 .073 -.046 .130 .257 -.006 1.0 .121 .052 .006 -.061 .012 
eGFR -.177 .038 .073 -.075 -.084 .070 .024 .121 1.0 -.064 .038 .027 -.042 
SBP -.246 -.006 .045 .045 .126 -.012 -.008 .052 -.064 1.0 -.031 .021 .067 
INR -.008 .075 -.027 -.141 .062 .088 .019 .006 .038 -.031 1.0 -.042 -.144 
TC -.105 -.159 -.004 .033 -.069 -.062 .003 -.061 .027 .021 -.042 1.0 .066 
V Size -.666 -.100 .047 .312 -.057 .022 -.009 .012 -.042 .067 -.144 .066 1.0 
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4.4 Multivariable Associations 
When there are various individual predictors in the data set, model selection 
procedure is very helpful to develop a prognostic model that makes use of the 
independent predictor variables. The researcher used backward stepwise model 
selection procedures. In backward selection all the selected variables are firstly 
entered at the same time into a model. Subsequently the variables with the highest p-
values are removed (i.e. those variables contributing the least). Then the model is re-
run. This step is repeated until there are no variables left with a p-value greater than 
0.05. Selection is based on the statistical significance of covariables in the data set 
under study. When the researcher entered significant variables (p < 0.25) in 
multivariable analysis, it removed non-significant variables (Table 18). An odds ratio 
(OR), confidence interval (CI) and level of significance was measured. An odds ratio 
is a measure of association between an exposure (independent variables such as 
gender, vein size) and an outcome (dependent variable such as maturation of AVF). 
The OR represents the odds that an outcome will occur given a particular exposure, 
compared to the odds of the outcome occurring in the absence of that exposure 
(Szumilas 2010). An OR of 1.00 means that the two groups were equally likely to 
have outcome or event (maturation). An OR higher than 1 means that the first group 
(no evidence of PVD group) was more likely to experience the event (maturation) 
than the second group (with PVD). An OR of less than 1 means that the first group 
(females) was less likely to experience the event (maturation) than the second group 
(males) (McHugh 2009). 
Three variables were recognised which have an effect on fistula maturation in the 
multivariable model. Males were twice as likely to undergo fistula maturation, 
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compared to that of females (OR 0.514; 95% CI: 0.308-0.857; p = 0.011). 
Participants with no evidence of PVD were three times more likely to mature their 
fistula (OR 3.140; 95% CI: 1.596-6.177; p = 0.001). A pre-operative vein diameter 
greater than 2.5mm resulted in a fivefold increase in fistula maturation compared to a 
vein size less than 2.5mm (OR 4.532; 95% CI: 2.063-9.958; p < 0.001).  
A predictor score developed using the regression coefficients of these independent 
variables is shown in Table 18. To generate a score for each predictor variables, the 
score is assigned by dividing Beta Coefficient to significant error. The overall 
probability for each patient was analysed by adding the scores of each factor. The 
following prognostic model was derived by using the above prediction model. 
 
Table 18. Multivariable Predictors of AVF Maturation in the Retrospective 
Data 
Clinical 
Characteristics 
Adjusted OR 95% C.I. P Value 
Gender (Male) 0.514 0.308-0.857 0.011 
PVD (No) 3.140 1.596-6.177 0.001 
Vein Size (>2.5) 4.532 2.063-9.958 <0.001 
 
The overall risk score for each patient was estimated by summing the scores of each 
significant independent variable. Using the prediction model, the following 
prognostic equation was developed: 
𝑹𝒊𝒔𝒌 𝑺𝒄𝒐𝒓𝒆(− 𝐥𝐨𝐠 𝒐𝒅𝒅𝒔) =  𝜷𝟎 + 𝜷𝟏𝑿𝟏 + 𝜷𝟐𝑿𝟐+. . . . . . +𝜷𝒏𝑿𝒏 
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Where 
 Β0 is the intercept, β1 till βn are the regression coefficients and X1 to Xn are 
independent variables. 
 
Where all variables are coded 0 for no or 1 for yes. The value −0.182 is called the 
intercept and the other numbers are the estimated regression coefficients for the 
predictors, which indicate their mutually adjusted relative contribution to the 
outcome risk. 
4.4.1 Hosmer-Lemeshow Goodness of Fit Test 
It is imperative to assess the performance of developed models. The hypothesis was 
the model does not fit and the alternative or the null hypothesis for this test was that 
the model fits the data. The Hosmer-Lemeshow statistic (which tests the null 
hypothesis is no difference between observed and predicted data) was not significant 
(p > 0.79). 
4.4.2 Receiver Operating Characteristic Area 
The receiver operating characteristic (ROC) area was studied as an indicator of the 
model performance which suggests how well a parameter can distinguish between 
two predictive outcomes (mature or immature). The ROC curve, which is defined as 
a plot of test sensitivity as the y coordinate versus its 1-specificity or false positive 
rate as the x coordinate, is an effective method of evaluating the performance of 
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prognostic model (Park et al. 2004). Sensitivity and specificity, which are defined as 
the number of true positive decisions/the number of actually positive cases and the 
number of true negative decisions/the number of actually negative cases, 
respectively, constitute the basic measures of performance of diagnostic tests (Park et 
al. 2004; Fawcett 2003)  (Table 19). 
Table 19. The Decision Matrix 
Test Results Positive Negative Total 
Positive TP FP TP/(TP+FP) 
Negative FN TN TN/(FN+TN) 
Total TP/(TP+FN) TN/(FP+TN)  
 
Where TP: true positive = test positive in actually positive cases, FP: false 
positive = test positive in actually negative cases, FN: false negative = test 
negative in actually positive cases, TN: true negative = test negative in actually 
negative cases. Sensitivity and Specificity of a Test are Defined as TP/(TP+FN) 
and TN/(FP+TN) respectively. Positive predictive value and Positive predictive 
value are defined as TP/(TP+FP) and TN/(FN+TN) respectively. 
 
ROC graphs are two-dimensional graphs in which true positive rate is plotted on the 
Y axis and false positive rate is plotted on the X axis. In this study ROC curve was 
created by calculating the sensitivity and specificity for consecutive cut-off points 
according to the predicted probabilities from the logistic regression models. The area 
under the ROC curve for prediction of maturation of fistula was 0.677 (95% bias-
corrected CI: 0.615, 0.738), which indicates good model discrimination (Figure 24, 
Table 20). For binary outcomes, c is equal to the area under the ROC curve; value of 
c fluctuates between 0.5 and 1.0 for functional models; greater value indicates the 
valuable performance of prognostic model (Harrell et al. 1996, Miller et al. 1993). 
Tables 20 shows the best cut-off score for prediction of maturation was 0.619 
(sensitivity 85.7%, specificity 40.2%, PPV 64.5% and NPV 68.8%). 
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Figure 24. Receiver Operating Curve Analysis for Prognostic Model 
Performance 
 
Figure 24 showing Receiver operating characteristics of AVF maturation. Area under 
the curve was 0.677 (95% CI: 0.615-0.738), indicating good discriminatory ability of 
AVF maturation.  
 
Table 20. Specificity and Sensitivity of Model 
Area under the 
Curve 
Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
0.677 85.7% 40.2% 64.5% 68.8% 
 
Table 20 showing the area under the ROC is 0.67, which is indicating 68% ability to 
discriminate between patients with fistula maturation. 
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4.5 Validation of Prognostic Model 
4.5.1 Baseline Characteristics 
Clinical and demographic characteristics of patients in the development and 
validation sets are shown in Table 21. Patients in the development and validation set 
were aged 60.14±15.9 and 58±15 years respectively (p = 0.208). The significant 
difference between the development and validation set was evaluated against p 
<0.05. Baseline exploration of patients’ characteristic discovered the four variables 
to be significantly different in both development and validation cohort. Patients in 
the development set compared with the patients in the validation set were more 
frequently male. Percentage of diabetics and peripheral vascular disease were higher 
in the development set. However no statistical significant difference was observed (p 
> 0.05). Percentage of hypertensive patients and history of prior haemodialysis 
therapy was statistically different in development and validation cohort. Mean of 
prothrombin time and total cholesterol was statistically different in development and 
validation set. Overall both cohort participant characteristics were similar. 
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Table 21. Summary of the Baseline Characteristic of Independent Variables 
Characteristic Development Set Validation  Set P-Value 
Gender (Male/Female) 66.7/33.3 57/43 0.08 
Arm (Left/Right) 73.7/26.3 59/41 0.006* 
DM (Yes/No) 38/62 28/72 0.07 
HTN (Yes/No) 78/22 65/35 0.02* 
PVD (Yes/No) 16/84 12/88 0.33 
Smoker (Yes/No) 13.7/86.3 13/87 0.87 
Dialysis prior to surgery (Yes/No) 37.3/62.7 51/49 0.02* 
Type of AVF (BC/RC/BB) 63/27/10 72/20/8 0.24 
BMI mean ±SD (Kg/m2) 28±9.1 26.3±6.8 0.69 
Urea, mean ±SD (mmol/L) 17.9±9 16±7.7 0.06 
Creatinine, mean ±SD (µmol/L) 425±197 398±183 0.18 
eGFR mean ±SD (ml/min/1.73m2) 14.4±10 14.9±2.7 0.82 
K, mean ±SD (mmol/L) 4.5±0.8 4.4±0.8 0.73 
Na, mean ±SD (mmol/L) 140.8±31.5 138±3.9 0.04 
Ca, mean ±SD (mmol/L) 2.3±0.2 2.3±0.2 0.13 
HCO3, mean ±SD (mmol/L) 24.9±5 24.8±5.1 0.85 
PT, mean ±SD (second) 10.8±3.8 11.6±1.5 0.01* 
INR, mean ±SD (ratio) 1.1±0.4 1±0.1 0.12 
TC, mean ±SD (mmol/L) 4.3±1.3 4.5±1.4 0.05* 
TG, mean ±SD (mmol/L) 2.2±1.5 2.2±1.3 0.08 
HDL, mean ±SD (mmol/L) 1.2±0.5 1.2±1.1 0.07 
Vein Size, mean ±SD (mm) 3.6±1 3.6±1.1 0.53 
*Is used for significant difference between two cohorts p value <0.05, ±SD, Standard Deviation, DM-
Diabetes Mellitus, HTN-Hypertension, PVD-Peripheral Vascular Disease, BC-Brachiocephalic, RC- 
Radiocephalic, BB- Brachiocephalic, BMI- Body Mass Index, e-GFR- Estimated Glomerular 
Filtration Rate, K-Potassium, Na-Sodium, Ca-Calcium, HCO3-Bicarbonate, PT-Prothrombin Time, 
INR- International Normalization Ratio, TC- Total Cholesterol, TG- Triglyceride, HDL- High Density 
Lipoprotein. 
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4.5.2 External Validation 
Optimism is a well-known problem of predictive models: Their performance in new 
patients is often worse than expected based on performance estimated from the 
development data set (Harrell et al. 1996, Van Houwelingen and Le Cessie 1990). 
External validation of the prognostic model was performed by using data obtained 
from an independent data set of patients who received AVF at the Royal Infirmary of 
Edinburgh between year 2010 and 2011. The discriminative ability of the final model 
for the maturation of fistula was calculated by measuring the area under the ROC 
curve. The ROC area as the primary indicator of the model performance (Steyerberg 
et al. 2003). To assess the fit of a logistic regression model is to see what proportion 
of true positives it classifies as being positive (the sensitivity) and what proportion of 
true negatives it classifies as being negative (the specificity). Discrimination 
indicates how well the model discriminates between people with and without the 
outcome. An AUC of 0.5 indicates that the model is not discriminating very well (no 
different to tossing a coin); an AUC of 1.0 indicates perfect discrimination. ROC 
curve for external validation was developed, based on the predicted probabilities for 
every patient and calculating the sensitivity and specificity for consecutive cut-off 
points according to the predicted probabilities from the logistic regression models.  
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑒(𝛽0+𝛽1𝑋1+𝛽2𝑋2+⋯+𝛽𝑛𝑋𝑛)
1 + 𝑒(𝛽0+𝛽1𝑋1+𝛽2𝑋2+⋯+𝛽𝑛𝑋𝑛)
 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
1
1 + 𝑒−(𝛽0+𝛽1𝑋1+𝛽2𝑋2+⋯+𝛽𝑛𝑋𝑛)
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Where 
 Β0 is the intercept, β1 till βn are the regression coefficients and X1 to Xn are 
independent variables. 
 
By using above formula predicted probability of each patient was calculated. The 
area under the ROC curve for the prediction of maturation of fistula was calculated 
using predicted probabilities and patients outcomes (mature or immature) of each 
patient. The area under the ROC curve for the prediction of maturation of fistula in 
the validation set was 0.591 (95% bias-corrected CI: 0.471-0.712), consistent with 
good model discrimination (Figure 25).  
Figure 25. Receiver Operating Curve Analysis for Validation of Prognostic 
Model 
 
Figure 25 showing receiver operating characteristics of AVF maturation. Area under the 
curve was 0.591 (95% CI: 0.471-0.712), indicating good discriminatory ability of AVF 
maturation.  
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A better way of assessing the fit of a logistic regression model is compare the 
expected and observed numbers of positives for different subgroups of the data. If 
the observed and expected numbers are sufficiently close, then we can assume that 
we have an adequate model. In a calibration plot groups of predicted probabilities of 
the outcome are plotted against groups of observed probabilities. Subsequently it can 
assess the extent to which these groups lie along the perfect calibration line, which 
forms a 45 degree angle with the horizontal axis (Steyerberg 2009; Harrell 2001). 
The calibration ability of the validation model for the maturation of the fistula is 
shown in plot (Figure 26). Predicted and observed values lie along the calibration 
line, which forms a 45 degree angle with the horizontal axis. 
Figure 26. Calibration Plot of the Prediction Model 
 
Figure 26 showing calibration plot in which groups of predicted probabilities of the 
outcome (mature or immature) are plotted against groups of observed probabilities. 
Figure shows groups lie along the calibration line, which forms a 45 degree angle 
with the horizontal axis. 
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5.1 Success Rate of AVF Maturation 
This study set out with the aim of assessing the importance of independent markers 
in the prediction of maturation of AVF. The results of this study identify three 
clinical factors, each of which was independently associated with maturation of 
AVF: male gender, PVD, and vein diameter. AVF efficiently developed in 168 
patients, accounting for 56% of the total number of patients. Similar results have 
been obtained by Feldman et al. (1993), with 44.5% out of a total of 348 patients 
exhibiting unsuccessful AVF development. This high percentage is not surprising, 
taking into consideration the various problems of development that have always 
characterised the fistula, as well as the problems related to the process of dialysis. If 
a fistula fails to mature at four to eight weeks, then it is not likely to be available for 
cannulation later on (Kian and Vassalotti 2005; Robbin et al. 2002), especially 
without intervention.  
5.2 Age and AVF Maturation 
In this study, age of patient was not found to be an independent marker of AVF 
maturation in univariable and multivariable analysis. In a similar manner, the study 
results achieved by Renaud et al. (2012) indicated that neither the primary nor the 
secondary accessibility of the radiocephalic and brachiocephalic AVF, nor their 
applicability, was influenced by age. Demographic and clinical factors affecting 
fistula maturation were retrospectively compared among 280 patients with incident 
ESRD at a single centre. Study results suggested that primary fistula strategy in 
elderly ESRD patients is feasible and does not result in inferior outcomes. Age 
should therefore not be a determinant for primary fistula creation. Similarly Weale et 
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al. (2008) identified the outcomes of all patients undergoing a first surgical access 
procedure for a radiocephalic and brachiocephalic AVF. From a total of 658 patients, 
361 had a radiocephalic, and 297 had a brachiocephalic AVF. The study results 
concluded that age do not affect usability, primary or secondary patency of either 
radiocephalic or brachiocephalic AVF. Bessias et al. (2008) argued that, despite the 
fact that it is essential to choose patients accordingly, any patients, irrespective of 
age, can undergo this surgical procedure, provided that they are considered capable 
of withstanding it.  
In this study 76.3%, participants were aged more than 50 years and 23.7% were aged 
below 50 years. Nowadays, ESRD is usually encountered mostly in old patients who 
also suffer from other related conditions, including hypertension, diabetes, and 
obesity. In particular, the combination of age and diabetes impairs fistula outcome 
with significantly higher failure rates up to 42% (Tordoir et al. 2007). The 
association between increasing age and greater risk for failure to mature is related 
with the normal aging process and are damaged by concurrent disease; this finding is 
supported by other studies (Feldman et al. 2003; Huber et al. 2002). The results 
obtained by other researchers (Swindlehurst et al. 2011; Peterson et al. 2008; Lok et 
al. 2006; Miller et al. 1999b), corroborate the findings of previous research regarding 
the direct connection between advanced age and underdeveloped fistula. Lok et al. 
(2006) observed that older patients generally had a greater risk of AVF maturation 
failure (hazard ratio, 1.7) than those with higher age, but that secondary patency was 
equivalent between age groups for all types of autogenous access. A recent meta-
analysis of thirteen relevant studies (all cohort observational studies, 11 
retrospective) were included. The meta-analysis results revealed a statistically 
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significantly higher rate of radial-cephalic AVF failure in elderly patients compared 
with non-elderly adults at 12 (odds ratio [OR], 1.525; p = 0.001) and 24 months (OR, 
1.357, p = 0.019). The primary radial-cephalic AVF rate was also in favour of the 
non-elderly adults (OR, 1.79; p = 0.012). Secondary analysis revealed a pooled effect 
in favour of the brachiocephalic AVF that was statistically significant (p = .004) 
compared with distal fistulas in elderly patients and has recommended that this 
finding should be considered when planning access surgery (Lazarides et al. 2007). 
However, the definitions of “elderly” in the included studies ranged from 50 to 70 
years, and the review was specific to wrist AVFs. 
5.3 Gender and AVF Maturation 
The present study results indicate a gender difference in the maturation of AVF, 
mature rates of 60% for men and of 48% for women. Miller et al. (1999b) found that 
the AVF creation is more successful in men than in women. Similar results were 
obtained by El Ters et al. (2012), Iyem (2011) and Gibbons (2006). This study also 
revealed that the efficiency of fistula development in men is double, in comparison to 
women (OR being 0.514 and the 95% CI: 0.308 to 0.857). A number of other studies 
(Wolford et al. 2005; Ernandez et al. 2005; Patel et al. 2003; Feldman et al. 2003; 
Prischl et al. 1995; Solomonson et al. 1994) which examined agents related to AVF 
adequacy or patency supported this result; the most rational explanation for this 
difference is the smaller size of vessels in women. Moreover, women within the 
study population often had diabetes mellitus or hypertension or were classified as 
“early postmenopausal”, all of which are conditions that may produce a form of 
atherosclerosis that accelerates more rapidly than that in men (Schild 2010). In this 
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study gender emerged as a significant marker for the prediction of maturation of 
AVF in both univariate (OR – 0.615; p = 0.049) and multivariate (OR - 0.514; p = 
0.011) analysis. Some other studies also found female gender to be associated with 
immature fistula (Peterson et al. 2008; Lok et al. 2006; Huber et al. 2002; Robbin et 
al. 2002; Thomsen et al. 1983; Kinnaert et al. 1977). It is commonly believed that 
the vascular anatomical differences between the two different genders influence to 
decreased creation of AVF in women. However, Caplin et al. (2003) employed a 
group of 192 patients to carry out detailed mapping of upper arm vessels using 
duplex Doppler ultrasonography. The diameter of the blood vessels was measured at 
29 locations (17 on the vein and 12 on the artery). Comparison of the measurements 
revealed that there was no considerable distinction in the vein diameter between men 
and women at any location. Other studies have demonstrated that the sex 
differentiation is also minimal. Palmes et al. (2011) did not find any gender 
differences on AVF patency in elderly patients. In their study, that involved the 
creation of 132 AVFs on 114 subjects, Baser et al. (2006) did not observe any gender 
differentiations with regard to initial or delayed maturation failure of the AVFs or in 
their patency. Similarly, Erkut et al. (2006) did not find any sex distinctions in the 
evaluation of the efficiency of AVFs in a sample group composed of 310 men and 
102 women. Ekicei et al. (2008) found no considerable gender distinctions in the 
success rate of AVFs either.  
5.4 Right/Left Fistula and AVF Maturation 
AVF was generally created at the distal end compare to proximal location and of the 
less used arm compare to dominant arm to preserve dominant arm to allow daily 
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living activities. Arterial inflow is a key component that is necessary for AVF 
maturation. A native vein fistula that has poor inflow from the artery fails to dilate 
and develop into a usable access for haemodialysis. In this study success rate of 
maturation was 53.4% in left side AVF and 63.3% was in right sided AVF. The 
researcher found side of arm significant in the univariate analysis but did not show 
significance in the multivariable analysis. This finding is supported by a 
retrospective analysis of a prospective computerized vascular access database 
performed by Shingarev et al. (2012) to compare primary failure and cumulative 
survival of upper extremity AVFs and AVGs. Among those patients received an 
AVF (233 patients), neither the primary failure rate nor cumulative access survival 
differed significantly between AVFs placed in the right and left upper extremities. It 
might seem obvious, the ideal time to assess which arm has the best vessel for an 
AVF is before the first AV access is placed and when patient’s hopes and confidence 
are high. After one or more failed procedures in the non dominant arm, it is harder 
for the patients to accept switching to the dominant side. These technical and 
emotional difficulties can be avoided by the rule that AVF should be placed in the 
arm with the best vessels regardless or side of arm.  A single centre, randomised 
study was conducted by Koksoy et al. (2009) to compare outcome, patency, and 
complication rates in these two autogenous upper arm AV accesses (B/B AVF or 
B/C AVF). A total of 100 patients (50 B/C and 50 B/B AVF) were recruited and 
univariate analysis showed that risk factors associated with poorer patency rates to be 
use of dominant arm for fistula creation. The smaller sample size may have obscured 
this association in this investigation. 
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5.6 Type of Fistula and AVF Maturation 
In the current study, 62.7% of AVF were brachiocephalic, 27% were radiocephalic, 
and 10.3% were brachiobasilic. The results indicate 60% brachiocephalic, 52% 
radiocephalic and 42% brachiobasilic AVF were successfully mature and adequate 
for cannulation. However, due to the fact that predictive and pathophysiological 
factors are directly linked, the positioning of the AVF in the forearm or arm had no 
effect on the study prediction model as a suitable inflow and outflow are necessary 
regardless of the position of the fistula. The results of the present study are coherent 
with other studies (Koksoy et al. 2009; Saran et al. 2004; Robbin et al. 2002) 
whereas Miller et al. (1999b) discovered that fistulas in the upper arm are more 
likely to develop successfully and Monroy-Cuadros et al. (2010) results showed that 
forearm fistula are independently associated with loss of primary patency. Lazarides 
et al. (2007) carried out meta-analysis of the results of the dialysis access in old 
individuals and found an increased risk of AVF failure in the forearm and significant 
maturation of brachiocephalic fistulas. In the case of patients who have no suitable 
vessels in the lower arm, it may be possible to create brachiobasilic fistula in the arm. 
The constriction or blockage of the cephalic vein in the antecubital area, where it 
often undergoes the process of cannulation for phlebotomy, can hinder the creation 
of a fistula. On the other hand, the basilic vein can withstand the creation of a fistula 
as it is of considerable diameter and it is not so close to the surface as the cephalic 
vein and thus it is not punctured during the phlebotomy. Nevertheless, as noted by 
Oliver et al. (2001), the fact that it is not a superficial vein means that the basilic vein 
cannot undergo cannulation of a brachiobasilic fistula in its original location. One 
solution would be to section and gouge out the basilic vein in the superficial tissue 
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layer of the forearm, where it could be reached with a dialysis needle. However, at 
present, there is no general agreement as to which method of AVF is most suitable. 
In this study success rate of forearm AVF was lower than upper arm and that is 
consistent with previous studies (Peterson et al. 2008; Lok et al. 2006). 
Arteriosclerosis is usually more manifest distally, a more proximal fistula location at 
the proximal forearm, the elbow and upper arm region may be advantageous in 
elderly CKD patients suffering from diabetes and peripheral arterial disease (Palmes 
et al. 2011; Allon et al. 2000). However, the incidence of thrombotic and infectious 
complications is low and long-term outcome is good (Fitzgerald et al. 2004). There is 
one important negative aspect of positioning a fistula at the elbow; namely, a risk of 
high blood flow, which can cause distal hypo-perfusion as well as elevated output 
heart failure, especially in individuals with ischaemic cardiac disease (van Hoek et 
al. 2006; Fitzgerald et al. 2004).  
5.7 Surgeon and AVF Maturation 
The construction of fistulas was undertaken by surgeons with significant experience. 
The main objective of these surgical procedures was to expand the development 
success rate of fistulas, regardless of the pre-surgery assessment and the actual 
operation. The surgeons carried out the procedures themselves (rather than training 
residents), relying on their vast experience. These differences in surgeon were found 
to have no influence in the outcome of surgery. However, the findings of the current 
study do not support the previous research that indicates that surgical selection is a 
major predictor of AVF success rate and outcome (Kats and Wasse 2008). The study 
conducted by Huijbregts et al. (2007) focused on determining alterable and 
Chapter 5 
173 
 
unalterable agents, which play a part in the initial functionality of the AVF in eleven 
medical centres in the Netherlands. It was demonstrated that the likelihood of initial 
maturation failure has a close correlation to the location of the AVF, highlighting the 
importance of the decisions made by the surgeons, as well as their capabilities. 
An emphasis on haemodialysis access procedures and number of AVFs created 
during surgical training influences the type of access created and AVF survival 
(Saran et al. 2008). In addition, surgical centre volume (Greater than 30 access 
procedures per year), surgeon volume, and surgical subspecialty have all been shown 
to increase the creation of AVFs over arteriovenous grafts (Choi et al. 2008; 
O'Hareet et al. 2003; Lazarides et al. 2002). Overall, early nephrology referral and 
timely referral to a dedicated surgeon, in co-operation with a multidisciplinary team, 
offer the progressive kidney disease patient the best chance of using an AVF at the 
initiation of dialysis. 
5.8 PVD and AVF Maturation 
The presence of peripheral vascular disease has been associated with an increased 
risk of AVF failure because an insufficient artery or vein may be unable to increase 
blood flow sufficiently and undergo adequate maturation. Modern high-frequency 
ultrasound machines capable of high-resolution imaging can determine the intima 
media thickness of small arteries such as the radial artery at the wrist. Ku et al. 
(2006) reported that intima media thickness measurements during preoperative 
duplex ultrasound imaging correlated significantly to histologic measures and, more 
importantly, to AVF thrombosis and to inadequacy of an AVF to maintain dialysis at 
1 year. Similarly, ankle-brachial pressure index, a reliable marker for peripheral 
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vascular disease, had a significant association with access failure after adjusting for 
other variables (Chen et al. 2009). The result of this study showed that AVF 
maturation rate was 59.7% in a group with no history of PVD and 33.3 in patients 
with PVD. In current study, PVD emerged as one of the predictive markers in the 
maturation of fistula in both univariate and multivariate analysis. The chances of 
patients without peripheral vascular disease to attain full development of the fistula 
increased threefold. Similar results have been obtained by Lok et al. (2006) and 
Woods et al. (1997) also discovered a connection between PVD and AVF success 
rate. According to one study, the attributable risk of AVF failure from PVD was 24% 
higher and may carry a relative risk three times normal (Woods et al. 1997). Obialo 
et al. (2003) observed a PVD associated relative risk of 1.9. There is a high 
prevalence of PVD in diabetic patients (83% in this study). By extension, vascular 
access failure rates are predictably high among diabetic patients (Dixon et al. 2002; 
Miller et al. 1999b). Chan et al. (2008) conducted a retrospective cohort analysis 
using 1486 patients’ data. It was revealed that patients who suffer from PVD are 
more likely to experience failure of AVF maturation (OR 2.78, 95% CI 1.01–7.63, p 
= 0.047). A large multicentre study data comprising of 6400 patients from 145 US 
dialysis units and 101 units in five Europe countries (France, Germany, Italy, Spain, 
and the United Kingdom) was found AVF to be strongly related (P < 0.01) to the 
absence of peripheral vascular disease (Pisoni et al. 2002). In contrast a retrospective 
study (Peterson et al. 2008) of 205 patients did not find a significant association 
between fistula maturation and peripheral vascular disease. The smaller sample size 
may have obscured this association in this investigation. 
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5.9 Diabetes and AVF Maturation 
European patients have a less propensity to have diabetes than Americans but still 
have substantial comorbidity (Mendelssohn et al. 2005). The current study comprise 
of 38% diabetic in which rate of AVF maturation was 50%. Diabetes as an 
independent predictor was significant in univariate analysis but after multivariable 
analysis, the researcher did not find it as a predictor of maturation. This finding is in 
agreement with Ekicei et al. (2008) and Wolowczyk et al. (2000) findings, which 
showed diabetes has no effect on AVF maturation rates. A number of studies (Allon 
et al. 2000; Hirth et al. 1996), have debated whether diabetes increases the likelihood 
of fistula failure or occurs as a result of other factors and conditions, including sex 
(women are more likely to develop diabetes), advanced age, obesity or PVD. 
Although this finding corroborates the findings of Feldman’s and other studies 
(Monroy-Cuadros et al. 2010; Huijbregts et al. 2008; Patel et al. 2003; Obialo et al. 
2003). In contrast, these results differ from some published studies (Ernandez et al. 
2005, Miller et al. 1999b) which demonstrated diabetic state did not significantly 
change AVF maturation rate. However, other studies have omitted PVD or employed 
a more broad characterization (Lauvao et al. 2009; Wolford et al. 2005). PVD often 
accompanies diabetes, becoming integrated in the symptoms of diabetes; thus, it is 
overlooked as a disease in its own right. Cheng Wu et al. (2010) and Robbin et al. 
(2002) discussed the negative effect of diabetes on the structure of the veins, which 
makes them unsuitable for the construction of fistulas. 
Sedlacek et al. (2001) reported that despite increased arterial calcification, vessel 
diameters and arterial peak systolic volume were not significantly different between 
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diabetic and non-diabetic patients in their population. Subsequent AVF formation in 
their diabetic patients was effective, and outcomes were similar regardless of the 
presence of diabetes. Konner et al. (2002) reported increased use of proximal fistulas 
in diabetic patients but with primary access survival similar to that of non-diabetic 
patients. Secondary survival at 24 months was reduced compared with non-diabetic 
subjects, however, and steal syndrome was more common in the diabetic group. 
Functional maturity rates for AVFs in diabetic patients have been suggested to be 
increased by the use of routine vessel mapping (Konner et al. 2002). As such, the 
effects of diabetes on overall AVF outcomes may be minimized by careful 
preoperative vessel imaging and AVF site selection. 
5.10 Smoking and AVF Maturation 
Ozdemir et al. (2005) drew attention to the threat posed by smoking to the 
development of vascular blockages in all patients, irrespective of whether or not they 
suffer from ESRD. Few studies have investigated the history of smoking in the 
context of the rate of incidence of vascular disease, but no conclusive results were 
obtained (Churchill et al. 1992; Reilly et al. 1982). Previous peripheral vascular 
damage in former and active smokers may lead to acute access thrombosis, which 
may partially explain the inconsistency in results. Surprisingly, the prevalence of 
smoking in this study participant was very low (13.7%). This result may be explained 
by the fact that the poor data transcription (Data transcription is the process of 
converting voice-recorded reports, procedures and notes as dictated by physicians or 
other healthcare professionals, into text format in order to create files representing 
the treatment history of patients). The results of this study did not show the 
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maturation difference of AVF in smoking and non-smoking group (61% and 55.2% 
respectively). This study did not detect any evidence of smoking as an independent 
marker for the prediction of maturation of AVF. However, recent study (Kaygin et 
al. 2012) findings showed strong association between AVF outcomes and smoking 
habits. According to Ozdemir et al. (2005), the possibility of occurrence of AVF 
thrombosis is increased by smoking and a high number of eosinophils. Wetzig et al. 
(1985) found that the failure rate of AVF maturation (early and delayed) among 
patients with haemodialysis who smoked regularly was considerably higher. The 
discrepancies in the results can be attributed, in part, to acute access thrombosis 
caused by previous peripheral vascular disruptions in erstwhile and current smokers. 
A number of endothelial cells functions are affected by the substances derived from 
cigarette smoking such as nicotine, carbon monoxide and tar. In the long run, the 
ability of endothelial cells of anticoagulation can be affected, as can their ability to 
prevent the formation of blockages and reduced their fibrinolytic activity. What is 
more, smoking can alter vaso-dilatation, which depends on the endothelium by 
disrupting the processing and release of nitric oxide. As explained by Newby (1999), 
a diminished quantity of nitric oxide can determine a growth in the compression, 
multiplication, and movement of vascular smooth muscle cells. Thus, smoking can 
lead to constriction as well as blockage of blood vessels, affecting the AVF.  
5.11 Hypertension and AVF Maturation 
In this study, 78% of all patients had a history of arterial hypertension, which was 
distinguished as independent risk factors (systolic blood pressure) associated with a 
decreased AVF maturation rate in univariate analysis. However, hypertension did not 
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find to be a significant predictor of maturation in multivariable analysis. The findings 
of the current study are consistent with those of Monroy-Cuadros et al. (2010) who 
did not show a significant association between hypertension and AVF maturation. 
Results of another retrospective study including 298 vascular access procedures 
concluded that hypertension, tobacco use, and prior dialysis catheter placement had 
no effect on fistula maturation by univariate or multivariate analysis (Lauvao et al. 
2009). 
Although, these results differ from Kaygin et al. (2012) who observed a negative 
association between hypertension and fistula maturation. Similarly results of a 
retrospective study of 105 patients found arterial hypertension as an independent risk 
factor that was significantly associated with AVF failure (OR: 3.4; 95% CI: 1.1–9.9) 
(Palmes et al. 2011). AVF maturation depends on the availability of a suitable vein 
and likewise on the ability of the artery to dilate, the dispensability of the arterial 
wall being an additional factor (Kheda et al. 2010). Since, during the primary fistula 
creation, more vessel calcifications were detected in diabetics and hypertensive 
patients, a more proximal fistula location has proven successful for fistula maturation 
(Chin et al. 2004; Konner 2000).  
5.12 Dialysis and AVF Maturation 
In this study, the success rate was 57.4% who have not been on dialysis before and in 
contrast 53.6% success rate in the patients on dialysis. The researcher included 
variable in multivariable analysis, but did not find to have any impact on fistula 
maturation in this study. This finding is in agreement with Palmes et al. (2011) 
findings, which suggested no any impact of dialysis treatment before surgery on the 
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patency rate and fistula maturation. However, the findings of the current study do not 
support the recent research, which found earlier utilization of central venous 
catheters as a strong independent risk factor for lack of AVF maturation (El Ters et 
al. 2012; Erkut et al. 2006). 
The assessment of the accomplishments and drawbacks of AVF construction over a 
two year period at one institution, prior to the commencement of dialysis, has been 
carried out by Weber et al. (2009). It was revealed that AVF construction prior to 
dialysis had a success rate of 72%. According to Arora et al. (1999), 40% of the 
patients who have been referred to a kidney specialist in the early stages of renal 
disease exhibited a functional vascular access upon commencement of dialysis, in 
contrast to 4% of the patients who have been referred to a specialist in the late stages 
of the disease. Astor et al. (2001) noted that in patients referred early the initial 
vascular access is a fistula rather than a graft, as in the patients with late referral. In 
the case of the delay, the accessibility and development of the fistula can be 
disrupted by the use of a provisional CVC to start the dialysis. Catheter 
complications can lead to a premature fistula cannulation with consecutive AVF 
failure due to haematoma formation, fibrosis, and damage to the great vein (Ravani 
et al. 2004; Avorn et al. 2002; Roubicek et al. 2000).  
5.13 Electrolytes, Urea, Creatinine and eGFR and AVF Maturation 
Aronson et al. (1996) have drawn attention to the fact that disruptions to the 
metabolism determined by diabetes can lead to pro-thrombotic condition, endothelial 
dysfunction, deregulation of the growth factor, and augmentation of the extracellular 
matrix deposition. Whilst undergoing dialysis, the risk of hyperkalaemia is 
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considerably high among patients with progressive renal disease. This is caused by 
external intake of potassium or by abrupt disruption of the potassium sources from 
the interior to the exterior of the cells. In the present study success rate of maturation 
was 57.8% and 56.2% in patients having an abnormal value of potassium (45.7%) 
and with normal value of potassium (54.3%) respectively. The study did not find the 
potassium as a predictor of maturation as it was not significant in univariate and 
multivariate analysis. 
In chronic kidney disease, the acidosis is normally mild and the concentration of 
serum bicarbonate does not usually decrease below 15-18 mmol/L until the start of 
the ESRD (Palevsky 2004). In the present study, 45% of the participants had less 
than 23 mmol/L of bicarbonate, whereas the other 55% exceeded this amount. The 
development rate did not display any substantial discrepancies, with 57% in the 
former group and 55.2% in the latter. 
Chronic kidney disease is generally accompanied by mild hypocalcaemia, which is a 
disruption of calcium homeostasis that occurs often. This condition does not create 
particular problems in the pre-surgery interval (Slatopolsky and Hruska 2001). In the 
present study, the level of serum calcium of 87% of patients was below 2.5 mmol/L 
whilst the level of serum calcium of 13% of patients exceeded 2.5 mmol/L. Different 
haemostatic disruptions are considered to be the cause of bleeding diathesis and pro-
thrombotic condition in uraemia. However, we did not find urea, Creatinine and 
eGFR as predictive markers for the maturation of fistula. Bhan et al. (2007) found a 
rapid loss of eGFR in the year preceding dialysis was a significant negative predictor 
for a fistula however, eGFR at dialysis start was not found to be a significant marker. 
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5.14 BMI and AVF Maturation 
As noted by Fouque et al. (2007), the body mass index (BMI) is the standard method 
used in studies of epidemiology to calculate body size, as well as in evaluations of 
dietary status and supervision in ESRD. Surprisingly, no considerable discrepancies 
with regard to the development rate between patients with a BMI lower and greater 
than 30 kg/m2 were recorded in the present study, the development rate being 55% 
and 58.8%, respectively. In the present study, BMI did not emerge as an independent 
predictive marker in both univariate and multivariable analysis. Nevertheless, Miller 
et al. (1999b) discovered that patients with a BMI lower than 27 kg/m2 had a 
decreased possibility of the AVF developing into a functional access. According to 
Stehman-Breen et al. (2000), every standard deviation exceeding the average BMI of 
a patient was accompanied by a 30% decrease in the possibility of constructing AVF, 
in contrast to AVG. This result was corroborated by Polkinghorne et al. (2003), who 
noted the likelihood of patients with a BMI greater than 30 kg/m2 to have an AVG 
increased with 79%. Obesity is considered to be one of the agents that can have a 
negative impact on the efficacious creation of AVF (Allon et al. 2000). A recent 
study was conducted by Gagliardi et al. (2012) to evaluate the role of body mass 
index on arteriovenous fistula dysfunction in 84 patients. The study results did not 
find BMI as an independent predictor of thrombosis and stenosis of AVF. 
There can be no doubt about the connection between obesity and diabetes, which 
increases the risk of developing advanced arterial occlusive disease especially in the 
lower arm, thus having a negative effect on the development of AVF. A number of 
researchers (Colli and Sirtori 2010; Eichinger et al. 2008; Yusuf et al. 2005) have 
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observed that obesity increases the chances of developing venous and arterial 
thrombosis, which could have a negative influence on AVF access. Colli and Sirtori 
(2010) explained that, despite the fact that the manner in which obesity determines 
vascular thrombosis is, as yet, unknown, it has been observed that the adipokines and 
pro-inflammatory cytokines generated by the adipose tissue determine a growth in 
the number of pro-coagulant proteins, fibrinogen and factor VII. However, this 
biochemical connection between obesity and vascular thrombosis has not helped to 
identify exactly how obesity leads to the development of initial AVF thrombosis, 
particularly as the arteriovenous accesses have considerable blood flow. Initial AVF 
thrombosis in two obese female patients with a BMI of 34 kg/m2 and 39 kg/m2, 
respectively, was found by Plumb et al. (2007) to develop as a result of anatomic 
factors, namely, the obstruction of the axillary-subclavian veins during arm flexion. 
The study conducted by Kats et al. (2007) focused on determining the AVF 
development success rate in a group of 183 patients, of which 54 were obese and 129 
had a normal weight. The results revealed that the likelihood of initial AVF 
breakdown between the two groups was relatively the same, with 46% in the obese 
and 41% in the normal weight patients.  
5.15 Clotting Factor (PT, INR) and AVF Maturation 
Early AVF failure occurs in up to 60% of newly created AVFs, and results from 
thrombosis or marked in-flow stenosis, leading to non-maturation (Dember et al. 
2008; Dember and Dixon 2007). The typical lesion of vascular access thrombosis is 
neointimal vascular smooth muscle cell proliferation in the anastomotic draining 
vein. Platelet activation from endothelial injury may play an important role in 
Chapter 5 
183 
 
stimulating platelet aggregators such as platelet-derived growth factor and 
thromboxane A2, in addition to directly stimulating vascular intimal proliferation 
(Roy-Chaudhury et al. 2006). In patients suffering from uraemia, the development of 
thrombosis could be confusing, as uraemia is generally accompanied by bleeding 
diathesis. It is well-known that patients with ESRD experience abnormal bleeding. 
On the contrary, advanced intravascular coagulation could be a sign of thrombosis. 
In order for the fistula to develop, it is highly important to keep access unblocked, as 
it is difficult to reconstruct if vascular thrombosis develops during the initial couple 
of weeks subsequent to the construction of the fistula. On this basis, it has been 
conjectured that deterrence of fistula breakdown increases its chances of developing 
fully.  
In the present study, multivariable analysis did not corroborate the hypothesis that 
fistula access is favourably influenced by high pro-thrombin time and international 
normalised ratio (INR), despite the considerable values displayed by the earlier in 
univariate analysis. Even if coagulation and vascular obstruction are avoided, fistula 
development could still be hampered by constriction of the draining vein. As noted 
by Kaufman (2000), initial fistula blockage can be prevented by applying anti-
platelet agents, thus contributing to increase the AVF development success rate. In a 
study conducted by the Dialysis Access Consortium, 877 patients with newly 
constructed fistulae were randomly selected to have clopidogrel and placebo 
administered for a month and a half (Dember et al. 2008). The administration of 
clopidogrel determined a considerable decrease in the development of initial fistula 
thrombosis of 12.2% in contrast to 19.5%; however, a percentage of 61.8% and 
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59.5% of fistulae in both groups were inadequate for dialysis within half a year of 
their construction.  
Ghorbani et al. (2009) conducted a double-blind, randomized trial to determine the 
effects of clopidogrel on the incidence of primary AVF failure among newly created 
AVFs in ninety three patients. Study results showed a significant risk reduction in the 
primary AVF failure in active treatment group compared to placebo group. These 
results were supported by a Cochrane report (Da Silva et al. 2003). This meta-
analysis confirmed the beneficial effect of antiplatelet treatment as an adjuvant to 
increase the patency of AVFs in the short term. However, there have been multiple 
studies showing variable results of antiplatelet agents on vascular access failure. 
Yevzlin et al. (2006) showed a negative association between antiplatelet therapy and 
access patency. Previous double-blind randomized study has conducted to determine 
the association of antiplatelet drug ticlopidine with AVF maturation; however, none 
has found a beneficial effect on the maturation of AVF. In the study over 1 month, 
two of six fistulas in the ticlopidine group and five of nine in the placebo group 
failed. A further one placebo and two ticlopidine patients still had functioning 
fistulas at the time of withdrawal for technical reasons from the trial. Ticlopidine 
appears, therefore, to enhance the efficacy of fistulas, at least in the short term 
(Fiskerstrand et al. 1985). 
In contrast, the association between vascular access patency and the use of specific 
drugs was studied in a large sample of US haemodialysis patients enrolled in the 
Dialysis Outcomes and Practice Patterns Study, an international, prospective, 
observational study. Study results did not find an association of aspirin and warfarin 
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therapy with AVF maturation (Saran et al. 2002). The differences between the 
effects of high PT and INR on fistula maturation and patency may be an indication 
that thrombosis is a manifestation of AVF failure, and not the cause of it. Further 
research is required to find more efficient methods of increasing the fistula success 
rate, particularly with regard to the influence of the vascular function and anatomy 
on fistula development. 
5.16 Lipid Profile (TC, TG, HDL) and AVF Maturation 
In the current study, well established proatherogenic factors; hypercholesterolemia, 
triglycerides, and high-density lipoproteins, did not influence the risk of AVF 
maturation. A similar result was observed in a retrospective study including 298 
vascular access procedures concluded that hyperlipidaemia had no effect on fistula 
maturation by univariate or multivariate analysis (Lauvao et al. 2009). The results of 
this study show that 76% participants having their cholesterol level equal or below 5 
mmol/L. Total cholesterol was found significant in univariate analysis but no 
significant influence was found on the maturation in multivariable analysis. 
However, results of a recent case controlled study conducted in the Italy (Gagliardi et 
al. 2011) suggested that the total plasma cholesterol is an important risk factor of 
AVF failure in haemodialysis patients. However, the patient numbers (91) were 
relatively small in the study. The success of the maturation was 53.7% in patients 
having a triglyceride value below 2.1 mmol/L and 60% was in those having above 
2.1 mmol/L. Overall this study did not demonstrate any significant association 
between lipid profile and AVF maturation. Between 20 and 80% of patients that had 
undergone renal replacement therapy exhibited hyperlipidaemia with a growth in the 
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levels of cholesterol and triglyceride (Tse et al. 2004; Castelao et al. 1992). The 
results of a retrospective study (Kirkpantur et al. 2008) suggested that not TC, but 
lipid sub fractions (LDL-C and HDL-C) were associated with AVF thrombosis. 
Atherosclerosis has the potential to promote thrombotic events in the venous system 
or the two conditions (atherosclerosis and venous thrombosis) may share common 
risk factors like dyslipidaemia (Prandoni 2007; Prandoni et al. 2003). Previous 
studies of serum from ESRD patients have documented decreased HDL-C and LDL-
C, increased small dense LDL particles, and elevated TGs level with a normal TC 
level compared with the general population (Quaschning et al. 2001; Deighan et al. 
2000. Hulthe et al. 2000) indicated that all components of this type of dyslipidaemia 
are independently atherogenic. Therefore, focusing on TC alone may underestimate 
the complex atherogenic dyslipidaemia associated with uraemia and the presence of a 
lipid profile consistent with uraemic dyslipidaemia in the context of normal plasma 
TC highlights the need to look beyond the basic assessment of plasma concentrations 
of TC when assessing the AVF thrombosis risk to be presented by dyslipidaemia in 
maintenance haemodialysis patients (Kirkpantur et al. 2008).  
5.17 Vein Diameter and AVF Maturation 
In this series of 300 patients undergoing AVF access creation success of maturation 
was 60.3% in a group having vein diameter greater than 2.5 mm and 26.3 % in equal 
or smaller than 2.5 mm vein size. The result of this study found vein diameter is 
strongly significant independent predictive marker (p<0.001) in the maturation of 
fistula both in univariate and multivariate analysis. A pre-operative vein diameter 
greater than 2.5 mm resulted in a fivefold increase in fistula maturation compared to 
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a vein size less than 2.5 mm (OR 4.532; 95% CI 2.063 to 9.958). The results of the 
current study are consistent with Zadeh et al. (2012) and Lauvao et al. (2009) 
findings, which showed, vein diameter associated with successful maturation of 
fistula. Wong et al. (2011) also discovered that initial fistula failure can be brought 
about if the diameter of the radial artery and cephalic vein is below 1.6 mm. Kinnaert 
et al. (1977) proposed that the reduced dimensions of blood vessels in women makes 
them more predisposed to developing AVF failure. The results of a current 
prospective, observational study (Jemcov 2013) showed that female gender was 
associated with prolonged maturation of AVF, having a significantly smaller radial 
artery compared to men. . If the diameter of the cephalic veins exceeds 2 mm, there 
is a 76% success rate of functional dialysis access, whereas if the diameter is less 
than 2 mm, there is only a 16% success rate (Mendes et al. 2002). The pre-surgery 
ultrasound scan generates valuable data regarding vein thickness, compressibility, 
anatomic diversity and veins depth below the skin. The cut-off value identified by 
Brimble et al. (2002) was 2.6 mm; however, only women exhibited a substantial 
discrepancy between AVF success and failure with regard to vein diameter. In 
contrast, Wong et al. (1996) did not observe any discrepancies between AVF success 
and failure in the mean vein diameter at the wrist, but indicated AVF failure in all 
cases where the vein diameter was below 1.6 mm. Korten et al. (2007), on the other 
hand, did not observe any connection between vessel diameter and fistula 
development.  
It is important for the draining vein to have a particular size in order to ensure needle 
access as well as appropriate blood flow. Furthermore, fistulae, which have increased 
chances of developing, and those which have not have to be differentiated. Enhanced 
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vascular access is believed to be favoured by the use of pre-surgery vascular 
mapping (KDOQI 2006). This can offer the surgeon important data about vessel 
diameter, and the occurrence of vessel stenosis or thrombosis (Allon and Lok 2010). 
Assessment of haemodialysis access can be made with the help of ultrasonography, 
the fact that it is easily accessible, non-invasive, and relatively cheap, making it an 
efficient technique. Furthermore, this technique eliminates the hazards, which 
accompany the use of iodinated contrast material and ionizing radiation. One of the 
objectives of the present study was to verify whether the diameter of the outflow vein 
could be used as an indicator of fistula development. 
What is more, fistula development also depends on an adequate supply of intra-
access blood and pressure, which, in turn, rely on efficient heart output/systemic 
blood pressure as well as a supply vessel of high quality, capable of shifting the high 
pressure to a secondary, flexible, and dilatable outflow vein. According to Lyem 
(2011), the risk of early fistula thrombosis could be reduced by mechanical 
distension of the blood vessels prior to commencing anastomosis and the use of 
agents that cause dilatation of vessels. 
Preoperative Vein Mapping 
Robbin et al. (2002) suggested that ultrasonography may help to identify early fistula 
suitability and is even capable of generating predicted markers, if the anatomic as 
well as the functional parameters are employed. The kidney specialist and the 
vascular surgeon can refer to the predicted markers to better organise the procedure. 
Patel et al. (2003) revealed that patients who underwent physical examinations prior 
to surgery had an 80% maturation rate. It is possible that vessels, which can be 
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discerned and palpated during a general examination, differ from the vessels, which 
can be identified only through radiologic imaging. A number of researchers (Parmley 
et al. 2002; Huber et al. 2002; Robbin et al. 2000; Silva et al. 1998) have drawn 
attention to the fact that the use of pre-surgery imaging protocols, such as routine 
venous duplex ultrasonography scanning, in association with selective venography 
and arteriography may involve considerable risks, as it was observed that they were 
employed in cases where there was a growth in AVF preponderance.  
5.18 Validation of Prognostic Model for Maturation of AVF 
The efficiency of a predictive model has to be tested on a new group of subjects. In 
the present case, the performance of the predictive model with regard to the external 
verification of fistulae that had been constructed in the same hospital was good. The 
purpose of a predictive model is to assess potential risks and to manage treatment 
accordingly, to ensure the success of the AVF construction procedure. This practice 
can help to structure the process, ensure efficient management of resource 
distribution, and limit expenses. The ultimate objective is to expand the number of 
successfully created, permanent accesses and limit CVC reliance and its implicit 
risks. 
The long-term objective of this research effort was to identify factors predicting 
fistula maturation. The purpose of this study was to develop and validate a 
prognostic model in the prediction of AVF. We hypothesized that blood and patient 
factors could be used to stratify risk of self-report of maturation of AVF. In brief, 
using the development dataset of 300 subjects, we identified three variables 
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associated with maturation of fistula: gender, PVD and vein size and these variables 
were validated by using validation dataset of 100 subjects.  
As highlighted by Wong et al. (1996), most of the times, the kidney specialist or the 
vascular surgeons are unable to remedy certain risk factors, such as vessel diameter 
or properties, and intravascular blood flow. In the present study, it was the first time 
that the patients had fistulae constructed so the predictive model regarding earlier 
fistula failures could not be applied. Feldman et al. (2003) revealed that fistulae 
constructed for patients who had had earlier fistulae had an increased likelihood of 
successful development. However, our prognostic model performed well in the 
external validation of fistulae that involved patients who had not experienced earlier 
AVF creation or failure. Despite the fact that the external validation was illustrative 
of patients who had received first time AVF with an acceptable sample size of 100 
participants, the verification did not take into account the medical recommendations 
with regard to the risk factors associated with AVF maturation failure.  
The performance of the developed model in this study was assessed by 
discrimination and calibration of the model. The area under the ROC curve for a 
prognostic model is classically between 0.6 and 0.85 (Royston et al. 2009). In our 
study ROC curves was primarily designed for prognostic models, rather for 
diagnostic models. ROC curve was 0.68 in the development model and 0.59 in the 
validation stage, meaning that the model had reasonable capacity to correctly 
distinguish between mature and immature fistulae. For clinical practice, providing 
insight beyond the c statistic has been a motivation for some recent measures, 
especially in the context of extension of a prediction model with additional predictive 
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information from a biomarker or other sources (Cook 2007; Pencina et al. 2008; 
Pepe et al. 2008) 
Accuracy of the model was assessed by examining calibration (Grzegorczyk-Martin 
et al. 2012). To assess the validity of the predictive model developed using the 
development dataset, we applied the model to an independent or a validation dataset 
composed of 100 subjects. There was excellent agreement between the predicted and 
observed percentage in predicting maturation of AVF. We further note that a 
substantial size will be required for a validation sample to quantify validity in a 
reliable way, i.e. with enough power to substantial decrease in discriminative ability 
(Steyerberg et al. 2004). 
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This chapter will provide a summary of the study, relate the findings with their 
implications, discuss the limitations of this study, and suggest possible directions for 
future studies. 
6.1 Conclusion of Study 
Successful vascular access provision is the foundation on which successful 
haemodialysis is built. This thesis has provided a detailed evaluation of the risks to 
health conferred by some of the key elements of haemodialysis AVF provision and 
maintenance. In order to identify which fistulae have greater potential to develop, a 
pre-surgery prediction rule was formulated and thoroughly verified. It was facile and 
could be readily employed in predictive risk classification systems. Three factors 
were recognized as being important indicators of AVF development, namely, gender, 
peripheral vascular disease, and vein diameter. Due to time restrictions, assessments 
were carried out pre operatively and post operatively without a further follow up 
assessment, which could provide information on the longer-term consequences. 
However, additional assessment of the clinical benefits of such a risk classification 
system in relation to AVF development, based on a larger sample, is necessary. It is 
of considerable importance that many of the issues described in this thesis continue 
to be explored, solutions developed, and outcomes improved in this especially large 
population of vulnerable patients. The safe and effective provision of haemodialysis 
vascular access therefore remains an area in which considerable improvements in the 
health of renal patients may be made in the future. 
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6.2 Clinical Implication of Research 
Determining the type of vascular access has prime significance for maximizing a 
successful maturation of fistula and avoiding surgical revision. Unfortunately, 
despite being a common form of surgery performed today, there are no consistent 
criteria that can be applied before creation of arteriovenous fistula at present. The 
surgeon has to rely on his clinical judgement and other investigatory parameters 
including a pre-operative duplex scan, which has a major role in determining the 
success of maturation of fistula. However, it is not an entirely reliable tool and 
should be used only as one of the factors rather than the only factor to determine the 
maturation of fistula. This study makes this complex decision making easier and adds 
to the lists of the markers, which can play a role in the successful maturation of 
fistula. 
This study has an impact not just on the patients but also on the staff involved in the 
creation of AVF including revision procedure, and other type of vascular access after 
failure of AVF maturation. The failure of maturation has an impact not just on the 
patient but also the health system. The three factors, which the study has shown to be 
of significance, namely gender, PVD and vein diameter that are routinely done on 
patients in a clinical setting.  
Despite the fact that AVF failure is more frequent in women than in men, the many 
benefits of the AVF procedure are an indication that it should be used more often-in 
women as well. If undertaken correctly, there is no reason why AVFs in women 
should not reach a similar success rate observed with men. The risk factors 
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previously identified can be relied upon to structure a more efficient AVF screening 
protocol. 
The challenge that both medical specialists and patients will soon be confronted with 
is related to the high cost of the staged method of AVF development, which can 
require several operations. As stated by Manns et al. (2005), most of the people 
suffering from chronic kidney disease are admitted to hospital for vascular surgery, 
which, together with its associated problems, poses a considerable financial strain on 
health care institutions. 
6.3 Limitations of Research 
The present study has a number of limitations. The formulation of the prediction rule 
relied on 400 fistulae, constructed in the same medical centre in Scotland. It is 
possible that the recorded incidence of diabetes, peripheral vascular disease, and 
smoking is not illustrative of all the dialysis patients in Scotland. 
Second, the fistulae were constructed by surgeons who had a great deal of experience 
and were familiar with the procedure. The objective of the surgeons was to carry out 
the procedure in spite of the differences between pre-surgery examination and the 
actual intervention. The surgeons conducted the operations themselves; they did not 
delegate the task to interns. However, there were few staff changes during the five 
years when the fistulae were constructed. As argued by Pisoni et al. (2002), it is 
important to take into consideration non-measurable elements, such as surgical 
techniques, and principles of care, apart from ample case-mix adaptations 
highlighted by other studies. 
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Third, the surgical factor, intra-operative heparin, was not taken into account in this 
study (Feldman et al. 2003). The study aimed to identify the cases in which such an 
intervention would have been suitable, given the fact that it was proven to influence 
fistula development, and also considering available resources and expenses. 
Fourth, the connection between artery diameter and blood inflow rate was 
emphasised by a number of studies (Zadeh et al. 2012; Monroy-Cuadros et al. 2010; 
Parmar et al. 2007; Huijbregts et al. 2009). However, we did not included artery 
diameter and arterial blood flow in our study due to the unavailability of 
retrospective data.  
Another limitation was the duplex measurements of the vein diameter, that were 
carried out a single time represents an additional drawback of this study. 
Measurements of vessel diameter carried out during different times of day can show 
discrepancies. Day-to-day variations in venous diameter might have been due to 
differences in venous dilatation due to alterations in vascular tone (Planken et al. 
2006). Other factors such as temperature, physical activity, mental state, may also 
affect vessel breadth as it determines the dilatation of the vessels. 
Another limitation of this study was the considerable discrepancies in the 
measurements of vessel diameter in the same individual and between sonographers 
also represent a drawback. Despite the effort put into monitoring every potential 
source of inconsistency, inter-observer discrepancies in the patient sample were 
largely disregarded. 
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6.4 Future Research 
Further research studies are needed to determine how to predict, prevent, or treat 
failure of AVF maturation. In order to offer clinically meaningful solutions, have 
need of larger, multicentre trials. The quantity of patients needed for such a study 
will depend on the selection of primary outcome selected and the estimated event 
rates. 
Hyperparathyroidism observed in about half of all patients associated with 
significantly higher patency rates especially after forearm AVF and represented an 
independent protective factor related with fistula patency in the multivariate analysis 
(Palmes et al. 2011). Other published studies describe hyperparathyroidism as an 
independent risk factor for vascular access thrombosis, probably induced by micro 
calcification of the vessel wall (Diehm et al. 2010; Grandaliano et al. 2003; Rostand 
and Drueke 1999). Further investigations are necessary to clarify a potential 
relationship between hyperparathyroidism and vascular access patency. The 
beneficial effect of hyperparathyroidism on fistula patency and maturation warrants 
more extensive investigations. 
Recent studies have shown an important role of matrix metalloproteinase in the 
process of AVF maturation (Berceli, et al. 2006; Chan et al. 2007). A promising 
biomarker identified in human vein tissue, matrix metalloproteinase-2, may serve to 
predict AVF maturation (Lee et al. 2010). We did not look at matrix 
metalloproteinase as predicative marker. However, further studies are needed 
compare the relative importance of other matrix metalloproteinase isoforms in the 
process of AVF maturation. 
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Additional follow-up time is prerequisite to get hold of further understanding into 
long-term AVF patency.  
This study can have several follow-up studies. One of them could be the role of 
endothelial dysfunction markers in relation to the maturation of AVF. Some of the 
endothelial dysfunction markers including Endothelin-1, von Willibrand factor, 
vascular endothelial growth factor (VEGF) and homocysteine, have been shown to 
be useful predictors to determine maturation of AVF in patients who underwent AVF 
surgery. 
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We would like to invite you to take part in a research study examining the role of 
blood indicators such as blood clotting indicator, blood cholesterol, blood sugar, 
kidney functions and ultrasound imaging in predicting success of arteriovenous 
fistulae in patients with kidney failure. 
Before you decide if you would like to participate, you need to understand why the 
research is being done and what it would involve for you.  Please take time to read 
the information carefully. Talk to others about the study if you wish.  
Feel free to ask any question if there is anything that is not clear or if you would like 
more information. Contact details are at the end of the document. 
 
 
 
 
 
Appendix I 
280 
 
What treatment is available for kidney failure? 
The treatment for kidney failure is dialysis.  Dialysis is a way of removing the waste 
products from the blood stream when the kidneys cannot cope.  It is like having an 
artificial kidney. 
Dialysis is a method that requires access to the blood stream.  In other words it is a 
connection between the blood stream and the artificial kidney (dialysis machine).  
What is fistula and how it works? 
A direct connection between an artery and a vein is created at a surgical operation 
that is known as arteriovenous fistulae.  After arteriovenous fistulae formation the 
veins expand and the veins walls become much thicker over a period of 6 weeks that 
is known as maturation of fistulae. This is because arterial blood at a higher pressure 
is now flowing through the vein.  When dialysis is required needles are inserted into 
the vessels and connected to a dialysis machine. 
What is the purpose of this study? 
The purpose of the study is to explore the relationship between the blood indicators 
and success of arteriovenous fistulae maturation. These indicators include blood 
clotting indicator, blood cholesterol, blood sugar, kidney functions and ultrasound 
imaging. 
Am I suitable? 
You can participate in this study if you have kidney diseases with history of diabetes 
or hypertension, planned creation of upper arm arteriovenous fistula for dialysis. 
Unfortunately you cannot participate if you are pregnant, breastfeeding, or plan to be 
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pregnant during the course of the study, presence of on-going bleeding, on 
anticoagulant therapy or current history of chest pain. 
Do I have to participate? 
You participation in this research is entirely voluntary. The information pack given 
to you contains this information sheet and a consent form. Should you agree to 
participate, you will be required to sign the consent form before participation. You 
are free to withdraw at any time, without giving a reason.  
What will happen if I take part? 
Once your consent is obtained you will be assessed on the day of Duplex scan prior 
to fistula creation. It will last for approximately 30 minutes. Your visit plan will be as 
follows:        
All assessments will be conducted at the same time of day (+/-1 hour). Both the 
assessors are familiar with the testing equipment and procedure, one being a 
qualified nurse and the other vascular surgeon.  
At the time of your assessments, the following will happen: 
 At each visit you will have the chance to ask questions and raise any issues 
before, during and after each assessment. 
 Before surgery general physical examination and your weight and height will 
be measured  
 Before surgery your blood sample (1) will be taken and then the blood vessels 
diameter and blood flow will be measured using ultrasound device (2) 
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 After the surgery, physical examination and assessment of fistulae with 
ultrasound device will be carried out.  
For the assessment, you will have to remove your, jacket and outer clothing so that 
your weight and height are accurately recorded and your clothing does not interfere 
with the measurements.  
1) For the blood analysis about 10ml (2 tea spoons) blood will be obtained by 
inserting a needle into a vein in the arm. Blood sample will be taken by NHS 
staff as a regular procedure for pre operative tests. From these blood tests we 
will calculate your kidney function status, blood clotting profile, blood sugar 
level and blood cholesterol level.  
 
2) The ultrasound is a non-invasive method of obtaining pictures of the arteries 
and veins of the arm similar to that used for pregnant women to observe an 
unborn baby. The technique uses sound waves to construct a scan (picture). It 
is therefore not harmful in any way. We will look specifically around your 
upper arm. The test will require you to be lying down and will involve the 
placement of a small device on the skin of your arm. A sticky gel will be used 
to improve the quality of scan. The gel wipes and washes off easily and will 
not stain your skin or clothes.  
Will there be any disadvantages of taking part? 
Taking part in this study will not put you at risk of any bodily or mental harm. Your 
health status will not be altered in anyway by taking part. 
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We will need access to your whole arm for vessels diameter and blood flow for the 
ultrasound assessment. For your comfort and ease of testing, it is recommended that 
you wear a sleeveless top for the assessment. Assessments will be carried out with 
respect for your privacy and your comfort will be ensured before and during the 
entire period of assessment. 
What are the benefits of taking part in the study? 
You may learn about your body composition. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. If you have a concern about any 
aspect of this study, you could ask to speak to me and I will do my best to answer 
your questions (Queen Margaret University telephone: 01314740000). Alternatively, 
you could also contact the independent advisor (contact details given), if you should 
wish to complain formally. 
What if I do not want to continue my participation? 
You are free to withdraw from the study at any given point without having to give a 
reason for doing so.  
Will my taking part in the study be kept confidential? 
All information about you collected during the course of the study will be kept 
securely and will be accessible only to the research team members. 
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All information, which is collected, about you during the course of the research will 
be kept strictly confidential. 
All data will be anonymised as much as possible, and you will not be identifiable 
from any of the data collected from you. Your name will be replaced with a 
participant number and it will not be possible for you to be identified in any reporting 
of the data gathered. 
What will happen to the results of the study? 
If you are interested in the overall results of the study, these will be emailed to you as 
once the study complete. 
The results may be published in a journal, presented at a conference, or used as a part 
of a PhD thesis. Your anonymity will be preserved. 
Who has reviewed the study? 
This study has been reviewed and given favourable ethical opinion by the Queen 
Margaret University Research Ethics Committee 
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For further information contact details:  
 
Name of researcher:  Muhammad A Siddiqui 
Address:    Postgraduate Research Student 
 School of Health Sciences 
                                   Queen Margaret University  
                                   Queen Margaret University Drive, 
                                   Musselburgh, 
                                   EH216UU 
 
Email / Telephone: msiddiqui@qmu.ac.uk / 0131 474 0000  
 
 
 
Contact detail for independent advice 
 
Name:    Dr. Paddy Gibson  
Address:       Consultant Kidney Physician  
 Royal Infirmary of Edinburgh 
51 Little France Crescent 
Old Dalkeith Road 
 Edinburgh 
EH16 4SA 
 
Email: paddy.gibson@luht.scot.nhs.uk 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you have read and understood this information sheet, any questions you had have 
been answered, and you would like to be a participant in the study, please now see 
the consent form. 
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Appendix II- NHS EthicalApproval 
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Appendix III- Consent Form 
 
 
 
CONSENT FORM 
 
 
Title of Project: 
 
“The Role of haematological markers and factors in predicting fistula maturation in 
patients with renal failure: An Exploratory Study” 
 
       Please initial box 
 
1. I confirm that I have read and understood the information sheet and this consent form.    
I have had an opportunity to ask questions about my participation. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,    
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible  
 Individuals (Research Team) or from regulatory authorities where it is relevant to my 
 taking part in research.  I give permission for these individuals to have access to my  
 records. 
 
4. I agree to take part in the above study.    
 
 
___________________  _______________ _______________ 
Name of Patient  Date Signature 
 
 
____________________ ________________
 ________________ 
Researcher   Date  Signature 
 
Contact details of the researcher: 
Name of researcher: Dr Muhammad A Siddiqui 
Address: PhD Student, Podiatry, School of Health Sciences 
Queen Margaret University 
Edinburgh, EH21 6UU  
Email / Telephone: MSiddiqui@qmu.ac.uk / 0131 474 0000  
  
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix IV - Insurance Letter 
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